



ПРАВИТЕЛЬСТВО САНКТ-ПЕТЕРБУРГА
Комитет по науке и высшей школе




RUSSIAN
SOCIETY
OF CARDIOLOGY

RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY

SCIENTIFIC PROGRAMME

CARDIOLOGY 2017 – PROFESSIONAL EDUCATION,
SCIENCE AND INNOVATIONS

OCTOBER 24–27, 2017 | SAINT-PETERSBURG



www.scardio.ru



RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY (WITH INTERNATIONAL PARTICIPATION)

SCIENTIFIC PROGRAMME

CARDIOLOGY 2017 –
PROFESSIONAL EDUCATION, SCIENCE
AND INNOVATIONS

ОРГАНИЗАТОРЫ:

*Комитет по науке и высшей школе
Правительства Санкт-Петербурга*

*Общероссийская общественная организация
«Российское кардиологическое общество»*

OCTOBER 24–27, 2017 | SAINT-PETERSBURG



DEAR COLLEAGUES AND FRIENDS!

On behalf of the Russian Ministry of Health and from myself personally I am delighted to welcome the participants of the Russian National Congress of Cardiology.

The biggest annual scientific and practical forum, which is famous for its inter-disciplinary approach and is always a significant event in life of the Russian medical community, unites doctors and scientists by a common goal – reduction of cardiovascular mortality in the Russian population.

The members of the Russian Society of Cardiology representing practically all Russian regions are linked by a longstanding professional cooperation, exemplary in its innovative approach to integration of fundamental knowledge and clinical experience. Your joint efforts make it possible to move forward rapidly and take the most advanced positions in modern cardiology still saving everything, which is best in the Russian medicine.

The wide platform of inter-disciplinary interaction functions as a basis for the active involvement of the Society into development and realization of the programmes of continuous medical education as well as organization of social events aimed at cardiovascular prevention and health lifestyle advocacy, participation in observational and research projects, introduction of new diagnostic and treatment methods into clinical practice.

I am convinced that the Congress will be very successful, it will open new prospects for healthcare improvement on the basis of innovative medical technologies, and will become a new step on the way of the Russian cardiology development.

I wish you successful and fruitful work!

Minister



V.I. Skvortsova



DEAR FRIENDS!

Please accept my best congratulations on the opening of the Russian National Congress of Cardiology!

I am happy to know that this large-scale event, in which the leading specialists take part, is once again being held in Saint-Petersburg. Our city is known as a centre of the Russian medical thought. The unique scientific and clinical school is created here. Work of the outstanding researchers who glorified Saint-Petersburg is now the valued heritage of the Russian and the world medical science.

The Russian Society of Cardiology is headed by Professor Evgeny Shlyakhto, academician of the Russian Academy of Science, General Director of the Almazov National Medical Research Centre located in Saint-Petersburg. The Society is successfully coordinating the efforts of doctors, scientists and teachers in solving the key problems set by the government in the sphere of healthcare.

You are facing the important issues of the development of medical care on the basis of the latest achievements in cardiovascular prevention, diagnosis and treatment.

There is no doubt that the Congress will open new prospects of future development and will reinforce the position of Russia in the international medical community.

My best wishes for the successful and rewarding work at the Congress!

Governor of Saint-Petersburg



Grigory Poltavchenko



DEAR COLLEAGUES!

I am honoured and delighted to welcome participants of the Russian National Congress of Cardiology!

Every year we get together to exchange experience in the most vital issues of prevention, diagnosis and treatment of cardiovascular diseases. Our Congress is getting larger and more attractive for the delegates from different countries, new interesting topics emerge. This year, the Congress is held in Saint-Petersburg, a magnificent city, in which science, education and culture have been intertwined for three centuries. I think that traditions of innovations and progress established by Peter the First will contribute to the success of our event.


Developing an effective system of healthcare is one of the priorities in our country. The role of the Russian Society of Cardiology in achieving this goal cannot be overestimated. The largest medical association including more than 6,500 members unites the efforts of clinicians, scientists and teachers on the interdisciplinary basis to solve the most important problem of cardiovascular morbidity reduction.

Healthcare development today demands a wide introduction of translational medicine principles and a focused training of specialists in the area of innovative medical technologies. These are the two foundations on which the scientific programme of this Russian National Congress of Cardiology was developed. It will present the latest achievements in Cardiology and related areas of medicine. So, the Congress motto "Cardiology 2017: professional education, science and innovations" is at the cutting edge of our today's professional life.

I am firmly convinced that our Congress will once again become one of the most significant events in the life of the Russian medical community and will promote international acknowledgement of the Russian medical science.

I wish you all success and the most fruitful work at the Congress!

President
Russian Society of Cardiology



Prof. Evgeny Shlyakhto

PROGRAMME COMMITTEE

Chairman of the Programme Committee:

President of the Russian Society of Cardiology,

Prof. Evgeny Shlyakhto (Saint-Petersburg)

Congress Executive Secretary: Board Member of the Russian Society of Cardiology, **Professor Grigory Arutyunov** (Moscow)

Co-chairmen of the Program Committee Working Groups:

Akchurin R.S. (Moscow)	Mareev V.Yu. (Moscow)
Alekyan B.G. (Moscow)	Matskeplishvili S.T. (Moscow)
Baranova E.I. (Saint-Petersburg)	Nedogoda S.V. (Volgograd)
Belenkov Y.N. (Moscow)	Oganov R.G. (Moscow)
Boytsov S.A. (Moscow)	Paleev F.N. (Moscow)
Bokeria L.A. (Moscow)	Popov S.V. (Tomsk)
Vasyuk Y.A. (Moscow)	Revishvili A.S. (Moscow)
Galagudza M.M. (St.Petersburg)	Ruda M.J. (Moscow)
Golitsyn S.P. (Moscow)	Smolensky A.V. (Moscow)
Golukhova E.Z. (Moscow)	Sulimov V.A. (Moscow)
Dzemeshevich S.L. (Moscow)	Tereshchenko S.N. (Moscow)
Zateishnikov D.A. (Moscow)	Ternovoy S.K. (Moscow)
Ezhov M.V. (Moscow)	Tkachuk V.A. (Moscow)
Karaskov A.M. (Novosibirsk)	Chazova I.E. (Moscow)
Karpov R.S. (Tomsk)	Chumakova G.A. (Barnaul)
Karpov Y.A. (Moscow)	Shalnova S.A. (Moscow)
Kuznetsov V.A. (Tyumen)	Yavelov I.S. (Moscow)
Kuharchuk V.V. (Moscow)	

CONGRESS ABSTRACT COMMITTEE

Chairman: Prof. Dmitry Duplyakov (Samara)

Abugov S.A. (Moscow)	Nebieridze D.V. (Moscow)
Barbarash O.L. (Kemerovo)	Podzolkov V.I. (Moscow)
Gapon L.I. (Tyumen)	Pokushalov E.A. (Novosibirsk)
Gordeev M.L. (Saint-Petersburg)	Puzyrev V.P. (Tomsk)
Grinshtein Yu.I. (Krasnoyarsk)	Rotar O.P. (Saint-Petersburg)
Demin A.A. (Novosibirsk)	Ryzhkova D.V. (Saint-Petersburg)
Zemtsovsky E.V. (Saint-Petersburg)	Skibitsky V.V. (Krasnodar)
Kapustina A.V. (Moscow)	Tarlovskaya E.I. (Nizhny Novgorod)
Koziova N.A. (Perm)	Ternovoy S.K. (Moscow)
Kostareva A.A. (Saint-Petersburg)	Trufanov G.E. (Saint-Petersburg)
Lebedev D.S. (Saint-Petersburg)	Tsaregorodtsev D.A. (Moscow)
Libis R.A. (Orenburg)	Shlyk S.V. (Rostov-on-Don)
Lishmanov Yu.B. (Tomsk)	Shumakov D.V. (Moscow)
Miller O.N. (Novosibirsk)	Yakovlev A.N. (Saint-Petersburg)
Mitrofanova L.B. (Saint-Petersburg)	Yakushin S.S. (Ryazan)
Moiseeva O.M. (Saint-Petersburg)	

RUSSIAN SOCIETY OF CARDIOLOGY AWARD 2017 COMMITTEE

Chairman: Prof. Evgeny Shlyakhto (Saint-Petersburg)

Boytsov S.A. (Moscow), Galyavich A.S. (Kazan), Dovgalevsky P.Y. (Saratov), Duplyakov D.V. (Samara), Karpov R.S. (Tomsk), Koziolova N.A. (Perm), Konradi A.O. (Saint-Petersburg)

YOUNG SCIENTISTS AWARD COMMITTEE

Villevalde S.V. (Moscow), Grinshtein Yu.I. (Krasnoyarsk), Kontsevaya A.V. (Moscow), Mayanskaya S.D. (Kazan), Melekhov A.V. (Moscow), Nikulina S.Yu. (Krasnoyarsk), Osipova I.V. (Barnaul), Sumin A.N. (Kemerovo), Khaisheva L.A. (Rostov-on-Don)

BEST POSTER PRESENTATION JURY

Barbarash O.L. (Kemerovo), Blagova O.V. (Moscow), Galagoudza M. M. (Saint-Petersburg), Zavadovsky K.V. (Tomsk), Kapustina A.V. (Moscow), Kosmmacheva E.D. (Krasnodar), Lukianov M.M. (Moscow), Malashicheva A.B. (Saint-Petersburg), Miller O.N. (Novosibirsk), Moiseeva O.M. (Saint-Petersburg), Rotar O.P. (Saint-Petersburg), Rud S.D. (Saint-Petersburg), Tatarskiy R.B. (Saint-Petersburg), Filippov E.V. (Ryazan), Chesnikova A.I. (Rostov-on-Don), Shaposhnik I.I. (Chelyabinsk), Yakovlev A.N. (Saint-Petersburg)

SECRETARIAT OF THE CONGRESS PROGRAMME COMMITTEE

Konradi A.O. (Saint- Petersburg), Kontsevaya A.V. (Moscow), Nedoshivin A.O. (Saint-Petersburg), Ratova L.G. ,), Tanicheva A.A. (Saint-Petersburg), Chumak I.B. (Saint-Petersburg)

GENERAL INFORMATION

The Organizing Committee invites you to take part in the Russian National Congress of Cardiology to be held in Saint- Petersburg on 24-27 October, 2017.

CONGRESS VENUE

EXPOFORUM Convention and Exhibition Centre
(64/1 Peterburgskoye rdw., Saint-Petersburg)

HOW TO GET THERE:

By car:

5 minutes from the Pulkovo Airport; 5 minutes from the belt-way; 15 minutes from the Moskovskaya Metro Station.

By public transportation:

- Fixed-route taxi ## K-545, K-299. Bus #187. The route is everyday regardless of the events. Bus stop – Peterburgskoye sh., 7 minutes to the entrance to Passage.
- From the Moskovskaya Metro Station during the Congress days – bus #187a (from 8:45 till 19:00, every 16-18 minutes, tickets price is 40 rubles). Bus stop – at the entrance to Passage.
- From the Moskovskaya Metro Station (exit near the Mc.Donald's) by a free shuttle during the Congress days. Bus stop – at the entrance to Passage.



■ **24.10.17:****Moskovskaya Metro Station – EXPOFORUM**

7.30, 7.45, 8.00, 8.15, 8.30, 8.45, 9.00, 9.15

From 09.30 to 18.30 every 30 minutes.

Moskovskaya Metro Station – EXPOFORUM – Moskovskaya Metro Station

From 09.30 to 18.30 every 30 minutes.

EXPOFORUM – Moskovskaya Metro Station

19.00, 19.20, 19.40, 20.00, 20.20, 20.40, 21.10

■ **25.10.17:****Moskovskaya Metro Station – EXPOFORUM**

7.30, 7.45, 8.00, 8.15, 8.30, 8.45, 9.00, 9.15

Moskovskaya Metro Station – EXPOFORUM – Moskovskaya Metro Station

From 09.30 to 18.30 every 30 minutes.

EXPOFORUM – Moskovskaya Metro Station

19.00, 19.20, 19.40, 20.00, 20.20

■ **26.10.17:****Moskovskaya Metro Station – EXPOFORUM**

7.30, 7.45, 8.00, 8.15, 8.30, 8.45, 9.00, 9.15

Moskovskaya Metro Station – EXPOFORUM – Moskovskaya Metro Station

From 09.30 to 18.30 every 30 minutes.

EXPOFORUM – Moskovskaya Metro Station

19.00, 19.20, 19.40, 20.00, 20.20, 22.10

■ **27.10.17:****Moskovskaya Metro Station – EXPOFORUM**

7.30, 7.45, 8.00, 8.15, 8.30, 8.45, 9.00, 9.15

Moskovskaya Metro Station – EXPOFORUM – Moskovskaya Metro Station

From 09.30 to 18.30 every 30 minutes.

EXPOFORUM – Moskovskaya Metro Station

20.10, 22.10

- From Moskovskaya Metro Station (exit near the Mc.Donald's) free shuttle minivans (Russian National Congress of Cardiology) on October, 24-27. Minivan stop – at the entrance to Passage.

**Bus shuttle schedules:**

24 October		25 October		26 October		27 October	
Moskovskaya Metro Station – EXPOFORUM	EXPOFORUM – Moskovskaya Metro Station	Moskovskaya Metro Station – EXPOFORUM	EXPOFORUM – Moskovskaya Metro Station	Moskovskaya Metro Station – EXPOFORUM	EXPOFORUM – Moskovskaya Metro Station	Moskovskaya Metro Station – EXPOFORUM	EXPOFORUM – Moskovskaya Metro Station
07.40	13.10	07.40	13.10	07.40	13.10	07.40	13.10
08.00	13.40	08.00	13.40	08.00	13.40	08.00	13.40
08.20	14.10	08.20	14.10	08.20	14.10	08.20	14.10
08.40	14.40	08.40	14.40	08.40	14.40	08.40	14.40
09.00	15.10	09.00	15.10	09.00	15.10	09.00	15.10
09.20	15.40	09.20	15.40	09.20	15.40	09.20	15.40
09.40	16.10	09.40	16.10	09.40	16.10	09.40	16.10
10.00	16.40	10.00	16.40	10.00	16.40	10.00	16.40
10.20	17.10	10.20	17.10	10.20	17.10	10.20	
10.40	17.40	10.40	17.40	10.40	17.40	10.40	
11.40	18.10	11.40	18.10	11.40	18.10	11.40	
12.40	18.40	12.40	18.40	12.40	18.40	12.40	
13.40	19.10	13.40	19.10	13.40	19.10	13.40	
14.20	19.40	14.20	19.30	14.20	19.40		
14.50	20.10	14.50	20.10	14.50	20.10		
15.20		15.20		15.20			
15.50		15.50		15.50			
16.20		16.20		16.20			

By bus from the hotels

- Please, check the bus timetable with the official Congress partner – Business Travel Service Holding “A&A” +7 (495) 921-22-19.

REGISTRATION

On-line registration of the participants at the official website of the Russian Society of Cardiology www.scardio.ru is possible up to October 15, 2017. After October 15 – on-site registration only.

Admittance to all sessions and the exhibition is free of charge, admittance by name badges that are issued to the registered participants only.

On-site Registration Timetable

24 October — 07.30–17.00

25 October — 08.00–17.00

26 October — 08.00–18.00

27 October — 08.00–13.30

Registration desks can be found at the Congress Centre, Passage.

All registered at the RSC website www.scardio.ru and all those who paid for the Congress materials can get a congress bag and a badge in the registration area.

CONGRESS MATERIALS:

From October 1, 2017 — 2,500 rubles (for RSC members – 2,000 rubles).

One can pay for the Congress materials (congress bag, book of scientific programme, abstract book, exhibition catalogue, participant's certificate) in the registration area on any day of the Congress.

Congress materials are free of charge for RSC Board members, all session chairs and Young Scientists Award winners.

All participants registered at www.scardio.ru can receive a name badge in the registration area.

ATTENTION! All Congress sessions and the exhibition are free to attend after the registration procedure. Registration is required of all participants. Each participant will receive a name badge, which will serve as a pass to all sessions and the exhibition.

The Russian National Congress of Cardiology 2017 is accredited in the system of CME by the Coordination Council for Development of Continuous Medical and Pharmaceutical Education of the Ministry of Health of the Russian Federation.

In addition, the Conference «Cardiology 2017: professional education, science and innovations» within the Russian National Congress of Cardiology has been granted 25 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).

The Conference «Cardiology 2017: professional education, science and innovations», Saint Petersburg, Russia, 24/10/2017–27/10/2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 25 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/go/internationalcme

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.

POSTERS

Posters are to be presented on October 24–26 in Passage (near the cloakroom) from 09.00 to 18.00. Moderators of the poster sessions will be selecting the best posters every day during the lunch breaks on October 24 from 12.30 to 13.00, October 25 and 26 from 12.30 to 13.30.

Poster presenters should place their posters in accordance with the number of presentations specified in the scientific program on the presentation day from 08:00 to 09:00.

The posters must not exceed the following dimensions: 90 cm (width), 120 cm (height).

The posters must be removed after 18:00 on the presentation day.

CONGRESS SESSIONS TIMETABLE

24 October: 09.00–16.45
 25 October: 09.00–17.00
 26 October: 09.00–19.00
 27 October: 09.00–15.00

Lecture halls are located on three floors of the Congress Centre:

- | | |
|---|--|
| <ul style="list-style-type: none"> ■ 1st floor Plenary Session Hall Hall 1 (E8-E9) Hall 2 (E7) Hall 3 (D1) Hall 4 (D2) Hall 5 (D3) Hall 6 (D4) | <ul style="list-style-type: none"> ■ 2st floor Hall 7 (B1) Hall 8 (B2) Hall 9 (B6-B8)
 ■ 3st floor Hall 10 (A1-A3) Hall 11 (A4-A5) |
|---|--|

EXHIBITION

Exhibition of medical, diagnostic and therapeutic equipment, modern information technology, and specialized medical publications will be presented daily in Passage and Zone E of the Congress Centre.

Exhibition plan and participants' information are indicated in the Exhibition Catalogue.

24 October — 08.00 – 16.30
 25 October — 08.00 – 17.00
 26 October — 08.00 – 19.00
 27 October — 08.00 – 15.00

OFFICIAL CONGRESS EVENTS

- 24 October, 17.00 – 19.00
Opening Ceremony
Awarding Ceremonies: Russian Society of Cardiology Awards and Young Scientists Awards
 Venue: Plenary Session Hall

- 25 October, 17.15 – 18.30
Russian Society of Cardiology Board Meeting
 Venue: Plenary Session Hall

INFORMATION FOR SPEAKERS

- **Presentation specifications:**
- file format .ppt or .pptx (MS Office 2003/2007/2010)

- Standard animation
- Multimedia files (audio and video) must be at the same folder with presentation file
- Acceptable formats for video files avi, mp4, wmv
- Maximum size for video file is 200 Mb, maximum video file resolution – 640x480 px. Higher resolution (full HD) is acceptable in accordance with advanced agreement.

EQUIPMENT AND WORK WITH PRESENTATIONS:

- All lecture halls are equipped with laptops connected to the projector and/or widescreen panels.
- Using speakers' equipment is not allowed.
- All the laptops are equipped with a presenter (the device to switch slides) which can be replaced by a presenter of the lecturer after the consultation with technical personnel.
- Internet access (for broadcasting, video conferences, etc.) using the presentation equipment is possible only after the consultation the technical personnel.
- Presentations must be downloaded in advance, in any case no later than 20 minutes before the session starts.
- Presentations must be given to the technical personnel in the lecture hall.
- Speakers are strictly forbidden to work independently with the presentation equipment.

SIMULTANEOUS TRANSLATION

The official language of the Congress is Russian. Simultaneous English-Russian translation will be provided during plenary sessions and symposia with participation of foreign speakers.

Please, do not use mobile phones during the Congress sessions!

PRESENTATIONS BY YOUNG SCIENTISTS AWARD WINNERS

will be held on October 24 in the Congress Hall #9 (B6-B8), 2nd floor, 09.00–10.30.

INTERNET

Free Wi-Fi Internet is provided on the territory of EXPOFORUM.


ORGANIZING COMMITTEE ROOM

Organizing Committee Room is located at the Exhibition Area (1st floor, zone E).


SMOKING

The Russian Society of Cardiology actively promotes healthy lifestyle and considers smoking to be a serious risk factor of cardiovascular diseases. The Organizing Committee strongly recommends to all participants to refrain from smoking at the time of the Congress.


ExpoForum Congress Centre. 1st Floor



ExpoForum Congress Centre. 2nd Floor



ExpoForum Congress Centre. 3rd Floor



	1 floor						2 floor			3 floor	
	PLENARY HALL	CONFERENCE HALL №1 (E8-E9)	CONFERENCE HALL №2 (E7)	CONFERENCE HALL №3 (D1)	CONFERENCE HALL №4 (D2)	CONFERENCE HALL №6 (D4)	CONFERENCE HALL №7 (B1)	CONFERENCE HALL №8 (B2)	CONFERENCE HALL №9 (B6-B8)	CONFERENCE HALL №10 (A1-A3)	CONFERENCE HALL №11 (A4-A5)
07:30	REGISTRATION (MAIN ENTRANCE)						REGISTRATION (MAIN ENTRANCE)				
09:00–10:30	PLENARY SESSION Acute cardiac care 2017 (Joint session with the Russian Society of Acute Cardiology) On-line broadcasting Simultaneous translation	SYMPOSIUM Innovations in cardiovascular risk reduction On-line broadcasting	SYMPOSIUM Atherosclerosis and rheumatoid arthritis: inflammation or dyslipidemia – what is more important?	SYMPOSIUM International epidemiological programs in Siberia, the region of high cardiovascular risk, and their significance for practical healthcare	RUSSIAN-CZECH SYMPOSIUM Hypertrophic cardiomyopathy: 2014 ESC guidelines afterword Simultaneous translation	SYMPOSIUM Amyloidosis with the heart involvement: time to write guidelines for cardiologists	SYMPOSIUM Development of information and educational environment in professional training of cardiologists	SYMPOSIUM Current imaging technologies and systolic heart failure	Presentations by winners of Young Scientists Award	SYMPOSIUM Dilated cardiomyopathy: surgery	SYMPOSIUM Cardiotoxicity. Prognosis and early detection
10:30–11:00	BREAK						BREAK				
11:00–12:30	SYMPOSIUM Synergism that prolongs life of a cardiovascular patient. Investigation of the year On-line broadcasting Simultaneous translation	SYMPOSIUM Unity of the three in AH treatment On-line broadcasting	SYMPOSIUM How to protect a patient's future here and now? On-line broadcasting		SYMPOSIUM Space Cardiology Odyssey of the 21st century On-line broadcasting		SYMPOSIUM of RSC Young Cardiologists WG Cardiovascular risk management		SYMPOSIUM Dyspnea in patients with cardiorespiratory comorbidity: differential diagnosis and treatment	SYMPOSIUM of RSC Young Cardiologists WG Original research and clinical practice. Focus on atrial fibrillation	SYMPOSIUM Diseases of primarily genetic origin: from phenomenon to the routine practice
12:30–13:00	BREAK						BREAK				
13:00–14:30	PLENARY SESSION Unsolved issues in arrhythmology On-line broadcasting Simultaneous translation	SYMPOSIUM Highlights of CAD and CHF in 2017: from registries, clinical studies and guidelines to the new system of CHF care					SYMPOSIUM Hypertrophic cardiomyopathy: the concept evolution		SCIENTIFIC SESSION Imaging in cardiology: ultrasound and tomography	SYMPOSIUM Place of obesity in the cardiovascular continuum of the 21st century: the sword of Damocles or two-faced Janus	SYMPOSIUM Compendium ↔ practicum: arterial hypertension
14:30–15:00	BREAK						BREAK				

	1 floor						2 floor			3 floor	
	PLENARY HALL	CONFERENCE HALL №1 (E8-E9)	CONFERENCE HALL №2 (E7)	CONFERENCE HALL №3 (D1)	CONFERENCE HALL №4 (D2)	CONFERENCE HALL №6 (D4)	CONFERENCE HALL №7 (B1)	CONFERENCE HALL №8 (B2)	CONFERENCE HALL №9 (B6-B8)	CONFERENCE HALL №10 (A1-A3)	CONFERENCE HALL №11 (A4-A5)
15:00-16:45	PLENARY SESSION Innovations in Cardiology 2017. Session 1 On-line broadcasting Simultaneous translation			SYMPOSIUM Cardiovascular health in the elderly	SYMPOSIUM Current lipid-lowering therapy. Principles of safety and benefit Simultaneous translation		SYMPOSIUM Arterial hypertension: view into the future		SCIENTIFIC SESSION Epidemiology, prevention and rehabilitation. Sports medicine	SYMPOSIUM Genetic aspects of cardiovascular diseases	SYMPOSIUM Iatrogenic reasons of cardiovascular pathology

17:00-19:00

OPENING CEREMONY

AWARDING CEREMONY:
 Young Scientists Awards
 RSC Prize 2017

WELCOME RECEPTION

PLENARY HALL

09.00–10.30

PLENARY SESSION

Acute cardiac care 2017

(Joint session with the Russian Society of Acute Cardiology)

*On-line broadcasting / Simultaneous translation*Chairpersons: **Ruda M.** (Moscow), **Achenbach S.** (Switzerland)

- **Averkov O.** (Moscow). Myocardial infarction – 2017.
- **Tereschenko S.** (Moscow). Acute heart failure – 2017.
- **Golitsyn S.** (Moscow). Arrhythmia – 2017.
- **Yavelov I.** (Moscow). Pulmonary embolism – 2017.

CONFERENCE HALL №1 (E8-E9, 1 floor)

09.00–10.30

SYMPOSIUM

Innovations in cardiovascular risk reduction

Chairperson:

Shlyakhto E. (Saint-Petersburg)

- **Shlyakhto E.** (Saint-Petersburg). Prevention of cardioembolic stroke in the Russian clinical practice: GLORIA – AF data.
- **Baranova E.** (Saint-Petersburg). A patient with AF and ACS. New options – the results of RE-DUAL PCI study.
- **Yanishevsky S.** (Saint-Petersburg). A patient with AF and comorbidity: from innovations to making clinical decision.
- **Kobalava Z.** (Moscow). Focus on cardioprotective benefits in treatment of patients with type II diabetes mellitus.

CONFERENCE HALL №2 (E7, 1 FLOOR)

09.00–10.30

SYMPOSIUM

Atherosclerosis and rheumatoid arthritis: inflammation or dyslipidemia – what is more important?

Chairpersons: **Karpov Yu.** (Moscow), **Nasonov E.** (Moscow)

- **Nasonov E., Popkova T.** (Moscow). Role of inflammation in cardiovascular pathology in rheumatic diseases.
- **Karpov Yu.** (Moscow). Role of dyslipidemia in cardiovascular complication of rheumatic diseases.
- **Popkova T., Novikova D., Udachkina E.** (Moscow). Cardiovascular risk reduction in patients with rheumatic diseases.
- **Fomicheva O., Krugly L., Karpov Yu., Gerasimova E.** (Moscow). Coronary artery disease in patients with rheumatoid arthritis: diagnosis and treatment options.
- **Sineglazova A.** (Chelyabinsk). Arterial hypertension in patients with rheumatoid arthritis: pathogenesis and therapy.
- **Krugly L., Fomicheva O., Ansheles A., Karpov Yu., Sergienko V.** (Moscow). Inflammatory and immunological parameters and atherosclerosis progression in various vascular pools in patients with rheumatoid arthritis

CONFERENCE HALL №3 (D1, 1 FLOOR)

09.00–10.30

SYMPOSIUM

International epidemiological programs in Siberia, the region of high cardiovascular risk, and their significance for practical healthcare

Chairpersons:

Voevoda M. (Novosibirsk),
Gafarov V. (Novosibirsk),
Malyutina S. (Novosibirsk)

- **Voevoda M., Maksimov V.** (Novosibirsk). MONICA WHO programme, HAPIEE programme: molecular epidemiology of cardiovascular diseases – results and prospects of genetic passports.
- **Malyutina S.** (Novosibirsk). MONICA WHO programme, HAPIEE programme: long-term dynamics of cardiovascular health and preventive strategies.
- **Gafarov V.** (Novosibirsk). MONICA WHO programme, HAPIEE programme: long-term dynamics of psycho-social health and cardiovascular risk – from epidemiology to population-based prevention.
- **Denisova D.** (Novosibirsk). Thirty-year trends (1985-2016) of cardiovascular risk factors in the young Siberian population: unprecedented dynamics and significance for prognosis.
- **Akimova E., Gakova E., Kayumova M.** (Tyumen), **Gafarov V.** (Novosibirsk), **Kuznetsov V.** (Tyumen). From childhood to middle age: long-term dynamics of behavioral, psycho-social risk factors of cardiovascular diseases, prognosis and approaches to population-based preventive strategies.
- **Osipova I., Repkina T., Pyrikova N., Dekhar V., Borisova L.** (Barnaul). Long-term epidemiologic studies of cardiovascular risk factors in different population groups of the Altai Territory as the basis for developing effective preventive programmes.

CONFERENCE HALL №4 (D2, 1 FLOOR)

09.00–10.30

RUSSIAN-CZECH SYMPOSIUM

Hypertrophic cardiomyopathy:
2014 ESC guidelines afterword

Simultaneous translation

Chairpersons: **Gordeev M.** (Saint-Petersburg),
Kostareva A. (Saint-Petersburg), **Veselka J.** (Czech Republic)

- **Komissarova S.** (Belarus). Clinical manifestations of hypertrophic cardiomyopathy in patients with different sarcomere gene mutations.
- **Kostareva A.** (Saint-Petersburg). Prevention of sudden death in cardiomyopathies: bridging the knowledge gaps.
- **Gordeev M.** (Saint-Petersburg). Septal myectomy: new approaches to hypertrophic cardiomyopathy surgery.
- **Veselka J.** (Czech Republic). Long-term clinical outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry.

CONFERENCE HALL №6 (D4, 1 FLOOR)

09.00–10.30

SYMPOSIUM

Amyloidosis with the heart involvement: time to write
guidelines for cardiologists

Chairpersons: **Moiseeva O.** (Saint-Petersburg), **Rameev V.** (Moscow)

- **Rameev V.** (Moscow). The draft of the first Russian guidelines on diagnosis and treatment of cardiac amyloidosis.
- **Merzhina E., Sinityn V.** (Moscow). MRI of the heart in differential diagnosis of infiltrative diseases and myocardial storage diseases.
- **Gudkova A., Semernin E., Krutikov A., Kostareva A., Moiseeva O.** (Saint-Petersburg), **Ryzkova D., Shavlovsky M.** (Moscow). Amyloid cardiomyopathies: “difficult and easy” diagnoses. Clinical observations.
- **Blagova O., Nedostup A., Sedov V., Gagarina N., Pasha S.P., Kogan E.** (Moscow). Clinical masks of amyloidosis with the heart involvement: current diagnostics.

CONFERENCE HALL №7 (B1, 2 FLOOR)

09.00–10.30

SYMPOSIUM

Development of information and educational environment in professional training of cardiologists

Chairpersons: **Sozinov A.** (Kazan), **Shlyk S.** (Rostov-on-Don)

- **Shlyk S.** (Rostov-on-Don). Development prospects and new formats of additional professional training for cardiologists.
- **Sozinov A.** (Kazan). Innovation technologies in medical education.
- **Nedogoda S.** (Volgograd). Internet technologies in the system of continuous medical education.
- **Kontsevaya A.** (Moscow). Professional societies in the system of continuous medical education: RSC experience.
- **Balkizov Z.** (Moscow). Current state of the system of continuous medical education.

CONFERENCE HALL №8 (B2, 2 FLOOR)

09.00–10.30

SYMPOSIUM

Current imaging technologies and systolic heart failure

Chairpersons: **Boschenko A.** (Tomsk), **Popov S.** (Tomsk), **Ryzhkova D.** (Saint-Petersburg)

- **Boschenko A., Pavlyukova E., Sokolov A., Ryabova T., Vrublevsky A.** (Tomsk). Ultrasound technologies and systolic heart failure: known achievements and new options.
- **Shelkovnikova T., Mochula O., Belokopytova N.** (Tomsk). Magnetic resonance imaging in heart failure: much information without radiation exposure.
- **Ryzhkova D.** (Saint-Petersburg). PET imaging in heart failure: state-of-the art and future prospects.
- **Zavadovsky K., Saushkina Y., Saushkin V., Krivonogov N., Lishmanov Yu.** (Tomsk). Radionuclide imaging: options and limitations in examination of patients with HF.
- **Ryabov V., Batalov R., Rogovskaya Y., Ryabova T., Rebenkova M., Kruchinkina E.** (Tomsk). Endomyocardial biopsy: visualization of systolic cardiac dysfunction etiology.

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

09.00–10.30

PRESENTATIONS BY WINNERS OF YOUNG SCIENTISTS AWARD

Jury: **Villevalde S.** (Moscow), **Grinshtein Yu.** (Krasnoyarsk), **Duplyakov D.** (Samara), **Kontsevaya A.** (Moscow), **Mayanskaya S.** (Kazan), **Melekhov A.** (Moscow), **Nikulina S.** (Krasnoyarsk), **Osipova I.** (Barnaul), **Sumin A.** (Kemerovo), **Khaisheva L.** (Rostov-on-Don)

- **Budanova M.** (Saint-Petersburg). Complex approach to differential diagnosis of wide QRS arrhythmias.
- **Gombozhapova A.** (Tomsk). Congenital immunity in post-infarction myocardial regeneration: from experiment to clinic.
- **Damrina E.** (Astrakhan). ICD out-patient management: in-clinic testing or remote monitoring?
- **Kuskaeva A.** (Krasnoyarsk). Role of renin-angiotensin-aldosterone system genes in atrial fibrillation.
- **Mochula O.** (Tomsk). Contrast enhanced MRI in myocardial injury diagnosis and prospective control in AH patients.
- **Panov D.** (Novosibirsk). 23-year dynamics of the attitude to one's health and to cardiovascular prevention in the open Russian/Siberian population of 25-44 aged females.
- **Prokopova L.** (Saint-Petersburg). A one-year survival prognosis in CHF with low LV ejection fraction: Assessable Prognosis Project.

CONFERENCE HALL №10 (A1-A3, 3 FLOOR)

09.00–10.30

SYMPOSIUM

Dilated cardiomyopathy: surgery

Chairperson: **Dzemeshkevich S.** (Moscow)

- **Dzemeshkevich S., Frolova Y.** (Moscow), **Motreva A.** (Astrakhan). Three decades with a transplanted heart.
- **Pya Yu.** (Kazakhstan). Artificial left ventricle for a long-term use – Heart Mate-3.
- **Lebedeva V.** (Saint-Petersburg). Resynchronization therapy in DCM.
- **Malikova M., Frolova Y., Babaev M.** (Moscow), **Tarasov D.** (Astrakhan). Organ-preserving reconstruction of the heart in DCM.
- **Shipulin V., Bobokin V.** (Tomsk). Surgery for complicated aneurysms of the left ventricle.

CONFERENCE HALL №11 (A4-A5, 3 FLOOR)

09.00–10.30

SYMPOSIUM**Cardiotoxicity. Prognosis and early detection**

Chairpersons: **Matskeplishvili S.** (Moscow), **Tereshina O.** (Samara)

- **Matskeplishvili S.** (Moscow). Cardiotoxicity of anticancer chemotherapy: prevention and treatment.
- **Tereshina O.** (Samara). Evaluation of cardiotoxic effect of chemotherapy on the heart. Stress-echocardiography to assess contractile reserve.
- **Medvedeva E.** (Saint-Petersburg). Biomarkers in the diagnosis of cardiotoxicity.

PLENARY HALL

11.00–12.30

SYMPOSIUM**Synergism that prolongs life of a cardiovascular patient.
Investigation of the year**

On-line broadcasting / Simultaneous translation

Chairperson: **Shlyakhto E.** (Saint-Petersburg)

- **Shlyakhto E.** (Saint-Petersburg). Classic detective story: what is common in the histories of our patients?
- **Kobalava Zh.** (Moscow). Arterial hypertension: a quiet killer. Find and neutralize.
- **Susekov A.** (Moscow). Atherosclerosis: a cunning pirate of hearts. Give no chance.
- **Drapkina O.** (Moscow). Synergism: lifesaving protection.
- **Mareev V.** (Moscow). Our patients' life prolongation is in our hands. The investigation is over.

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

11.00–12.30

SYMPOSIUM**Unity of the three in AH treatment**

On-line broadcasting

Chairperson: **Karpov Yu.** (Moscow)

- **Karpov Yu.** (Moscow). Arterial hypertension nowadays: epidemiology and current approaches to treatment. Place of the triple therapy.
- **Nedogoda S.** (Volgograd). The potential of Triplixam in the clinical practice.
- **Kobalava Z.** (Moscow). Triple combination – new horizons.

CONFERENCE HALL №2 (E7, 1 FLOOR)

11.00–12.30

SYMPOSIUM**How to protect a patient's future here and now?**

Chairpersons: **Ageev F.** (Moscow), **Ostroumova O.** (Moscow)

- **Ostroumova O.** (Moscow). What do the guidelines say? To whom, when and how much?
- **Nebieridze D.** (Moscow). Choosing an antihypertensive drug – are they all the same?
- **Ageev F.** (Moscow). A fixed combination as an effective tool of a modern doctor.

CONFERENCE HALL №4 (D2, 1 FLOOR)

11.00–12.30

SYMPOSIUM**Space Cardiology Odyssey of the 21st century**Chairpersons: **Ageev F.** (Moscow), **Napalkov D.** (Moscow)

- **Ageev F.** (Moscow). From molecule pharmacology to cardiovascular risk management.
- **Kobalava Z.** (Moscow). Vascular age management: what is new?
- **Napalkov D.** (Moscow). Real life, real patient.

CONFERENCE HALL №7 (B1, 2 FLOOR)

11.00–12.30

SYMPOSIUM**RSC Working Group of Young Cardiologists
Management of cardiovascular risks**Chairpersons: **Garkina S.** (Saint-Petersburg), **Kashtalap V.** (Kemerovo), **Chernova A.** (Krasnoyarsk), **Shepel R.** (Moscow)

- **Chernova A.** (Krasnoyarsk), **Shepel R.** (Moscow). Work results and prospects of development of the RSC Working Group of Young Cardiologists.
- **Garkina S.** (Saint-Petersburg), **Starodubtseva I.** (Voronezh). International educational programmes for young specialists. Interdisciplinary cooperation between different professional societies.
- **Grokhovaya V.** (Saint-Petersburg), **Skorodumova E.** (Saint-Petersburg). Open tribune: discussion of new projects and opportunities for young cardiologists.
- **Belan I.** (Krasnodar). Experience of emergency cardio-surgical care organization in the Krasnodar region. The role of a cardiologist.
- **Dadashova E.** (Moscow). Experience of work of the anticoagulant therapy office.
- **Cherepanova N.** (Samara). Out-patient Pulmonary Hypertension Centre in the Samara region.
- **Posnenkova O.** (Saratov). The role of long-term follow-up programmes in treating AH patients: current status and the real-life needs.
- **Galenko V.** (Saint-Petersburg). Out-patient management of CHF patients. Experience of CHF Scientific and Research Department.

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

11.00–12.30

SYMPOSIUM**Dyspnea in patients with cardiorespiratory comorbidity:
differential diagnosis and treatment**Chairpersons: **Zykov K.** (Moscow), **Lopatin Yu.** (Volograd)

- **Lopatin Yu.** (Volograd). Dyspnea = heart failure?
- **Zykov K.** (Moscow). Dyspnea = respiratory problem?
- **Berezina A., Kozlenok A.** (Saint-Petersburg). A patient with dyspnea. What is the problem?
- **Ratova L., Fedotov P.** (Saint-Petersburg). A patient with dyspnea. What is to be done?

CONFERENCE HALL №10 (A1-A3, 3 FLOOR)

11.00–12.30

Symposium of RSC Young Cardiologists WG**Original research and clinical practice.****Focus on atrial fibrillation**Chairpersons: **Korneluk O.** (Belarus), **Osadchy A.** (Saint-Petersburg), **Rubanenko A.** (Samara), **Rubanenko O.** (Samara)

- **Skirdenko Yu.** (Omsk). Anticoagulant therapy in patients with atrial fibrillation: new approaches to efficacy and safety.
- **Rubanenko A.** (Samara). Hemodynamic, hemostatic and genetic indicators associated with left atrial appendage thrombosis in patients with atrial fibrillation.
- **Efimova O.** (Samara). Secondary prevention of cardioembolic stroke in patients with atrial fibrillation: unsolved issues.
- **Osadchy A.** (Saint-Petersburg). Implantation of the left atrial appendage occluders in patients with a high risk of thromboembolic complications.
- **Rubanenko O.** (Samara). Oxidative stress, inflammation and myocardial dysfunction indicators associated with postoperative atrial fibrillation in the elderly patients.
- **Korneluk O.** (Belarus). Life quality assessment with WHOQOL-BREF questionnaire to reveal indications for repeated RF ablation of pulmonary veins.

CONFERENCE HALL №11 (A4-A5, 3 FLOOR)

11.00–12.30

SYMPOSIUM

Diseases of primarily genetic origin: from phenomenon to the routine practice

Chairpersons: Zaklyazminskaya E. (Moscow), Zateischikov D. (Moscow), Kostareva A. (Saint-Petersburg), Nikulina S. (Krasnoyarsk)

- **Chumakova O., Isaeva M., Nikitin A., Speshilov G., Zateischikov D.** (Moscow). Sudden cardiac death risk reduction in professional sports: the results of the first genetic study in Russia.
- **Zateischikov D.** (Moscow). Cardiac diseases of primarily genetic origin: screening in a cardiac hospital.
- **Kostareva A.** (Saint-Petersburg). New mutations in filamin C gene (FLNC) as a cause of restrictive cardiomyopathy.
- **Malashicheva A.** (Saint-Petersburg). Genetic and molecular mechanisms of Notch1 pathway dysfunction in patients with bicuspid aortic valve and aortic aneurysm.
- **Zaklyazminskaya E.** (Moscow). Will a genetic consultant help to avoid molecular autopsy?
- **Nikulina S., Chernova A.** (Krasnoyarsk). Russian-Italian laboratory of medical genetics. First steps.

PLENARY HALL

13.00–14.30

PLENARY SESSION

Unsolved issues in arrhythmology

On-line broadcasting / Simultaneous translation

Chairpersons:

Popov S. (Tomsk), **Revishvili A.** (Moscow), **Chudzik M.** (Poland)

- **Chudzik M.** (Poland). Why and how should we diagnose atrial fibrillation?
- **Golitsyn S.** (Moscow). Antiarrhythmic therapy sudden death prevention: from past hopes to current options.
- **Pinto F.** (Portugal). The new era of anticoagulation in atrial fibrillation: what do the ESC guidelines say?
- **Revishvili A.** (Moscow). Catheter ablation in atrial fibrillation: pros and cons.

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

13.00–14.30

SYMPOSIUM

Highlights of CAD and CHF in 2017: from registries, clinical studies and guidelines to the new system of CHF care

Chairpersons:

Tereschenko S. (Moscow), **Shalnova S.** (Moscow)

- **Shalnova S.** (Moscow). The biggest CAD registry CLARIFY: what have we learned?
- **Ageev F.** (Moscow). Stable angina treatment: clinical benefits of Ivabradine and Trimetazidine.
- **Tereschenko S.** (Moscow). The biggest CHF registry QUALIFY and the new system of CHF care.
- **Zhirov I.** (Moscow). Chronic heart failure: do new guidelines meet possibilities of clinical practice?

CONFERENCE HALL №7 (B1, 2 FLOOR)

13.00–14.30

SYMPOSIUM

Hypertrophic cardiomyopathy: the concept evolution

Chairpersons:

Krylova N. (Moscow), **Yakushin S.** (Ryazan)

- **Dzemeshevich S.** (Moscow). The morphology and function of the heart in HCM. Hypotheses and reality.
- **Krylova N.** (Moscow). Clinical portrait of a patient with HCM at different ages.
- **Zaklyazminskaya E.** (Moscow). HCM genetics: from academic interest to diagnostic practice.
- **Gordeev M.** (Moscow). Current surgical aspects in HCM.

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

13.00–14.30

SCIENTIFIC SESSION

Imaging in cardiology: ultrasound and tomography

Chairpersons: Duplyakov D. (Samara),
Zheleznyak I. (Saint-Petersburg), Nikiforov V. (Saint-Petersburg)

- **Ryumshina N., Pekarskaya S., Mordvin V., Lukyanenok P., Usov V.** (Tomsk). MRI of kidney cysts in patients with resistant AH. Effectiveness of renal denervation, two-year follow-up.
- **Veselova T., Barysheva R., Merkulova I., Mironov V., Ternovoi S.** (Moscow). Multislice spiral CT scan in ACS.
- **Tereshina O., Ryabova E., Usenko E.** (Samara). Global longitudinal peak strain assessment during dobutamine stress echocardiography to evaluate myocardial viability.
- **Khadzhieva D., Kulagina N., Sandrikov V., Ivanov V., Van E., Petrova Yu.** (Moscow). Left ventricular and left atrial biomechanics in patients with mitral valve insufficiency.
- **Rustamova Ya., Azizov V.** (Azerbaijan), **Maksimkin D., Faibushevich A.** (Moscow). MRI as compared to dobutamine stress echocardiography in hibernating myocardium assessment: two-centre randomized study.
- **Skripnik A., Mironchuk R., Fokin V., Trufanov G., Moiseeva O., Irtyuga O., Malev E., Murtazaliev P.** (Saint-Petersburg). CT angiography in aortic valve assessment in patients with aortic stenosis.

CONFERENCE HALL №10 (A1-A3, 3 FLOOR)

13.00–14.30

SYMPOSIUM

Place of obesity in the cardiovascular continuum of the 21st century: the sword of Damocles or two-faced Janus

Chairpersons: Drapkina O. (Moscow), Kuznetsova T. (Petrozavodsk),
Chumakova G. (Barnaul)

- **Drapkina O.** (Moscow). New cardiovascular risk factors associated with obesity.
- **Kuznetsova T., Druzhilov M.** (Petrozavodsk). From paradoxes to a paradigm or the evolution of ideas about the relationship between obesity and cardiovascular diseases.
- **Chumakova G.** (Barnaul). Metabolically healthy obesity: myth or reality.

CONFERENCE HALL №11 (A4-A5, 3 FLOOR)

13.00–14.30

SYMPOSIUM

Compendium ↔ practicum: arterial hypertension

Chairpersons: Galyavich A. (Kazan)

- **Galyavich A.** (Kazan). Compendium ↔ Practicum: etiopathogenesis.
- **Kamalov G.** (Kazan). Compendium ↔ Practicum: clinic, diagnostics.
- **Galeeva Z.** (Kazan). Compendium ↔ Practicum: treatment.
- **Baleyeva L.** (Kazan). Compendium ↔ Practicum: treatment.
- **Galyavich A.** (Kazan). Compendium ↔ Practicum: pick-up.

PLENARY HALL

15.00–16.45

PLENARY SESSION

Innovations in Cardiology 2017. Session 1

On-line broadcasting / Simultaneous translation

Chairpersons:
Shlyakhto E. (Saint-Petersburg), Pinto F. (Portugal)

- **Windecker S.** (Switzerland). Cardiovascular innovations in invasive cardiology of the 21st century.
- **Achenbach S.** (Germany). Bioresorbable vascular scaffolds – current status and recent data.
- **Ruschitzka F.** (Switzerland). The new ESC Heart Failure Guidelines.
- **Casadei B.** (Great Britain). What we need to think about when we think about atrial fibrillation.
- **Valentine M.** (USA). Leadership development skills for cardiologists – where do we start?

CONFERENCE HALL №3 (D1, 1 FLOOR)

15.00–16.30

SYMPOSIUM

Cardiovascular health in the elderly

Chairpersons: Boytsov S. (Moscow), Tkacheva O. (Moscow),

- **Shalnova S., Imayeva A.** (Moscow). Is it justified to increase the pension age limit in the Russian Federation from the viewpoint of population health?
- **Lazebnik L.** (Moscow). Comorbidity as the main health problem of the elderly population.
- **Tkacheva O.** (Moscow). Geriatric approaches to solving the problems in the elderly.
- **Kontsevaya A., Balanova Yu.** (Moscow). Is it justified to increase the pension age limit in the Russian Federation from the viewpoint of life quality and economic consequences?

CONFERENCE HALL №4 (D2, 1 FLOOR)

15.00–16.30

SYMPOSIUM

Current lipid-lowering therapy. Principles of safety and benefit

Simultaneous translation

Chairpersons: Kukharchuk V. (Moscow), Bubnova M. (Moscow)

- **Kukharchuk V.** (Moscow). Introduction.
- **Corsini A.** (Italy). European view on dyslipidemia correction. Basic points in the guidelines.
- **Sergienko I.** (Moscow). National guidelines on lipid-lowering therapy. Russian specificity.
- **Bubnova M.** (Moscow). Unsolved medical issues in the current lipid-lowering therapy.
- **Ezhov M.** (Moscow). Pitavastatin – its role in a lipid-lowering therapy: a patient's profile.
- Questions, discussion.

CONFERENCE HALL №7 (B1, 2 FLOOR)

15.00–16.30

SYMPOSIUM

Arterial hypertension: view into the future

Chairpersons:

Karpov R. (Tomsk), Konradi A. (Saint-Petersburg), Libis R. (Orenburg)

- **Konradi A.** (Saint-Petersburg). Antihypertensive medical treatment: new directions, new drugs.
- **Ripp T.** (Tomsk). Interventional approaches in hypertension. Organ protection effects today and in the future.
- **Zvartau N.** (Saint-Petersburg). Big data analysis and decision making support in hypertension treatment.
- **Kotovskaya Yu.** (Moscow). Management of hypertension in ageing population.

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

15.00–16.30

Scientific session

Epidemiology, prevention and rehabilitation. Sports medicine

Chairpersons:

Gafarov V. (Novosibirsk), Zemtsovsky E. (Saint-Petersburg)

- **Gafarov V., Gromova E., Panov D., Gafarova A., Gagulin I., Krymov E.** (Novosibirsk). Dynamics of awareness of cardiovascular risk factors and of the attitude of 25-44 year-old males in Russia/Siberia to cardiovascular prevention, to their health for the period of 28 years.
- **Gorbunova E., Kudryavtseva N., Salakhov R., Odarenko Yu., Mamchur S., Barbarash O.** (Kemerovo). Improvement of patient management after valvular defects surgery.
- **Kruchinova S., Kosmacheva E., Raff S.** (Krasnodar). Long-term outcomes of rehabilitation in ACS patients according to the total ACS registry in the Krasnodar region.

- **Raikh O., Sumin A., Indukaeva E., Artamonova G.** (Kemerovo). Psychosocial factors of cardiovascular risk according to ESSE study in the Kemerovo region.
- **Smirnova I., Tonkoshkurova A.** (Tomsk). A model of “ideal” cardiovascular health to define health groups and follow-up tactics in the working population.
- **Kaveshnikov V., Serebrennikova V., Trubacheva I.** (Tomsk), **Zhernakova Yu., Shalnova S.** (Moscow). Association of conventional risk factors with the probability of finding atherosclerotic plaques in carotid pool in an unorganized urban work-age population.
- **Bochkarev M., Korostovtseva L., Rotar O., Sviryaev Yu.** (Saint-Petersburg), **Zhernakova Yu., Shalnova S.** (Moscow), **Konradi A.** (Saint-petersburg), **Boytsov S., Chazova I.** (Moscow), **Shlyakhto E.** (Saint-Petersburg). Sleep-disordered breathing complains in the Russian regions and cardiovascular risk factors: ESSE-RF study.
- **Efimova L.** (Surgut). Personalized training of cardiovascular in-patients.
- **Evseyeva M., Eremin M., Koshel V., Baturin V., Schetin E.** (Stavropol). Connective tissue dysplasia and cardiovascular health screening in the youth.

CONFERENCE HALL №10 (A1-A3, 3 FLOOR)

15.00–16.30

SYMPOSIUM

Genetic aspects of cardiovascular diseases

Chairpersons:

Barbarash O. (Kemerovo), **Nikulina S.** (Krasnoyarsk), **Zateischikov D.A.** (Moscow)

- **Nikulina S., Chernova A., Kuskaeva A., Shturenkova Yu., Zotina E.** (Krasnoyarsk). Genes of the renin-angiotensin-aldosterone system in the atrial fibrillation genesis.
- **Aksutina N., Poplavskaya E., Krasulya I.** (Krasnoyarsk). rs2200733 polymorphism as a predictor of atrial fibrillation in patients without cardiovascular pathology.
- **Nikulina S., Chernova A.** (Krasnoyarsk). New genetic predictors of sick sinus syndrome.
- **Barbarash O., Kashtalap V.** (Kemerovo). Genetic markers of myocardial fibrosis in patients with CAD.
- **Lifshits G., Nikolaev K., Zelenskaya E., Tronin A.** (Novosibirsk). ACS outcomes in relation to coronary bed lesion severity and the patients' genetics.

CONFERENCE HALL №11 (A4-A5, 3 FLOOR)

15.00–16.30

SYMPOSIUM

Iatrogenic reasons of cardiovascular pathology

Chairpersons:

Fomin I. (Nizhny Novgorod), **Chesnikova A.** (Rostov-on-Don)

- **Tarlovskaya E.** (Nizhny Novgorod). Cardiovascular and non-cardiovascular side effects of antiarrhythmic drug.
- **Fomin I.** (Nizhny Novgorod). Possible iatrogenic causes of Takotsuba cardiomyopathy.
- **Koziova N.** (Perm). Antihyperglycemic drugs and risk of heart failure.
- **Chesnikova A.** (Rostov-on-Don). Cardiovascular pathology in iatrogenic thyrotoxicosis.

PLENARY HALL

17.00–19.00

OPENING CEREMONY

Simultaneous translation

- **Welcome greetings**
- **Opening lecture:**
Shlyakhto E. Cardiologist profession in a modern world: challenges and opportunities.
- **Awarding Ceremony:**
Young Scientists Awards
RSC Prize 2017

	1 floor					2 floor		3 floor		
	PLENARY HALL	CONFERENCE HALL №1 (E8-E9)	CONFERENCE HALL №2 (E7)	CONFERENCE HALL №3 (D1)	CONFERENCE HALL №4 (D2)	CONFERENCE HALL №5 (D3)	CONFERENCE HALL №7 (B1)	CONFERENCE HALL №9 (B6-B8)	CONFERENCE HALL №10 (A1-A3)	CONFERENCE HALL №11 (A4-A5)
09:00–10:30	PLENARY SESSION Why cannot we treat arterial hypertension effectively? On-line broadcasting Simultaneous translation	SYMPOSIUM Sleep and chronic heart failure (Joint session with the Lomonosov Moscow State University)	SYMPOSIUM Cardio-oncology: options and future prospects	SYMPOSIUM Hot topics in emergency cardiology	SCIENTIFIC SESSION Arrhythmias in heart failure patients – state-of-the art 2017 (Joint session with the European Heart Rhythm Society) Simultaneous translation			SYMPOSIUM Neuromodulation in cardiology	SYMPOSIUM New insights into cardiovascular disease in Russia. Early results of the international project IPCDR Simultaneous translation	SYMPOSIUM Modern megapolis – focus on centenarians' health
10:30–11:00	BREAK					BREAK				
11:00–12:30	SYMPOSIUM The problem of heart failure: it's time to settle bridges On-line broadcasting Simultaneous translation				SYMPOSIUM Life after ACS: focus on prevention of recurrent events	SYMPOSIUM Current issues in treatment of acute coronary syndrome		TRAINING SESSION FOR PRACTICING DOCTORS Introduction into transplant cardiology (Russian Transplantology Society)	JOINT RUSSIAN-TURKISH SYMPOSIUM Session 1 New methods of heart failure treatment and implementation of ESC guidelines Simultaneous translation	SYMPOSIUM Hemostasis and antiplatelet therapy in coronary heart disease. Do we know everything?
12:40–13:20	PLENARY LECTURE Catapano A. (Italy). PCSK9, LDL cholesterol and beyond. On-line broadcasting Simultaneous translation				PLENARY LECTURE Kedev S. (Macedonia). Minimalistic approach for transfemoral TAVI. On-line broadcasting Simultaneous translation					
12:30–13:30	BREAK					BREAK				

	1 floor					2 floor		3 floor		
	PLENARY HALL	CONFERENCE HALL №1 (E8-E9)	CONFERENCE HALL №2 (E7)	CONFERENCE HALL №3 (D1)	CONFERENCE HALL №4 (D2)	CONFERENCE HALL №6 (D4)	CONFERENCE HALL №7 (B1)	CONFERENCE HALL №9 (B6-B8)	CONFERENCE HALL №10 (A1-A3)	CONFERENCE HALL №11 (A4-A5)
13:30-15:00	PLENARY SESSION Russian and international guidelines on heart failure: similarities and differences On-line broadcasting Simultaneous translation	SYMPOSIUM Arterial hypertension in the elderly: pathogenesis, clinical manifestations and treatment On-line broadcasting	SYMPOSIUM AH combined therapy: simple choice and excellent results!	SYMPOSIUM Management of cardiovascular risk in patients with diabetes		SYMPOSIUM Cardiac transplantation and mechanical circulatory support: state-of-the-art		SYMPOSIUM Cardiomyopathy and multisystem hereditary diseases	JOINT RUSSIAN-TURKISH SYMPOSIUM Session 2. Anticoagulation approaches in patients with atrial fibrillation: from general recommendations to specific patient population Simultaneous translation	WORKING MEETING
15:00 - 15:30	BREAK									
15:30-17:00	PLENARY SESSION Heart failure: surgical strategies (Joint session with the Russian Association of Cardiovascular Surgeons and the Russian Transplantology Society) On-line broadcasting Simultaneous translation			DEBATES Pre-hospital care of ACS patients			SYMPOSIUM Current approaches to CAD risk stratification	SCIENTIFIC SESSION New approaches to choosing diagnostic criteria, treatment methods and prognosis evaluation in chronic heart failure	SYMPOSIUM “Zero and one” cardiology – how digital and telemedicine technologies will change the future? Simultaneous translation	SYMPOSIUM Antithrombotic therapy and bleeding: what a practicing doctor should know? (Joint session with the National Society for Atherothrombosis)
17:00-17:15	BREAK									

17:15-18:30

RUSSIAN SOCIETY OF CARDIOLOGY BOARD MEETING

PLENARY HALL

09.00–10.30

PLENARY SESSION

Why cannot we treat arterial hypertension effectively?

*On-line broadcasting / Simultaneous translation***Chairpersons:** Konradi A. (Saint-Petersburg), Libis R. (Orenburg)

- **Kobalava Z.** (Moscow). What do various guidelines say?
- **Nedogoda S.** (Volgograd). Do we intensify treatment in good time?
- **Omboni S.** (Italy), **Posokhov I.** (Nizhny Novgorod). 24-Hour monitoring of central blood pressure.
- **Baranova E.** (Saint-Petersburg). How does comorbidity affect the treatment?

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

09.00–10.30

SYMPOSIUM

Sleep and chronic heart failure

(Joint session with the Lomonosov Moscow State University)

Chairpersons: Kalinkin A. (Moscow), Matskeplischvili S. (Moscow), Svyryaev Yu. (Saint-Petersburg),

- **Matskeplischvili S.** (Moscow). What does a cardiologist need to know about sleep breathing disorders?
- **Medvedeva E.** (Saint-Petersburg). Sleep breathing disorders in patients with chronic heart failure.
- **Svyryaev Yu.** (Saint-Petersburg). Dynamics of sleep parameters in patients with chronic heart failure after heart transplantation.
- **Kalinkin A.** Cheyne-Stokes respiration and latent iron deficiency in patients with CHF – links of the same chain?

CONFERENCE HALL №2 (E7, 1 FLOOR)

09.00–10.30

SYMPOSIUM

Cardio-oncology: options and future prospects

Chairperson: Vasyuk U. (Moscow)

- **Vasyuk U.** (Moscow). Speckle tracking technology for early diagnosis, prognosis and treatment of cardiotoxicity of chemotherapy.
- **Mitkovskaya N.** (Belarus). A method of cardiotoxic effect prevention in complex treatment of breast cancer.
- **Emelina E.** (Moscow). Manifestations of cardiotoxicity in cancer patients.
- **Gendlin G.** (Moscow). Early and long-term cardiac consequences of radiation therapy.

CONFERENCE HALL №3 (D1, 1 FLOOR)

09.00–10.30

SYMPOSIUM

Hot topics in emergency cardiology

Chairpersons:

Barbarash O. (Kemerovo), Kosmacheva E. (Krasnodar).

- **Yakovlev A.** (Saint-Petersburg). Main errors in management of ACS patients having died on the first day of hospitalization.
- **Nemik D., Matiushin G., Ustyugov S., Protopopov A.** (Krasnoyarsk). Primary PCI and early pharmaco-invasive strategy in the elderly STEMI patients (clinical data).
- **Barbarash O., Fedorova N.** (Kemerovo). Difficulties in diagnosing ACS at prehospital and hospital stages.
- **Boldueva S.** (Saint-Petersburg). Myocardial infarction and non-obstructive lesions of coronary arteries.
- **Pevsner A.** (Moscow). Management of patients with syncope resulting from bradyarrhythmias. Role of electrocardiostimulation.
- **Shlevkov N.** (Moscow). Supraventricular and ventricular tachyarrhythmias as causes of syncope. Medication and surgery.

CONFERENCE HALL №4 (D2, 1 FLOOR)

09.00–10.30

Arrhythmias in heart failure patients – state-of-the art 2017 (Joint session with the European Heart Rhythm Association)

Simultaneous translation

Chairpersons:

Popov S. (Toms), **Merkely B.** (Hungary), **Romanov A.** (Novosibirsk)

- **Chudzik M.** (Poland). Pharmacological therapy in HF patients with atrial fibrillation.
- **Pokushalov E.** (Novosibirsk). Catheter ablation – when should it be the first approach in AF?
- **Duplyakov D.** (Samara). Antiarrhythmic treatment of ventricular arrhythmias in HF patients.
- **Merkely B.** (Hungary). Cardiac resynchronisation therapy and ICD for reducing arrhythmic death.
- **Peichl P.** (Czech Republic). Catheter ablation of PVC and VT/VF – when it prolongs life in heart failure patients?

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

09.00–10.30

SYMPOSIUM

Neuromodulation in cardiology

Chairpersons:

Tsyrlin V. (Saint-Petersburg), **Mikhailov E.** (Saint-Petersburg),
Pokushalov E. (Novosibirsk)

- **Tsyrlin V.** (Saint-Petersburg). Central regulation of the cardiovascular system: norm and pathology.
- **Zvartau N.** (Saint-Petersburg). Neuromodulation in AH treatment.
- **Mikhailov E.** (Saint-Petersburg). Neuromodulation in the complex treatment of heart failure and ventricular tachycardia.
- **Romanov A.** (Novosibirsk). Interventions on the autonomic nervous system for AF treatment.

CONFERENCE HALL №10 (A1-A3, 3 FLOOR)

09.00–10.30

SYMPOSIUM

New insights into cardiovascular disease in Russia. Early results of the international project IPCDR

Simultaneous translation

Chairpersons: **Boytssov S.** (Moscow), **Leon D.** (UK)

- **Leon D.** (UK). How comparable are data on CVD mortality?
- **Shkolnikov V.** (Germany). The recovery in Russian life expectancy and roles of the principal cause-of-death groups.
- **Drozdova L.** (Moscow). Secondary and primary prevention of CVD in the health system: primary care.
- **Kontsevaya A.** (Moscow). Secondary and primary prevention of CVD in the health system: MI study.
- **Timonin S.** (Moscow). Secondary and primary prevention of CVD in the health system: population access to PCI.
- **Leon D.** (UK). Is the CVD profile of the Russian population different to anywhere else? Design and early findings of Know Your Heart study.
- Discussion.

CONFERENCE HALL №11 (A4-A5, 3 FLOOR)

09.00–10.30

SYMPOSIUM

Modern megapolis – focus on centenarians' health

Chairpersons: **Tkacheva O.** (Moscow)

- **Tkacheva O.** (Moscow). Why and how do we age or biology of longevity?
- **Kotovskaya Yu.** (Moscow). Portrait of a city centenarian, results of the Moscow Centenarian Study.
- **Vorobjeva N.** (Moscow). Predictors of longevity, results of a 5-years prospective observation study.
- **Kashtanova D.** (Moscow). Gut microbiota and vascular ageing.
- **Orlova Ya.** (Moscow). Practical approaches to ageing prevention.

PLENARY HALL

11.00–12.30

SYMPOSIUM

The problem of heart failure: it's time to settle bridges

*On-line broadcasting / Simultaneous translation***Chairperson: Shlyakhto E.** (Saint-Petersburg)

- **Shlyakhto E.** (Saint-Petersburg). Epidemiology and heart failure in the Russian Federation.
- **Seferovic P.** (Serbia). The European approach to the problem of heart failure.
- **Lopatin Yu.** (Volgograd). The European view on the prevention of heart failure.
- **Konradi A.** (Saint-Petersburg). From hypertension to chronic heart failure: how to break the vicious circle?

CONFERENCE HALL №4 (D2, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Life after ACS: focus on prevention of recurrent events

Chairperson: Staroverov I. (Moscow)

- **Akhmedzhanov N.** (Moscow). Data of clinical practice in Russia.
- **Staroverov I.** (Moscow). Current guidelines on anti-platelet therapy in ACS patients.
- **Obrezan A.** (Saint-Petersburg). Case study of a patient with ACS and after it.

CONFERENCE HALL №5 (D3, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Current issues in treatment of acute coronary syndrome

Chairpersons: Yakushin S. (Ryazan), **Tereschenko S.** (Moscow)

- **Tereschenko S.** (Moscow). Pharmacoinvasive strategy in STEMI.
- **Markin S.** (Moscow). The results of FREEDOM 1 study. A single bolus of Fortelyzin®.
- **Yakushin S.** (Ryazan). Non-STEMI treatment. Focus on antiplatelet and anticoagulant therapy.
- **Khripun A.** (Rostov-on-Don). Registry of ACS patients in the Rostov Region. Results of the 8-year observation.

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

11.00–12.30

TRAINING SESSION FOR PRACTICING DOCTORS

Introduction into transplant cardiology
(Russian Transplantology Society)**Speakers: Gautier S.** (Moscow), **Shevchenko A.** (Moscow)

- Clinical transplantology and deceased organ donation in Russia and abroad. Legal and organizational aspects of cardiac transplantation.
- Critical heart failure: choosing a method of treatment. Management of patients on waiting list for heart transplantation.
- Heart transplantation and mechanical support of blood circulation in the treatment of patients with critical heart failure.
- Clinical protocols for long-term follow-up of heart recipients.
- Interactive knowledge control in Cardiac Transplantology

CONFERENCE HALL №10 (A1-A3, 3 FLOOR)

11.00–12.30

JOINT RUSSIAN-TURKISH SYMPOSIUM

Session 1

New methods of heart failure treatment and implementation of ESC guidelines

Simultaneous translation

Chairpersons: Duplyakov D. (Samara), Kozan Ö. (Turkey).

- **Atalar E.** (Turkey). International guidelines for treatment of coronary artery disease.
- **Zoghi M.** (Turkey). Any changes on chronic heart failure guidelines.
- **Demin A.** (Russia). Inflammatory heart diseases – 2017: guidelines update.
- **Lebedeva V.** (Russia). CRT devices for patients with heart failure.

CONFERENCE HALL №11 (A4-A)

11.00–12.30

SYMPOSIUM

Hemostasis and antiplatelet therapy in coronary heart disease. Do we know everything?

Chairpersons:

Grinshtein Yu. (Krasnoyarsk), Zateischikov D. (Moscow)

- **Barbarash O.** (Kemerovo). Disaggregants before coronary bypass grafting: pro and contra.
- **Grinshtein Yu.** (Krasnoyarsk). Insufficient response to antiplatelet drugs in coronary heart disease: possible causes, diagnosis, outcomes.
- **Vyshlov E.** (Tomsk). Antiplatelet therapy in coronary artery bypass grafting in patients with acute coronary syndrome.
- **Petrova M.** (Krasnoyarsk). Hemostasis dysregulation in patients with acute coronary syndrome and anxiety-depressive disorders.
- **Kosinova A.** (Krasnoyarsk). Genetic predictors of cardiovascular accidents after interventions on the coronary arteries.

PLENARY HALL

12.40–13.20

PLENARY LECTURE

On-line broadcasting / Simultaneous translation

Moderator: Ezhov M. (Moscow)

- **Catapano A.** (Italy). PCSK9, LDL cholesterol and beyond.

CONFERENCE HALL №4 (D2, 1 FLOOR)

12.40–13.20

LECTURE

Simultaneous translation

Moderator: Karpenko M. (Saint-Petersburg)

- **Kedev S.** (Macedonia). Minimalistic approach for transfemoral TAVI.

PLENARY HALL

13.30–15.00

PLENARY SESSION

Russian and international guidelines on heart failure: similarities and differences

On-line broadcasting / Simultaneous translation

Chairpersons: Belenkov Yu. (Moscow), Lopatin Yu. (Volgograd), Anker S. (Germany)

- **Anker S.** (Germany). The obesity paradox in heart failure – update 2017.
- **Fomin I.** (Nizhny Novgorod). Principles and structure of HF guidelines.
- **Ageev F.** (Moscow). HF diagnostics.
- **Mareev V.** (Moscow). HF pharmacotherapy.
- **Duplyakov D.** (Samara). Electrophysiological methods of HF treatment.

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

13.30–15.00

SYMPOSIUM

Arterial hypertension in the elderly: pathogenesis, clinical manifestations and treatment

On-line broadcasting

Chairpersons: Kobalava Z. (Moscow), Ostroumova O. (Moscow)

- **Baranova E.** (Saint-Petersburg). Pathogenesis of arterial hypertension in the elderly patients.
- **Ostroumova O.** (Moscow). Prevention of cerebrovascular complications in relation to the clinical specificities in arterial hypertension.
- **Kobalava Z.** (Moscow). AH treatment in the elderly patients – Arifam.

CONFERENCE HALL №2 (E7, 1 FLOOR)

13.30–15.00

SYMPOSIUM

AH combined therapy: simple choice and excellent results!

Chairpersons: Konradi A. (Saint-Petersburg), Arutyunov G. (Moscow)

- **Konradi A.** (Saint-Petersburg). Current view of a cardiologist on combined therapy of hypertension.
- **Arutyunov G.** (Moscow). Nephroprotection in patients with hypertension: new prospects and horizons.
- **Orlova Ya.** (Moscow). One step towards the goal: combined therapy of arterial hypertension.

CONFERENCE HALL №3 (D1, 1 FLOOR)

13.30–15.00

SYMPOSIUM

Management of cardiovascular risk in patients with diabetes

Chairperson: Khalimov Y. (Saint-Petersburg), Napalkov D. (Moscow)

- **Khalimov Y.** (Saint-Petersburg) New patterns of type 2 DM management: from glucocentric dogma to real organ protection.
- **Galstyan G.** (Moscow). EMPA-REG OUTCOME: two years later.
- **Napalkov D.** (Moscow). Atrial fibrillation and diabetes mellitus: a complicated clinical combination.

CONFERENCE HALL №6 (D4, 1 FLOOR)

13.30–15.00

SYMPOSIUM

Cardiac transplantation and mechanical circulatory support: state-of-the-art

Chairpersons: Gautier S. (Moscow), Karpenko M. (Saint-Petersburg), Shevchenko A. (Moscow)

- **Gautier S.** (Moscow). Experience of 800 heart transplantations at the Shumakov Research Center of Transplantology and Artificial Organs.
- **Karpenko M., Sitnikova M., Fedotov P.** (Saint-Petersburg). Enlarging the list of inclusion criteria for the heart transplantation waiting list: a personalized approach.
- **Chernyavskiy A., Doronin D.** (Novosibirsk). Clinical experience with the Russian implantable circulatory support device.
- **Shevchenko A.** (Moscow). How to improve the long-term prognosis in cardiac transplant recipients. Comorbidity in patients after transplantation.

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

13.30–15.00

SYMPOSIUM

Cardiomyopathy and multisystem hereditary diseases

Chairpersons:

Zaklyazminskaya E. (Moscow), **Kostareva A.** (Saint-Petersburg)

- **Kostareva A.** (Saint-Petersburg). Cardiomyopathies in neuromuscular diseases.
- **Rumyantseva V.** (Moscow). Dilated cardiomyopathy in patients with Marfan syndrome.
- **Zaklyazminskaya E.** (Moscow). Danon disease as a rare form of metabolic myocardial hypertrophy.
- **Kotlukova N.** (Moscow). Syndromic forms of myocardial hypertrophy: mutations in RAS cascade genes.

CONFERENCE HALL №10 (A1-A3, 3 FLOOR)

13.30–15.00

JOINT RUSSIAN-TURKISH SYMPOSIUM

Session 2

Anticoagulation approaches in patients with atrial fibrillation: from general recommendations to specific patient population

Simultaneous translation

Chairpersons: **Kozan Ö.** (Turkey), **Lebedev D.** (Saint-Petersburg)

- **Ertaş F.** (Turkey). Overview of non-valvular atrial fibrillation management: historical perspective.
- **Okuyan E.** (Turkey). From seminal studies to real world data for NOACs.
- **Vavilova T.** (Saint-Petersburg). Controlling direct oral anticoagulants effects: whether it is needed and how to do it.
- **Okuyan E.** (Turkey). Anticoagulation in patients undergoing cardiac surgery and percutaneous coronary intervention.
- **Mikhaylov E.** (Saint-Petersburg). What to do with patients who cannot take oral anticoagulants?

PLENARY HALL

15.30–17.00

PLENARY SESSION

Heart failure: surgical strategies (Joint session with the Russian Association of Cardiovascular Surgeons and the Russian Transplantology Society)

On-line broadcasting / Simultaneous translation

Chairpersons: **Barbarash O.** (Kemerovo), **Golukhova E.** (Moscow), **Gautier S.** (Moscow),

- **Shevchenko A.** (Moscow). Critical heart failure: management of patients on the heart transplant waiting list.
- **Gautier S.** (Moscow). Surgical aspects of critical heart failure treatment: results and future prospects.
- **Bokeria L.** (Moscow). Alternative methods of myocardial revascularization: what do we know and what do we aim at?
- **Gordeev M.** (Saint-Petersburg). Left ventricular reconstructive surgery: options and prognoses.
- **Alshibaya M.** (Moscow). Post-infarction myocardial rupture.
- Discussion.

CONFERENCE HALL №3 (D1, 1 FLOOR)

15.30–17.00

DEBATES

Pre-hospital care of ACS patients

Chairperson: **Ruda M.** (Moscow)

- Biochemical markers of myocardial necrosis in ACS patients should be determined at the pre-hospital period.
Repin A. (Tomsk). Pro.
Zateischikov D. (Moscow). Contra.
- ACS patients should receive antiplatelet therapy at the pre-hospital stage.
Shalaev S. (Tyumen). Pro.
Averkov O. (Moscow). Contra.

CONFERENCE HALL №7 (B1, 2 FLOOR)

15.30–17.00

SYMPOSIUM

Current approaches to CAD risk stratification

Chairpersons: **Gavrilova N.** (Moscow), **Shalnova S.** (Moscow)

- **Kontsevaya A.** (Moscow). Population approach to stratification and prognosis of cardiovascular risk.
- **Gavrilova N.** (Moscow). What is the benefit of biomarkers in individual CAD risk stratification?
- **Ezhov M.** (Moscow). Lipid markers of CAD risk stratification.
- **Duplyakov D.** (Samara). Risk stratification of acute CAD forms.

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

15.30–17.00

SCIENTIFIC SESSION

New approaches to choosing diagnostic criteria, treatment methods and prognosis evaluation in chronic heart failure

Chairpersons: **Rebrov A.** (Saratov), **Shlyk S.** (Rostov-on-Don)

- **Reznik E., Gendlin G., Komissarova M., Nikitin I.** (Moscow). Prognostic value of EchoCG in comorbid patients with chronic heart failure with reduced ejection fraction and chronic renal disease.
- **Shilov S., Popova A., Berezikova E., Teplyakov A., Grakova E., Neupokoeva M., Grebenkina I.** (Novosibirsk, Tomsk). Risk evaluation of cardiovascular complications in cancer patients receiving anthracycline therapy.
- **Kulikov A., Okovitiy S., Ivkin D., Karpov A., Smirnov A., Kayukov I., Lisitskiy D., Lyubishin M., Pitukhina N., Alekseeva P., Vaulina D.** (Saint-Petersburg). Inhibitor SGLT-2 empagliflozin for CHF treatment in patients without carbohydrate metabolism disorders (experimental study).
- **Lelyavina T., Sitnikova M., Galenko V., Kozlov P., Bortsova M., Urina S.** (Saint-Petersburg). Long-term aerobic training assist in physiological myocardial reverse remodeling in patients with chronic heart failure.

- **Simonenko M., Fedotov P., Sazonova Yu., Rubinchik V., Pervunina T., Krasnov V., Privorotsky V., Zverev D., Sitnikova M., Nikolaev G., Gordeev M., Karpenko M.** (Saint-Petersburg). Frequency of cardiovascular complications in patients after cardiac transplantation.
- **Solovieva A., Bayarsaikhan M., Villevalde S., Kobalava Z.** (Moscow). Hepatic density in fibroelastometry is associated with hyperhydration in patients with decompensated heart failure.
- **Liskova Yu., Stadnikov A., Salikova S., Tverdokhlib N., Rozhkov V., Erkhov A., Avchenko G.** (Orenburg, Saint-Petersburg). Significance of cardiac biomarkers in prognosis of cardiac surgery outcomes in patients with CHF.
- **Svarovskaya A., Teplyakov A., Lavrov A.** (Tomsk). Efficacy of endovascular myocardial revascularization in patients with IHD associated with type 2 diabetes mellitus and reduced left ventricular ejection fraction (5-year follow-up).
- **Berezin A., Kremzer A.** (Zaporozhie, Ukraine). Prognostic value of circulating endothelial progenitor cells with CD14+CD309+ and CD14+CD309+TIE2+ phenotypes in chronic heart failure.
- **Vlasov A., Salikova S., Grinevich V., Osipov G., Bystrova O., Zaplatina A.** (Saint-Petersburg, Moscow). Microbial markers of gram-negative bacteria in blood and functional status of patients with chronic heart failure decompensation.

CONFERENCE HALL №10 (A1-A3, 3 FLOOR)

15.30–17.00

SYMPOSIUM

“Zero and one” cardiology – how digital and telemedicine technologies will change the future?

Simultaneous translation

Chairpersons: **Kuznetsov V.** (Tyumen), **Matskeplishvili S.** (Moscow)

- **Matskeplishvili S.** (Moscow). Digital medicine 2017 – myths and reality.
- **Omboni S.** (Italy). Telemedicine and m-Health in hypertension management: current status and perspectives.
- **Yaroslavskaya E.** (Tyumen). Coronary angiography database for medical calculators of coronary atherosclerosis.
- **Dyachkov S.** (Tyumen). Clinical system of medical decision-making support in cardiology.
- **Bledzhyants G.** (Moscow). Automated system of pharmacological therapy control in cardiology.

CONFERENCE HALL №11 (A4-A5, 3 FLOOR)

15.30–17.00

SYMPOSIUM**Antithrombotic therapy and bleeding: what a practicing doctor should know?****(Joint session with the National Society for Atherothrombosis)**


Chairpersons:

Panchenko E. (Moscow), **Yavelov I.** (Moscow)

- **Komarov A.** (Moscow). How to assess different types of bleeding.
- **Panchenko E.** (Moscow). How to minimize the risk of bleeding.
- **Yavelov I.** (Moscow). How to resume antithrombotic treatment after the bleeding event.

PLENARY HALL

17.15–18.30

RUSSIAN SOCIETY OF CARDIOLOGY BOARD MEETING

	1 floor							2 floor			3 floor
	PLENARY HALL	CONFERENCE HALL №1 (E8-E9)	CONFERENCE HALL №2 (E7)	CONFERENCE HALL №3 (D1)	CONFERENCE HALL №4 (D2)	CONFERENCE HALL №5 (D3)	CONFERENCE HALL №6 (D4)	CONFERENCE HALL №7 (B1)	CONFERENCE HALL №8 (B2)	CONFERENCE HALL №9 (B6-B8)	CONFERENCE HALL №10 (A1-A3)
09:00-10:30	PLENARY SESSION Molecular cardiology: time to implement into practice On-line broadcasting Simultaneous translation	SYMPOSIUM New technologies for diagnosis and treatment of arterial hypertension	SYMPOSIUM To add years to life and to add life to years	SYMPOSIUM Acute heart failure: tracking clinical guidelines	SYMPOSIUM Sudden cardiac death. Rescue and prevention strategies Simultaneous translation	SYMPOSIUM Interactive quiz on cardiovascular imaging – Jeopardy	SYMPOSIUM Polypill in clinical practice: the missed opportunities	SYMPOSIUM Primary non-syndromic cardiomyopathies	SYMPOSIUM Electrophysiological approaches to CHF treatment	SCIENTIFIC SESSION Fundamental aspects of clinical medicine	WORKING MEETING Charter of cardiology journals
10:30-11:00	BREAK							BREAK			
11:00-12:30	PLENARY SESSION Radiology imaging and progress in cardiology On-line broadcasting Simultaneous translation	BATTLE OF SCHOLARS – 2017. FINAL COMPETITION	SYMPOSIUM New approaches to prevention of chronic heart failure decompensation	ROUND TABLE Hypertensive heart disease: yes or no?	SYMPOSIUM Sudden death in athletes: reality and future prospects		SYMPOSIUM Vascular age as an effective argument for a patient at the era of low adherence		SYMPOSIUM Assessment and correction of the cardiac complications risk in non-cardiac surgery	SCIENTIFIC SESSION Current tendencies in diagnosis and treatment of non-coronary diseases and congenital defects of the main arteries	Meeting of the Editorial Board of the Russian Journal of Cardiology
12:40-13:20	PLENARY LECTURE Asteggiano R. (Italy). Syncope: a common problem for all physicians – from guidelines to practice. On-line broadcasting / Simultaneous translation							PLENARY LECTURE Asteggiano R. (Italy). Syncope: a common problem for all physicians – from guidelines to practice. On-line broadcasting / Simultaneous translation			
12:30-13:30	BREAK							BREAK			
13:30-15:00	PLENARY SESSION Four questions to prevention On-line broadcasting Simultaneous translation	SYMPOSIUM Stable ischemic heart disease: hot topics of diagnosis and treatment	CLINICAL CASE Cardiac arrhythmias in a patient with coronary heart disease and comorbidity	SYMPOSIUM Diagnostic options in myocardial deformation assessment	SYMPOSIUM From obesity and diabetes to heart failure: a straight path or a winding road?	SYMPOSIUM Controversies and unsolved problems in the diagnosis and treatment of obstructive lesions of coronary arteries in stable coronary artery disease	SYMPOSIUM Multifactorial diseases: the role of genetics	SYMPOSIUM Cerebrovascular complications in patients with obesity		SCIENTIFIC SESSION Non-drug treatment of arterial hypertension	SYMPOSIUM Cardiovascular diseases and pregnancy
15:00 - 15:30	BREAK							BREAK			

	1 floor							2 floor			3 floor
	PLENARY HALL	CONFERENCE HALL №1 (E8-E9)	CONFERENCE HALL №2 (E7)	CONFERENCE HALL №3 (D1)	CONFERENCE HALL №4 (D2)	CONFERENCE HALL №5 (D3)	CONFERENCE HALL №6 (D4)	CONFERENCE HALL №7 (B1)	CONFERENCE HALL №8 (B2)	CONFERENCE HALL №9 (B6-B8)	CONFERENCE HALL №10 (A1-A3)
15:30-17:00	PLENARY SESSION Myocarditis: from pathogenesis to diagnosis and treatment On-line broadcasting Simultaneous translation	SCIENTIFIC SESSION Current strategies of cardiovascular disease prevention: concept of cardiovascular and psychosocial risk factors	SYMPOSIUM New concepts of blood vessels assessment in patients with AH and CAD and their effect on outcomes improvement	SYMPOSIUM Rare and difficult diagnoses in cardiology	SCIENTIFIC SESSION What is new in cardiorheumatology?	SYMPOSIUM Results of regional ACS registries	SYMPOSIUM Atherosclerosis and hypercholesterolemia. New genetic, etiopathogenetic markers and approaches to therapy	TRAINING SEMINAR An obese patient seeing a cardiologist	JOINT SCIENTIFIC SESSION with the Physiology Section of the Russian Academy of Science	SCIENTIFIC SESSION Arrhythmias and heart failure: electrophysiological approaches	WORKING MEETING ICD and ACS Registries Young Cardiologists WG Meeting
17:00 - 17:30	ПЕРЕРЫВ							ПЕРЕРЫВ			
17:30-19:00	PLENARY LECTURES Hendel R. (USA). Assessment of coronary physiology: impact on clinical decision-making. Beleslin B. (Serbia). Invasive coronary physiology: master mind algorithm for evaluation of coronary artery disease. Simultaneous translation	CLINICAL CASE A difficult obese patient	SCIENTIFIC SESSION Diagnosis and treatment of sleep disordered breathing: from new concepts to practical solutions	SYMPOSIUM About 1,000,000 people in Russia are affected by familial hypercholesterolemia. How to find and save these patients?	SYMPOSIUM Syncope – from guidelines to everyday practice	SYMPOSIUM Cardiac arrhythmias in young adults: causes and consequences	SYMPOSIUM Pulmonary embolism – 2017	SYMPOSIUM Complicated issues in comorbid patients with CAD	SYMPOSIUM Hot topics in cardiovascular imaging	SCIENTIFIC SESSION CAD, lipids and atherosclerosis: results of epidemiological and genetic studies	DEBATES Ischemic cardiomyopathy and CHF: pro and contra

PLENARY HALL

09.00–10.30

PLENARY SESSION

Molecular cardiology: time to implement into practice

On-line broadcasting / Simultaneous translation

Chairpersons: Voevoda M. (Novosibirsk), Galagudza M. (Saint-Petersburg), Arad M. (Israel), Ferrari R. (Italy)

- **Arad M.** (Israel). Amyloidosis: from molecular and genetic defects to clinical manifestations.
- **Zateishikov D.** (Moscow). Current approaches to diagnosis of diseases of predominantly genetic origin: role of molecular-genetic testing.
- **Ferrari R.** (Italy). Ischaemic and reperfusion damage: a metabolic approach.
- **Kurochkin I.** (Moscow). Current molecular diagnostic methods in cardiology.

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

09.00–10.30

SYMPOSIUM

New technologies for diagnosis and treatment of arterial hypertension

Chairpersons: Karpov R. (Tomsk), Popov S. (Tomsk)

- **Boschenko A., Koshelskaya O., Zhuravleva O.** (Tomsk). Is evaluation of coronary artery function in AH necessary?
- **Mordovin V., Pekarsky S., Ripp T., Falkovskaya A., Sitkova E., Usov V.** (Tomsk). Current diagnostic techniques for the heart condition and its dynamics resulting from treatment in patients with resistant hypertension.
- **Zavadovsky K., Efimova N., Vesnina Z., Efimova I., Lishmanov Yu.** (Tomsk). Scintigraphic aspects of target organ damage imaging in hypertension.
- **Ripp T., Mordovin V., Pekarskiy S., Semke G., Falkovskaya A., Lichikaki V., Popov S.** (Tomsk). Current techniques of diagnosis and treatment of vascular reactivity disorders in hypertension.

- **Falkovskaya A., Mordovin V., Pekarskiy S., Semke G., Ripp T., Baev A., Gusakova A., Sukhareva A.** (Tomsk). A hypertensive patient with type 2 diabetes mellitus: new diagnostic and therapeutic approaches in the era of "modern technologies".
- **Pekarskiy S., Mordovin V., Baev A., Ripp T., Semke G., Falkovskaya A., Sitkova E., Lichikaki V., Zyubanova I., Popov S.** (Tomsk). Role of endovascular renal denervation in hypertension therapy.

CONFERENCE HALL №2 (E7, 1 FLOOR)

09.00–10.30

SYMPOSIUM

To add years to life and to add life to years

Chairperson: Tkacheva O. (Moscow)

- **Tkacheva O.** (Moscow). Geriatric approach: what, when and for whom?
- **Runikhina N.** (Moscow). A geriatrician and a cardiologist – a team that prolongs life and improves its quality.
- **Kotovskaya Yu.** (Moscow). Cardiovascular ageing – from stiffness to fragility.
- **Duplyakov D.** (Samara). Acute coronary syndrome in patients aged 80 years and more.

CONFERENCE HALL №3 (D1, 1 FLOOR)

09.00–10.30

SYMPOSIUM

Acute heart failure: tracking clinical guidelines

Chairpersons: Bagnenko S. (Saint-Petersburg), Tereschenko S. (Moscow)

- **Zhirov I.** (Moscow). Acute heart failure – state-of-the-art.
- **Bagnenko S., Teplov V.** (Saint-Petersburg). Acute heart failure at a prehospital and hospital stages.
- **Smirnov A.** (Saint-Petersburg). Predictive diagnosis of acute cardio-renal syndrome in patients with AHF: nephrologist perspective.
- **Nasonova S.** (Moscow). Clinical case of a patient with acute heart failure.

CONFERENCE HALL №4 (D2, 1 FLOOR)

09.00–10.30

SYMPOSIUM

Sudden cardiac death. Rescue and prevention strategies

Simultaneous translation

Chairpersons: Boytsov S. (Moscow). Umans V. (Netherlands)

- **Linchak R.** (Moscow). Epidemiology of sudden cardiac death in Russia. GERMINA registry data.
- **Boytsov S.** (Moscow). Primary SCD prevention in high-risk populations.
- **Umans V.** (Netherlands). Management of out-hospital cardiac arrest in patients with STEMI and the role of the civil program of automatic external defibrillators.
- **Revishvili A.** (Moscow). Priorities of secondary SCD prevention. Role of interventional procedures.

CONFERENCE HALL №5 (D3, 1 FLOOR)

09.00–10.30

SYMPOSIUM

Interactive quiz on cardiovascular imaging – Jeopardy

Chairperson: Matskeplishvili S. (Moscow)

- **Matskeplishvili S.** (Moscow). Interactive quiz on cardiovascular imaging – Jeopardy.

CONFERENCE HALL №6 (D4, 1 FLOOR)

09.00–10.30

SYMPOSIUM

Polypill in clinical practice: the missed opportunities

Chairpersons:

Lopatin Yu. (Volgograd), **Nedoshivin A.** (Saint-Petersburg)

- **Nedoshivin A.** (Saint-Petersburg). Concept of Polypill in cardiology.
- **Arutyunov G.** (Moscow). Undisputed questions in Polypill administration.
- **Lopatin Yu.** (Volgograd). Controversial issues in Polypill administration.
- **Nedogoda S.** (Volgograd). Polypill as a key to solving the problem of comorbidity.

CONFERENCE HALL №7 (B1, 2 FLOOR)

09.00–10.30

SYMPOSIUM

Primary non-syndromic cardiomyopathies

Chairperson: Zaklyazminskaya E. (Moscow)

- **Myasnikov R.** (Moscow). Registry of patients with noncompaction cardiomyopathy: the results of a complex clinical, instrumental and genetic investigation.
- **Zaklyazminskaya E.** (Moscow). Clinical and genetic polymorphism of left ventricular noncompaction.
- **Parmon E.** (Saint-Petersburg). Arrhythmogenic right ventricular cardiomyopathy: diagnosis and treatment.
- **Shestak A.** (Moscow). New genetic technologies in diagnosis of arrhythmogenic right ventricular cardiomyopathy.
- **Komissarova S.** (Belarus). A frequent Slavic mutation in MyBPC3 gene as a cause of hypertrophic cardiomyopathy.
- **Bukaeva A.** (Moscow). The case of molecular autopsy: one answer and many questions.

CONFERENCE HALL №8 (B2, 2 FLOOR)

09.00–10.30

SYMPOSIUM

Electrophysiological approaches to CHF treatment

Chairpersons:

Lebedev D. (Saint-Petersburg), **Sitnikova M.** (Saint-Petersburg)

- **Sitnikova M.** (Saint-Petersburg). Current approaches to HF therapy. Benefits and limitations of the existing methods of treatment.
- **Lebedeva V.** (Saint-Petersburg). Implantable devices for CHF electrotherapy.
- **Tatarsky R.** (Saint-Petersburg). Catheter ablation of tachyarrhythmias in patients with CHF.
- **Mikhailov E.** (Saint-Petersburg). Neuromodulation in CHF.

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

09.00–10.30

SCIENTIFIC SESSION

Fundamental aspects of clinical medicine

Chairpersons:

Kostareva A. (Saint-Petersburg), **Parfenova E.** (Moscow)

- **Beloglazova I., Zubkova E., Dergilev K., Ratner E., Molokotina Yu., Dyikanov D., Parfenova E.** (Moscow). Role of urokinase system in developing vasculature by endothelial cells in contact with mesenchymal cells.
- **Shakhtshneider E., Ivanoschuk D., Orlov P., Maksimov V., Malyutina S., Gafarov V., Voevoda M.** (Novosibirsk). Panel of genetic markers to assess the risk of long-term negative cardiovascular prognosis.
- **Tsokolaeva Z., Dergilev K., Kanevskaya D., Beloglazova I., Zubkova E., Boldyreva M., Menshikov M., Makarevich P., Parfenova E.** (Moscow). Role of Notch signaling pathway in regulation of cardiac progenitor cells characteristics.
- **Khokhlova A.** (Ekaterinburg), **Iribe G.** (Japan), **Solovieva O.** (Ekaterinburg). Transmural specificities of cardiomyocytes contractile function abnormality in experimentally modeled myocardial ischemia.

- **Liskova Yu., Stadnikov A.** (Orenburg), **Salikova S.** (Saint-Petersburg). Clinical value of functional morphology mutation of myocardial telocytes in patients with chronic heart failure.
- **Scherbakova N., Ershova A., Zharikova A., Kiseleva A., Shalnova S., Boytsov S., Meshkov A.** (Moscow). Molecular-genetic analysis of lipid profile in patients with confirmed familial hypercholesterolemia (ESSE-RF sub-study data).
- **Balatsky A., Tkachuk V.** (Moscow). Specific cell structure of typical sites of atherosclerosis development.

PLENARY HALL

11.00–12.30

PLENARY SESSION

Radiology imaging and progress in cardiology

On-line broadcasting / Simultaneous translation

Chairpersons: **Vasyuk Yu.** (Moscow), **Golukhova E.** (Moscow), **Kuznetsov V.** (Tyumen), **Matskeplishvili S.** (Moscow), **Ternovoy S.** (Moscow)

- **Alekhin M.N.** (Moscow), **Vasyuk Yu.A.** (Moscow), **Golukhova E.Z.** (Moscow), **Kuznetsov V.A.** (Tyumen), **Matskeplishvili S.T.** (Moscow), **Saidova M.A.** (Moscow), **Sedov V.P.** (Moscow), **Mashina T.V.** (Moscow), **Meikaev D.V.** (Moscow). Echocardiography: history, present experience and future prospects.
- **Ternovoy S.K.** (Moscow), **Veselova T.N.** (Moscow), **Basek I.V.** (Saint-Petersburg). CT in a cardiology clinic: advances and prospects.
- **Trufanov G.E.** (Saint-Petersburg), **Fokin V.A.** (Saint-Petersburg), **Stukalova O.V.** (Moscow), **Ryzhkov A.V.** (Saint-Petersburg). Cardiac MRI: why and when?
- **Zavadovsky K.V.** (Tomsk), **Aslanidi I.P.** (Moscow), **Ryzhkova D.V.** (Saint-Petersburg). Current radionuclide methods in cardiology.

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

11.00–12.30

BATTLE OF SCHOLARS – 2017. FINAL COMPETITION

Jury:

Gilyarevsky S. (Moscow), **Gavrilova N.** (Moscow),
Drozdova L. (Moscow), **Duplyakov D.** (Samara),
Kontsevaya A. (Moscow), **Napalkov D.** (Moscow),
Nikulina S. (Krasnoyarsk), **Tatarsky R.** (Saint-Petersburg)

Finalists:

- Lege Cordis (Astrakhan)
- QUINTESSENCE (Krasnoyarsk)
- Heart of Samara (Samara)

CONFERENCE HALL №2 (E7, 1 FLOOR)

11.00–12.30

SYMPOSIUM

New approaches to prevention of chronic heart failure decompensation

Chairpersons:

Begrambekova Yu. (Moscow), **Fomin I.** (Nizhny Novgorod)

- **Fomin I.** (Nizhny Novgorod). Heart failure clinics as a new model of CHF management in Russia.
- **Orlova Ya.** (Moscow). Rehabilitation of the elderly patients with CHF.
- **Begrambekova Yu.** (Moscow). Guidelines of the Russian Society of Heart Failure Specialists on exercise training in patients with heart failure.

CONFERENCE HALL №3 (D1, 1 FLOOR)

11.00–12.30

ROUND TABLE

Hypertensive heart disease: yes or no?

Chairpersons: **Stryuk R.** (Moscow), **Yakushin S.** (Ryazan)

- **Stryuk R.** (Moscow). Hypertension and pregnancy: who suffers more: a mother or a fetus?
- **Nebieridze D.** (Moscow). Hot issues in detection of target organ damage in hypertension: focus on left ventricle hypertrophy.
- **Yakushin S.** (Ryazan). Hypertensive heart disease: pros.
- **Filippov E.** (Ryazan). Hypertensive heart disease: contras.
- Discussion: **Nebieridze D.** (Moscow), **Yakushin S.** (Ryazan), **Filippov E.** (Ryazan).

CONFERENCE HALL №4 (D2, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Sudden death in athletes: reality and future prospects

Chairpersons:

Bondarev S. (Saint-Petersburg), **Mikhailova A.** (Moscow),
Smolensky A. (Moscow)

- **Smolensky A.** (Moscow). Electrical instability of myocardium and sudden death in the sports.
- **Gurevich T.** (Saint-Petersburg). Clinical case of sudden death in a young athlete with connective tissue heart dysplasia.
- **Bagmanova Z.** (Ufa). Non-invasive diagnosis of right ventricle arrhythmogenic cardiomyopathy and coronary artery abnormalities in young athletes.
- **Bondarev S.** (Saint-Petersburg). Atrial fibrillation in sportsmen: causes, consequences and prevention.
- **Mikhailova A.** (Moscow). Overtraining of the cardiovascular system in athletes as a borderline state in sports cardiology.

CONFERENCE HALL №6 (D4, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Vascular age as an effective argument for a patient at the era of low adherence

Chairpersons: Karpov Yu. (Moscow), Nedogoda S. (Volgograd)

- **Karpov Yu.** (Moscow). How to find an argument for a young and an old patient?
- **Nedogoda S.** (Volgograd). How to find an argument for a slim and a fat patient?
- **Rotar O.** (Saint-Petersburg). How to find an argument for a male and female patient?

CONFERENCE HALL №8 (B2, 2 FLOOR)

11.00–12.30

SYMPOSIUM

Assessment and correction of cardiac complications risk in non-cardiac surgery

Chairpersons:

Belyalov F. (Irkutsk), Duplyakov D. (Samara), Sumin A. (Kemerovo)

- **Sumin A.** (Kemerovo). Current algorithms of risk assessment in non-cardiac surgery.
- **Duplyakov D.** (Samara). Non-cardiac surgery after coronary stenting.
- **Belyalov F.** (Irkutsk). Clinical scales in assessing the risk of non-cardiac surgery.
- **Korok E.** (Kemerovo). Routine coronary angiography and preventive myocardial revascularization: any need in non-cardiac surgery?
- **Medvedeva E.** (Saint-Petersburg). Pharmacological strategies of risk reduction in non-cardiac surgery.

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

11.00–12.30

SCIENTIFIC SESSION

Current tendencies in diagnosis and treatment of non-coronary diseases and congenital defects of the main arteries

Chairpersons: Gendlin G. (Moscow), Karpov R. (Tomsk)

- **Moiseev S., Novikov P., Sinitsyn V., Mershina E., Moiseev A., Fomin V.** (Moscow). Heart in the Fabry disease.
- **Pavlyukova E., Evtushenko A., Kanev A., Smyshlyaev K., Karpov R.** (Tomsk). Mitral valve dysfunction in hypertrophic obstructive cardiomyopathy.
- **Polyakova A., Gudkova A., Semerni E., Krutikov A., Davydov V., Klenina I., Pyko S., Kostareva A., Shlaykhto E.** (Saint-Petersburg). Contribution of obesity and polymorphic variants of madd modifying gene into myocardial remodeling in the elderly patients with hypertrophic cardiomyopathy.
- **Namitokov A., Kosmacheva E.** (Krasnodar). Coronary artery abnormalities.
- **Bykov A., Arkhipov M., Iofin A.** (Ekaterinburg). Medication and surgery strategies in patients with left main coronary artery compression by enlarged pulmonary trunk in idiopathic pulmonary arterial hypertension.
- **rtyuga O., Scherbavichute M., Malko V., Kruk L., Murtazalieva P., Zhiduleva E., Sibagatullina Yu., Malev E., Moiseeva O.** (Saint-Petersburg). Clinical and instrumental aspects of aortal stenosis, results of the Almazov Centre registry.

PLENARY HALL

12.40–13.20

PLENARY LECTURE

On-line broadcasting / Simultaneous translation

Moderator: Turina T. (Saint-Petersburg)

- **Asteggiano R.** (Italy). Syncope: a common problem for all physicians – from guidelines to practice.

PLENARY HALL

13.30–15.00

PLENARY SESSION

Four questions to prevention

On-line broadcasting / Simultaneous translation

Chairpersons: Drapkina O. (Moscow), **Shalnova S.** (Moscow)

- **Tkacheva O.** (Moscow). Long-living: is it genetics or healthy lifestyle?
- **Boytsov S.** (Moscow). Genetics proposes, epigenetics disposes?
- **Parfenova E.** (Moscow). Functional state of stem cells as a risk factor and a possible target in secondary prevention of cardiovascular complications.
- **Kashtanova D.** (Moscow). What is more important in prevention – organism or microbiom?

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

13.30–15.00

SYMPOSIUM

Stable ischemic heart disease: hot topics of diagnosis and treatment

Chairpersons: Karpov Yu. (Moscow), **Mirolyubova O.** (Arkhangelsk)

- **Karpov Yu., Sorokin E.** (Moscow). Stable IHD as a global problem in contemporary medicine.
- **Mironov V.** (Moscow). Endovascular diagnostics in stable IHD: old and new.
- **Kozlov S.** (Moscow). Treatment of stable IHD in patients with type 2 diabetes.
- **Ageev F., Matchin Yu., Basinkevich A.** (Moscow). One-day hospitalization for PCI in patients with stable IHD. Necessary? Safe? Effective?
- **Komarov A., Sorokin E.** (Moscow). Antithrombotic drugs in stable IHD: One? Two? Three?

CONFERENCE HALL №2 (E7, 1 FLOOR)

13.30–15.00

CLINICAL CASE

Cardiac arrhythmias in a patient with coronary heart disease and comorbidity

Chairpersons:**Gromyko G.** (Moscow), **Kakorin S.** (Moscow), **Novikova N.** (Moscow), **Pervova E.** (Saint-Petersburg), **Tavluva E.** (Kemerovo)

- **Kakorin S.** (Moscow). A complicated clinical situation: cardiac arrhythmia in a patient with coronary artery disease and comorbidity.
- **Pervova E.** (Saint-Petersburg). Diagnostics of cardiac arrhythmias. Controversies and difficulties with body-surface ECG registration methods.
- **Tavluva E.** (Kemerovo). Clinical guidelines on treatment of supraventricular arrhythmias in comorbid patients.
- **Gromyko G.** (Moscow). Coronary ventricular arrhythmias: a prognostic factor or a clinical symptom?
- **Novikova N.** (Moscow). Controversies in antiarrhythmic and anticoagulation therapy in patients with atrial fibrillation and coronary artery disease.

CONFERENCE HALL №3 (D1, 1 FLOOR)

13.30–15.00

SYMPOSIUM

Diagnostic options in myocardial deformation assessment

Chairpersons: Alekhin M. (Moscow), Vasyuk Yu. (Moscow), Oleynikov V. (Penza)

- **Alekhin M.** (Moscow). Echocardiography for assessment of myocardial systolic deformation in non-coronary cardiac diseases.
- **Oleynikov V., Galinskaya V., Romanovskaya E., Melnikova E.** (Penza). Can myocardial deformation study change our understanding of post-myocardial remodeling?
- **Kalinin A.** (Latvia). Left atrial deformation in clinical practice.
- **Chumakova O.** (Moscow). Imaging in differential diagnosis of the hypertensive heart disease and hypertrophic cardiomyopathy.
- **Karev E., Verbilo S., Prokudina M., Kozlenok A.** (Saint-Petersburg). Myocardial deformation in physical exercise: new insight in stress-echocardiography.

CONFERENCE HALL №4 (D2, 1 FLOOR)

13.30–15.00

SYMPOSIUM

From obesity and diabetes to heart failure: a straight path or a winding road?

Chairpersons: Koshelskaya O. (Tomsk), Chumakova G. (Barnaul)

- **Chumakova G.** (Barnaul), **Veselovskaya N.** (Kemerovo). From obesity to heart failure: is it possible to stop the inevitable?
- **Kuznetsova T., Druzhilov M.** (Petrozavodsk). Obesity, atrial fibrillation, heart failure as three stages of one problem.
- **Koshelskaya O.** (Tomsk). Deadly duet – diabetes mellitus and heart failure: how to improve the prognosis.

CONFERENCE HALL №5 (D3, 1 FLOOR)

13.30–15.00

SYMPOSIUM

Controversies and unsolved problems in the diagnosis and treatment of obstructive lesions of coronary arteries in stable coronary artery disease

Chairpersons:

Berstein L. (Saint-Petersburg), **Duplyakov D.** (Samara), **Sumin A.** (Kemerovo)

- **Sumin A.** (Kemerovo). Unsolved issues in stable CAD diagnosis: evaluation of pretest probability – which method is better?
- **Korok E.** (Kemerovo). Difficulties in the diagnosis of obstructive coronary lesions: SPECT and CT angiography.
- **Duplyakov D.** (Samara). Is there a need to improve the algorithm of CAD diagnosis?
- **Bershtein L.** (Saint-Petersburg). ISCHEMIA: the largest study of stable CAD. Baseline characteristics of the patients.

CONFERENCE HALL №6 (D4, 1 FLOOR)

13.30–15.00

SYMPOSIUM

Multifactorial diseases: the role of genetics

Chairpersons:

Lifshits G. (Novosibirsk), **Minushkina L.** (Moscow), **Nikulina S.** (Krasnoyarsk)

- **Minushkina L., Brazhnik V., Selezneva N., Nikitin A., Zateishchikov D.** (Moscow). Polymorphism of estrogen receptor genes and myocardial changes in patients with hypertension.
- **Lifshits G., Nikolaev K., Zelenskaya E.** (Novosibirsk). Outcomes of acute coronary syndrome in relation to severity of the coronary artery lesion and genetic characteristics of patients.
- **Polyakova A., Gudkova A., Semernin E.** (Saint-Petersburg). MADD gene polymorphisms as a predictor of myocardial hypertrophy of various origin.

- **Muslimova E., Rebrova T., Afanasiev S., Nonka T., Repin A.** (Tomsk). Association of NOS3, ACE, ITGB3, and CYP2C19 genes polymorphisms with the severity of ischemic heart failure in female patients.
- **Tipteva T., Chumakova O., Brovkin A., Nikitin A., Reznichenko N., Zateischikov D.** (Moscow). Genetic markers of myocardial fibroses and predicting adverse outcomes in patients with aortic stenosis.
- **Rebrova T., Muslimova E., Afanasiev S., Nonka T., Repin A.** (Tomsk). Superoxide dismutase gene SOD1 polymorphism and lipid peroxidation in patients with coronary artery disease and type 2 diabetes mellitus.

CONFERENCE HALL №7 (B1, 2 FLOOR)

13.30–15.00

SYMPOSIUM

Cerebrovascular complications in patients with obesity

Chairpersons:

Konradi A. (Saint-Petersburg), **Nedogoda S.** (Vologograd),
Ostroumova O. (Moscow)

- **Konradi A.** (Saint-Petersburg). Stroke: a hot issue in cardiology.
- **Ostroumova O.** (Moscow). Principal stroke prevention strategies in patients with hypertension and metabolic syndrome.
- **Nedogoda S.** (Vologograd). Residual inflammatory risk in metabolic syndrome and cognitive functions.
- **Zueva I.** (Saint-Petersburg). Current understanding of pathogenesis and therapy approaches to vascular cognitive disorders in arterial hypertension and metabolic syndrome.
- **Shaposhnik I.** (Chelyabinsk). Stroke risk in obese patients: lipid-lowering therapy.

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

13.30–15.00

SCIENTIFIC SESSION

Non-drug treatment of arterial hypertension

Chairpersons:

Gapon L. (Tyumen), **Garganeeva A.** (Tomsk)

- **Pekarsky S., Baev A., Mordovin V., Ripp T., Semke G., Falkovskaya A., Lichikaki V., Zyubanova I.** (Tomsk). Distal renal denervation: double-blind randomized controlled trial of efficacy and safety in comparison with conventional intervention.
- **Shugushev Z., Maksimkin D., Ryumina A.** (Moscow). Immediate results of renal sympathetic denervation in patients with resistant hypertension.
- **Abdulgasanov R., Arakelyan V., Abdulgasanova M., Kuznetsova E., Provotorova Yu., Gasymov E., Porsukova M., Ivanov A., Musaev O.** (Moscow). Methods of diagnostics and treatment of secondary hypertension (examination results, 2,900 patients).
- **Abdulgasanov R., Arakelyan V., Abdulgasanova M., Gasymov E., Ivanov A., Provotorova Yu., Kuznetsova E., Musaev O., Porsukova M.** (Moscow). Methods of diagnostics and treatment of hormonally active adrenal tumors.
- **Shevchenko A., Nikitina E., Koloskova N., Bolshakova K., Gautier S.** (Moscow). Hypertension in heart transplant recipients.
- **Romanova T., Nikitina N., Rebrov A.** (Saratov). Circadian rhythms of arterial stiffness in patients with rheumatoid arthritis with or without hypertension.

CONFERENCE HALL №10 (A1-A3, 3 FLOOR)

13.30–15.00

SYMPOSIUM

Cardiovascular diseases and pregnancy

Chairpersons: Moiseeva O. (Saint-Petersburg), Stryuk R. (Moscow), Chesnikova A. (Rostov-on-Don)

- **Stryuk R., Berns S., Gomova T., Filippova M., Kozina E., Barkova E., Brytkova Ya., Borisov I., Ivanova E.** (Moscow, Tula). Cardiovascular risk factors of unfavourable course of pregnancy and perinatal outcomes.
- **Irtuga O., Moiseeva O.** (Saint-Petersburg). A patient with a prosthetic valve, is pregnancy possible?
- **Gaisin I., Valeeva R., Shilina L., Maximov N., Abbazova D.** (Izhevsk). Management of pregnant patients with undifferentiated connective tissue dysplasia.
- **Chesnikova A., Kolomatskaya O.** (Rostov-on-Don). Arrhythmias in pregnant patients: causes, diagnostics and treatment.
- **Karelkina E., Moiseeva O.** (Saint-Petersburg). Management of pregnancy in patients with ventricular systolic dysfunction.
- **Gomova T., Fedotova E.** (Tula). Functional state of target organs in females with different variants of arterial hypertension one year after childbirth. Results of BEREG registry.

PLENARY HALL

15.30–17.00

PLENARY SESSION

Myocarditis: from pathogenesis to diagnosis and treatment

On-line broadcasting / Simultaneous translation

Chairpersons: Paleev N. (Moscow), Dzemeshevich S. (Moscow)

- **Frustaci A.** (Italy). Role of autoimmunity in human myocarditis.
- **Paleev F.** (Moscow). Current views on myocarditis pathogenesis and methods of its immunological diagnosis.
- **Moiseeva O.** (Saint-Petersburg). Informative value of non-invasive methods of myocarditis diagnosis.
- **Boldueva S.** (Saint-Petersburg). Tako-Tsubo cardiomyopathy: current views, clinical observations.
- **Blagova O.** (Moscow). Immunosuppressive therapy as the basis for myocarditis treatment: What do we know? Current guidelines and research.

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

15.30–17.00

SCIENTIFIC SESSION

Current strategies of cardiovascular disease prevention: concept of cardiovascular and psychosocial risk factors

Chairpersons: Garganeeva N. (Tomsk), Petrova M. (Krasnoyarsk)

- **Garganeeva N.** (Tomsk). Stress, anxiety, depression and other psychosocial risk factors in the renewed European guidelines on cardiovascular disease prevention in clinical practice.
- **Petrova M.** (Krasnoyarsk). Uncontrolled arterial hypertension and anxiety-depressive disorders. How to improve effectiveness of treatment?
- **Trubnikova O., Kupriyanova T., Maleva O., Barbarash O.** (Kemerovo). Risk factors of cognitive dysfunction in patients with coronary artery disease and trait anxiety.
- **Repin A., Lebedeva E.** (Tomsk). Depression and coronary artery disease: effect on prognosis and possible correction in the cardiology department.
- **Chumakova G., Veselovskaya N.** (Barnaul). Obesity and psychosomatic disorders: what goes first?
- **Belyalov F.** (Irkutsk). Treatment of arrhythmias with comorbid anxiety and depression.

CONFERENCE HALL №2 (E7, 1 FLOOR)

15.30–17.00

SYMPOSIUM

New concepts of blood vessels assessment in patients with AH and CAD and their effect on outcomes improvement

Chairpersons:

Karpov Yu. (Moscow), **Oleynikov V.** (Penza), **Orlova Ya.** (Moscow)

- **Karpov Yu.** (Moscow). Significance of determining early vascular ageing in increasing adherence to therapy in patients with AH.
- **Kotovskaya Yu.** (Moscow). In whom shall we assess arterial stiffness: young? elderly? everyone?
- **Orlova Ya.** (Moscow). Arterial stiffness in CAD: effect on prognosis and correction.

- **Oleynikov V., Salyamova L., Khromova A.** (Penza). Manifestation of CAD in the form of STEMI as a sign of the syndrome of early vascular ageing.
- **Strazhesko I.** (Moscow). New options in prevention of atherosclerosis and arteriosclerosis based translational medicine achievements.

CONFERENCE HALL №3 (D1, 1 FLOOR)

15.30–17.00

SYMPOSIUM

Rare and difficult diagnoses in cardiology

Chairpersons: **Andreev D.** (Moscow), **Syrkin A.** (Moscow)

- **Novikova N.** (Moscow). Unobvious causes of edema syndrome.
- **Gilarov M.** (Moscow). Takotsubo cardiomyopathy in a hospital: series of clinical cases.
- **Kopylov F., Lomonosova A.** (Moscow). Recurrent cerebrovascular disorders in a young female patient.
- **Andreev D.** (Moscow). Acute heart failure due to Valsalva sinus aneurysm rupture.
- **Poltavskaya M.** (Moscow). Acute coronary syndrome during chemotherapy.

CONFERENCE HALL №4 (D2, 1 FLOOR)

15.30–17.00

SCIENTIFIC SESSION

What is new in cardiorheumatology?

Chairpersons:

Novikova D. (Moscow), **Popkova T.** (Moscow), **Rebrov A.** (Saratov)

- **Novikova D.** (Moscow). Cardiovascular prevention in patients with rheumatoid arthritis and other forms of inflammatory joint disorders – 2017 (based on guidelines of the European League Against Rheumatism)
- **Popkova T.** (Moscow). Systemic lupus erythematosus and cardiovascular risk: new data.
- **Kirillova I.** (Moscow). Diastolic heart failure: lessons from rheumatology experience.

CONFERENCE HALL №5 (D3, 1 FLOOR)

15.30–17.00

SYMPOSIUM

Results of regional ACS registries

Chairpersons: **Duplyakov D.** (Samara), **Zateischikov D.** (Moscow), **Kosmacheva E.** (Krasnodar)

- **Khripun A.** (Rostov-on-Don). Organization of ACS care in the Rostov region based on the registry data.
- **Kruchinova S., Kosmacheva E., Raff S.** (Krasnodar). Acute coronary syndrome in the Krasnodar region: focus on rehabilitation.
- **Zateischikov D.** (Moscow). ORACLE I and ORACLE II registries: role of hereditary factors in ACS prognosis.
- **Duplyakov D., Luboyatnikova E.** (Samara). Acute coronary syndrome in patients with cancer.

CONFERENCE HALL №6 (D4, 1 FLOOR)

15.30–17.00

SYMPOSIUM

Atherosclerosis and hypercholesterolemia. New genetic, etiopathogenetic markers and approaches to therapy

Chairpersons: **Voevoda M.** (Novosibirsk), **Ragino Yu.** (Novosibirsk)

- **Voevoda M., Oshevsky S., Ragino Yu.** (Novosibirsk). Promising approaches to lipid metabolism modulation.
- **Maksimov V.** (Novosibirsk). Association of some molecular genetic markers of ageing with atherosclerosis and its risk factors: a population study.
- **Kashtanova E., Polonskaya Ya., Ragino Yu.** (Novosibirsk). Biochemical markers of the presence of unstable atherosclerotic plaques in the coronary arteries.

- **Shakhtshneider E.** (Novosibirsk). Analysis of the transcriptome profile of unstable atherosclerotic plaque: results of a pilot study.
- **Ershova A., Meshkov A.** (Moscow). Ultrasonic markers of atherosclerosis of the carotid and femoral arteries for cardiovascular risk assessment.
- **Bazhan S., Ragino Yu., Benimetskaya K.** (Novosibirsk). RENAISSANCE of atherosclerosis treatment options and cardiovascular risk management. PCSK9 protein and its association with biomarkers of atherosclerosis in familial hypercholesterolemia.

CONFERENCE HALL №7 (B1, 2 FLOOR)

15.30–17.00

TRAINING SEMINAR

An obese patient seeing a cardiologist

Chairpersons:

Baranova E. (Saint-Petersburg), **Nedogoda S.** (Volgograd)

- **Nedogoda S.** (Volgograd). Clinical case of a patient with obesity and comorbidities.
- **Lopatin Yu.** (Volgograd). How to protect the heart?
- **Nedogoda S.** (Volgograd). How to protect the vessels?
- **Arutyunov G.** (Moscow). How to protect the kidneys?
- **Drapkina O.** (Moscow). How to protect the liver?
- **Baranova E.** (Saint-Petersburg). Is it just drugs?

Conference Hall №8 (B2, 2 floor)

15.30–17.00

Joint scientific session with the Physiology Section of the Russian Academy of Science

Chairpersons:

Galagudza M. (Saint-Petersburg), **Matskeplishvili S.** (Moscow)

- **Makarevich P.** (Moscow). Therapeutic angiogenesis and gene therapy in cardiology.
- **Parfenova E.** (Moscow). Cardiac stem cells and myocardial regeneration.

- **Galagudza M.** (Saint-Petersburg). Myocardial transfer of genetic and cellular material.
- **Matskeplishvili S.** (Moscow). Evaluation of cardiac regenerative genetic and stem cell therapy effectiveness.

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

15.30–17.00

SCIENTIFIC SESSION

Arrhythmias and heart failure: electrophysiological approaches

Chairpersons:

Kuznetsov V. (Tyumen), **Lebedev D.** (Saint-Petersburg)

- **Lebedev D., Savenkova G., Krivolapov S., Popov S.** (Tomsk). Sinus rhythm restoration as a predictor of cardiac resynchronization therapy effectiveness in patients with severe CHF and persistent AF.
- **Chichkova T., Mamchur S., Mamchur I.** (Kemerovo). Cryoballoon vs radiofrequency ablation for pulmonary vein isolation in AF.
- **Khlynin M., Usenkov S., Batalov R., Popov S., Archakov E.** (Tomsk). Non-invasive mapping in cardiac arrhythmias diagnosis: Amicard software and hardware system.
- **Damrina E.** (Astrakhan). Management of outpatients with ICD: testing in clinic or remote monitoring?
- **Pervova E.** (Saint-Petersburg). ECG for patients with implanted CRT: attention to details.
- **Faibushevich A., Baranovich V., Maksimkin D., Safonov N.** (Moscow). Surgery safety in patients with implanted pacemakers.
- **Tsaregorodtsev D., Sokolov A., Nedostup A.** (Moscow). Impact of life quality on the choice of therapy in patients with idiopathic ventricular arrhythmias.
- **Melnik N., Tsaregorodtsev D., Sulimov V.** (Moscow). Predictors of arrhythmic events and general mortality in CAD patients with ICD.

CONFERENCE HALL №10 (A1-A3, 3 FLOOR)

15.30–17.00

WORKING MEETING**CICD and ACS Registries****Young Cardiologists WG Meeting****Chairpersons:****Shlyakhto E.** (Saint-Petersburg), **Tanicheva A.** (Saint-Petersburg)**PLENARY HALL**

17.30–19.00

PLENARY LECTURES*On-line broadcasting / Simultaneous translation***Moderator: Yakovlev A.** (Saint-Petersburg)

- **Hendel R.** (USA). Assessment of coronary physiology: impact on clinical decision-making.
- **Beleslin B.** (Serbia). Invasive coronary physiology: master mind algorithm for evaluation of coronary artery disease.

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

17.30–19.00

CLINICAL CASE**A difficult obese patient****Chairpersons: Kuznetsova T.** (Petrozavodsk), **Chumakova G.** (Barnaul), **Kushnarenko N.** (Chita)

- **Druzhilov M., Kuznetsova T.** (Petrozavodsk). From visceral obesity to arterial hypertension.
- **Veselovskaya N.** (Kemerovo), **Chumakova G.** (Barnaul). Complicated pregnancy in an obese patient.
- **Leonova N.** (Barnaul). A patient with obesity and diabetes mellitus seeing an endocrinologist.
- **Kushnarenko N.** (Chita). Arterial hypertension in a patient with gout.

CONFERENCE HALL №2 (E7, 1 FLOOR)

17.30–19.00

SCIENTIFIC SESSION**Diagnosis and treatment of sleep disordered breathing: from new concepts to practical solutions****Chairpersons: Buzunov R.** (Moscow), **Litvin A.** (Moscow)

- **Buzunov R.** (Moscow). Integration of diagnostic and treatment methods for obstructive sleep apnea syndrome into the practical work of a cardiologist.
- **Litvin A.** (Moscow). Obstructive sleep apnea syndrome and its complications: what does a cardiologist need to know?
- **Elfimova E.** (Moscow). CPAP-therapy in cardiac patients: to whom and when?
- **Kulikov A.** (Saint-Petersburg). Obesity – hypoventilation syndrome: we see but do not notice.

CONFERENCE HALL №3 (D1, 1 FLOOR)

17.30–19.00

SYMPOSIUM**About 1,000,000 people in Russia are affected by familial hypercholesterolemia. How to find and save these patients?****Chairpersons: Voevoda M.** (Novosibirsk), **Ezhov M.** (Moscow), **Meshkov A.** (Moscow)

- **Ershova A.** (Moscow). Familial hypercholesterolemia as the most common hereditary disease in cardiology.
- **Meshkov A.** (Moscow). Molecular genetic testing of familial hypercholesterolemia: pros and cons.
- **Kashtalap V., Pechorina T., Fedorova N., Barbarash O.** (Kemerovo). Lipid centers as a basis for effective detection and treatment of FH patients.
- **Ezhov M., Bazhan S.** (Novosibirsk). RENESSANS registry as a unique chance for FH patients to be heard.
- **Voevoda M., Bazhan S., Shakhtschneider E.** (Novosibirsk). Innovative therapies for FH: the impossible is possible.

CONFERENCE HALL №4 (D2, 1 FLOOR)

17.30–19.00

SYMPOSIUM**Syncope – from guidelines to everyday practice**Chairpersons: **Duplyakov D.** (Samara), **Pevzner A.** (Moscow)

- **Golovina G.** (Krasnodar). ACC Guidelines on syncope management 2017.
- **Kuchinskaya E.** (Moscow). Drug therapy for orthostatic syncope.
- **Pevzner A.** (Moscow). Molecular-genetic testing in patients with vasovagal syncope.
- **Duplyakov D.** (Samara). Syncope Unit as a new approach to syncope management.

CONFERENCE HALL №5 (D3, 1 FLOOR)

17.30–19.00

SYMPOSIUM**Cardiac arrhythmias in young adults: causes and consequences**Chairpersons: **Miller O.** (Novosibirsk), **Shaposhnik I.** (Chelyabinsk)

- **Lipchenko A.** (Ekaterinburg). Arrhythmias and connective tissue dysplasia syndrome.
- **Matyushin G.** (Krasnoyarsk). Arrhythmias in athletes.
- **Shaposhnik I.** (Chelyabinsk). Arrhythmias in pregnancy.
- **Miller O.** (Novosibirsk). Mistakes we make in the treatment of cardiac arrhythmias.

CONFERENCE HALL №6 (D4, 1 FLOOR)

17.30–19.00

SYMPOSIUM**Pulmonary embolism – 2017**

Chairpersons:

Panchenko E. (Moscow), **Yavelov I.** (Moscow)

- **Yavelov I.** (Moscow). Current approaches to pulmonary embolism diagnostics.
- **Panchenko E.** (Moscow). Treatment of pulmonary embolism: what's new?
- **Komarov A.** (Moscow). Secondary prevention of pulmonary embolism: how to provide a personalized approach.

CONFERENCE HALL №7 (B1)

17.30–19.00

SYMPOSIUM**Complicated issues in comorbid patients with CAD**

Chairpersons:

Borovkov N. (Nizhny Novgorod), **Vasilets L.** (Perm)

- **Borovkov N.** (Nizhny Novgorod). Drug therapy for stable CAD.
- **Vasilets L.** (Perm). Optimization of arrhythmia diagnosis and treatment in patients with CAD.
- **Borovkova N.** (Nizhny Novgorod). Complicated issues in the elderly comorbid patients with CAD.
- **Koryagina N.** (Perm). Coronary heart disease in female patients: diagnostic difficulties.
- **Borovkova N.** (Nizhny Novgorod). CAD and non-alcoholic fatty liver disease.

CONFERENCE HALL №8 (B2, 2 FLOOR)

17.30–19.00

SYMPOSIUM

Hot topics in cardiovascular imaging

Chairpersons:

Nikiforov V. (Saint-Petersburg), **Pavlyukova E.** (Tomsk),
Sokolskaya N. (Moscow)

- **Nikiforov V.** (Saint-Petersburg). Current approaches to cardiovascular imaging in patients with coronary heart disease.
- **Bokeria L., Sokolskaya N., Kopylova N., Alshibaya M.** (Moscow). Intraoperative transesophageal echocardiography in patients with post-infarction left ventricular aneurysm.
- **Pavlyukova E.** (Tomsk). Three-dimensional anatomy of the mitral valve: norm and pathology.
- **Shloido E.** (Saint-Petersburg). Imaging in the aortic valve and subvalvular stenosis.
- **Sukhov V.** (Moscow). Traditional and hybrid imaging techniques in nuclear cardiology.
- **Nikischenkova Yu., Nikiforov V.** (Saint-Petersburg). Cardiovascular imaging in the elderly and senile age.

CONFERENCE HALL №9 (B6-B8)

17.30–19.00

SCIENTIFIC SESSION

CAD, lipids and atherosclerosis: results of epidemiological and genetic studies

Chairpersons:

Martsevich S. (Moscow), **Yakhontov D.** (Novosibirsk)

- **Ershova A., Meshkov A., Bazhan S.** (Novosibirsk), **Storozhok M., Efanov A., Medvedeva I.** (Tyumen), **Indukaeva E., Danilchenko Ya., Kuzmina O.** (Kemerovo), **Bogdanov D., Nevzorova V.** (Primorsky region), **Barbarash O.** (Kemerovo), **Deev A., Shalnova S., Boytsov S.** (Moscow). Prevalence of familial hypercholesterolemia in three regions of the Russian Federation: ESSE-RF substudy.

- **Semenova A., Sergienko I., Ezhov M.** (Moscow), **García-Giustiniani D., Monserrat L.** (Spain), **Sonicheva N., Malakhov V., Popova A., Nozadze D., Kukharchuk V.** (Moscow). Incidence and range of pathogenic mutations in subjects with provisional diagnosis of familial hypercholesterolemia.
- **Inozemtseva A., Kashtalap V., Argunova Yu., Barbarash O., Gordeeva L.** (Kemerovo). Comparative analysis of association of various apolipoprotein polymorphisms with clinical severity, hospital and long-term prognosis in STEMI patients.
- **Yakhontov D., Ostanina Yu.** (Novosibirsk). Markers of early vascular ageing and multifocal atherosclerosis manifestations in CAD patients of various age groups.
- **Shakhtshneider E., Ivanoschuk D., Ragino Yu., Polonskaya Ya., Chernyavskiy A., Voevoda M.** (Novosibirsk). Analysis of transcriptomic profile of unstable atherosclerotic plaque.
- **Tolpygina S., Martsevich S.** (Moscow). Impact of comorbidities on long-term life prognosis in patients enrolled in CAD PROGNOSIS registry.
- **Bichurina D., Gaidukova I., Rebrov A.** (Saratov). Association of kidney and liver functions with the risk of morbid cardiovascular complications in patients with degenerative-dystrophic spinal changes taking non-steroidal anti-inflammatory drugs.
- **Yaroslavskaya E., Kuznetsov V., Pushkarev G., Krinochkin D., Bessonov I.** (Tyumen). Myocardial remodeling in female patients with transmural myocardial infarction and ischemic mitral regurgitation.

CONFERENCE HALL №10 (A1-A3, 3 FLOOR)

17.30–19.00

Debates

Ischemic cardiomyopathy and CHF: pro and contra

Chairpersons:

Yakushin S. (Ryazan), **Filippov E.** (Ryazan)

- **Nikulina N., Yakushin S.** (Ryazan). Terminology of ischemic cardiomyopathy from the standpoint of ICD-10/11.
- **Yakushin S.** (Ryazan). Ischemic cardiomyopathy: pro.
- **Filippov E.** (Ryazan). Ischemic cardiomyopathy: contra.

	1 floor							2 floor			3 floor
	PLENARY HALL	CONFERENCE HALL №1 (E8-E9)	CONFERENCE HALL №2 (E7)	CONFERENCE HALL №3 (D1)	CONFERENCE HALL №4 (D2)	CONFERENCE HALL №5 (D3)	CONFERENCE HALL №6 (D4)	CONFERENCE HALL №7 (B1)	CONFERENCE HALL №8 (B2)	CONFERENCE HALL №9 (B6-B8)	CONFERENCE HALL №10 (A1-A3)
09:00-10:30	PLENARY SESSION Hybrid technologies in cardiovascular treatment On-line broadcasting Simultaneous translation	SYMPOSIUM Hot topics in dyslipidemia management	SYMPOSIUM Microvascular angina: clinical cases	SYMPOSIUM Comorbidity, compliance and polypharmacy: a triune cardiology problem	RUSSIAN-AMERICAN SYMPOSIUM Chronic thromboembolic pulmonary hypertension: current approaches to treatment Simultaneous translation	SYMPOSIUM Modern arrhythmology. Dialogue of specialists. Part 1. Atrial fibrillation	SYMPOSIUM An elderly patient seeing a cardiologist. Is there life after stroke?	SYMPOSIUM Hot topics of stress echocardiography	SYMPOSIUM Hot topics in psycho-cardiology	SCIENTIFIC SESSION Emergency cardiology: from pathogenesis to treatment and outcomes improvement	SYMPOSIUM OF THE NATIONAL SOCIETY OF PREVENTIVE CARDIOLOGY Preventive Cardiology 2017: new studies and innovative approaches
10:30-11:00	BREAK							BREAK			
11:00-12:30	PLENARY SESSION Coronary artery disease, atherosclerosis, lipids On-line broadcasting Simultaneous translation	SYMPOSIUM Patients with ventricular arrhythmias – they are all different!	SYMPOSIUM Familial hypercholesterolemia: the diversity of clinical manifestations and the role of genetic testing	SYMPOSIUM Balancing at the tip of the spear: a difficult cardiovascular patient	SYMPOSIUM Non-invasive diagnosis of subclinical atherosclerosis: guidelines, clinical practice and cost-effectiveness Simultaneous translation	SYMPOSIUM Modern arrhythmology. Dialogue of specialists. Part 2. Combined approaches to management of difficult cases of atrial fibrillation	SYMPOSIUM Patients with atrial fibrillation: main aspects of rehabilitation	SYMPOSIUM New concept of responsible partnership between a doctor and a patient in AH treatment	SYMPOSIUM How do we treat a patient with hemodynamically significant stenosis of the internal carotid artery?	SCIENTIFIC SESSION Hybrid surgery and interventional cardiology	SYMPOSIUM Original research and clinical practice. Focus on chronic heart failure
12:30-13:00	BREAK							BREAK			
13:00-15:00	CLOSING PLENARY SESSION Innovations in Cardiology 2017. Session 2 On-line broadcasting / Simultaneous translation							CLOSING PLENARY SESSION Innovations in Cardiology 2017. Session 2 On-line broadcasting / Simultaneous translation			

PLENARY HALL

09.00–10.30

PLENARY SESSION

Hybrid technologies in cardiovascular treatment

On-line broadcasting / Simultaneous translation

Chairpersons:

Akchurin R. (Moscow), **Alekyan B.** (Moscow)

- **Akchurin R.** (Moscow). Hybrid surgery in adult aortic valve stenosis.
- **Abugov S.** (Moscow). Hybrid interventions in aortic aneurism.
- **Alekyan B.** (Moscow). Hybrid (surgical and endovascular) interventions in coronary artery disease.
- **Kavteladze Z.** (Moscow). Combined surgical and endovascular interventions in peripheral artery disease.
- **Alekyan B.** (Moscow). Hybrid interventions in some congenital heart defects.
- Discussion.

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

09.00–10.30

Symposium

Hot topics in dyslipidemia management

Chairpersons: **Ezhov M.** (Moscow), **Sergienko I.** (Moscow)

- **Reznik I.** (Ekaterinburg). Inter-drug interactions in a comorbid cardiac patient.
- **Ezhov M.** (Moscow). Familial hypercholesterolemia: etiology and diagnosis.
- **Shaposhnik I.** (Chelyabinsk). Familial hypercholesterolemia: treatment in adults and children.
- **Sergienko I.** (Moscow). Triglycerides – a subtle enemy.

CONFERENCE HALL №2 (E7, 1 FLOOR)

09.00–10.30

SYMPOSIUM

Microvascular angina: clinical cases

Chairpersons: **Soboleva G.** (Moscow), **Boldueva S.** (Saint Petersburg), **Karpov Y.** (Moscow)

- **Soboleva G.** (Moscow). Microvascular angina diagnostics based on pathogenetic concepts of the disease.
- **Boldueva S.** (Saint Petersburg). Do we treat pain syndrome or ischemia in patients with unchanged coronary arteries?
- **Karpova I., Soboleva G.** (Moscow). Do we confirm or exclude the diagnosis of microvascular angina by a pharmacological test with ATP with SPECT or VMCT.
- **Rishikova M.** (Moscow), **Boldueva S.** (Saint Petersburg). The “acute” form of microvascular angina? Clinical observations.
- **Leonova I.** (Saint Petersburg), **Zakharova O.** (Moscow), **Boldueva S.** (Saint Petersburg). Future prospects of treatment of patients with microvascular angina. Clinical observations.

CONFERENCE HALL №3 (D1, 1 FLOOR)

09.00–10.30

SYMPOSIUM

Comorbidity, compliance and polypharmacy: a triune cardiology problem

Chairpersons: **Vasyuk Yu.** (Moscow), **Tatarsky B.** (Saint-Petersburg), **Yakushin S.** (Ryazan)

- **Yakushin S.** (Ryazan). Comorbidity, compliance and polypharmacy in health institutions: clinical guidelines and practical experience.
- **Vasyuk Yu.** (Moscow). Interrelation of arterial hypertension and obesity: diagnosis and treatment.
- **Tatarsky B.** (Saint-Petersburg). Atrial fibrillation in a patient with chronic kidney disease: approaches to therapy and prevention.
- **Poltavskaya M.** (Moscow). Coronary problems of cancer patients.
- **Filippov E.** (Ryazan). Pericardial effusion: is it always necessary to treat?

CONFERENCE HALL №4 (D2, 1 FLOOR)

09.00–10.30

RUSSIAN-AMERICAN SYMPOSIUM

Chronic thromboembolic pulmonary hypertension: current approaches to treatment

Simultaneous translation

Chairpersons: **Gordeev M.** (Saint-Petersburg),
Chernyavsky A. (Novosibirsk), **Kim N.** (USA)

- **Kim N.** (USA). Chronic thromboembolic pulmonary hypertension: epidemiology, pathophysiology, and treatment.
- **Simakova M., Marukyan N., Karpova D., Gordeev M.** (Saint-Petersburg). Significance of national and regional registries of patients with chronic thromboembolic pulmonary hypertension.
- **Chernyavsky A.** (Novosibirsk). Surgery for chronic thromboembolic pulmonary hypertension.
- **Danilov N.** (Moscow). Balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension.
- **Novikova N.** (Novosibirsk). Non-pharmacological treatment of residual pulmonary hypertension after pulmonary thromboendarterectomy.

CONFERENCE HALL №5 (D3, 1 FLOOR)

09.00–10.30

SYMPOSIUM

Modern arrhythmology. Dialogue of specialists. Part 1. Atrial fibrillation

Chairpersons: **Ardashev A.** (Moscow), **Kosmacheva E.** (Krasnodar)

- **Ardashev A.** (Moscow). Significance of atrial fibrillation in cardiology. Current strategies of drug therapy and interventions.
- **Zotova I.** (Moscow). Acute coronary syndrome in a patient with atrial fibrillation: treatment strategy, antithrombotic therapy.
- **Kosmacheva E.** (Krasnodar). Atrial fibrillation in patients with the transplanted heart.

CONFERENCE HALL №6 (D4, 1 FLOOR)

09.00–10.30

Symposium

An elderly patient seeing a cardiologist. Is there life after stroke?

Chairpersons:
Kotovskaya Yu. (Moscow), **Tkacheva O.** (Moscow)

- **Nedogoda S.** (Volgograd). What must a cardiologist do within the standards of post-stroke rehabilitation?
- **Tkacheva O.** (Moscow). Management of an elderly patient after stroke.
- **Ostroumova O.** (Moscow). How to prevent cognitive dysfunction after stroke?

CONFERENCE HALL №7 (B1, 2 FLOOR)

09.00–10.30

SYMPOSIUM

Hot topics of stress echocardiography

Chairpersons:
Bobrov A. (Saint-Petersburg), **Chernov M.** (Moscow),
Prokudina M. (Saint-Petersburg)

- **Prokudina M.** (Saint-Petersburg). Exercise stress echocardiography: selection of patients for cardiac surgeries.
- **Chernov M.** (Moscow). A quarter of a century with stress echocardiography. Is it still necessary to diagnose CAD?
- **Bobrov A.** (Saint-Petersburg). Stress-echocardiography in patients with valvular heart disease.

CONFERENCE HALL №8 (B2, 2 FLOOR)

09.00–10.30

SYMPOSIUM

Hot topics in psycho-cardiology

Chairpersons: **Neznanov N.** (Saint-Petersburg),
Smulevich A. (Moscow), **Syrkin A.** (Moscow)

- **Neznanov N.** (Saint-Petersburg). Somatoform disorders in general practice: an isolated case or a routine.
- **Kopylov P., Novikova N., Grubova M.** (Moscow). Anxiety disorders and therapy adherence in cardiology practice.
- **Zueva I.** (Saint-Petersburg). What should a cardiologist know about anxiety and depression today?
- **Volel B.** (Moscow). Treatment of mental disorders in cardiology.
- **Syrkina E., Malyutina A.** (Moscow). Cardiopersonified syndrome in patients with chronic coronary artery disease.

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

09.00–10.30

SCIENTIFIC SESSION

Emergency cardiology: from pathogenesis to treatment and outcomes improvement

Chairpersons: **Skibitsky V.** (Krasnodar), **Yakovlev A.** (Saint-Petersburg)

- **Gaman S., Merkulova I., Shabanova M., Mironov V., Barysheva N., Sharia M.** (Moscow). Comparative analysis of atherosclerotic plaque parameters revealed with multi-layer spiral CT and intravascular ultrasound in symptom-associated and non-symptom-associated coronary arteries in ACS patients.
- **Shtegman O.** (Krasnoyarsk). Analysis of hospitalization refusals by patients with suspected ACS.
- **Kharitonov A., Shtegman O.** (Krasnoyarsk). Outcomes assessment in patients with suspected ACS seeking medical care in primary vascular centers.
- **Kochergin A., Leonova V., Kashtalap V.** (Kemerovo). 2STEPS: hemorrhage complications risk assessment model in STEMI patients.

- **Gazaryan G., Turina L., Nefedova G.** (Moscow). Impact of postponed coronary interventions in reperfusion therapy in STEMI patients.
- **Chichkova M., Kozlova O., Chichkov A.** (Astrakhan). MI complicated with acute ischemic stroke.
- **Mullova I., Duplyakov D.** (Samara). PESI and GRACE scales in risk assessment of pulmonary embolism hospital outcomes.
- **Berns S., Shmidt E., Nagirnyak O., Litvinova M., Barbarash O.** (Kemerovo). Therapy and outcomes assessment in non-STEMI patients during a five-year follow-up.

CONFERENCE HALL №10 (A1-A3, 3 FLOOR)

09.00–10.30

Symposium of the National Society of Preventive Cardiology

Preventive Cardiology 2017: new studies and innovative approaches

Chairpersons:
Badtieva V. (Moscow), **Pogosova N.** (Moscow)

- **Pogosova N.** (Moscow). New studies in preventive cardiology and their significance for clinical practice.
- **Pozdnyakov Yu.** (Moscow). Stroke prevention in the elderly.
- **Starodubova A.V.** (Moscow). Diet recommendations and cardiovascular diseases: unsolved issues.
- **Badtieva V.** (Moscow). Topical issues and their solutions in sports medicine.

PLENARY HALL

11.00–12.30

PLENARY SESSION

Coronary artery disease, atherosclerosis, lipids

*On-line broadcasting / Simultaneous translation*Chairpersons: **Kukharchuk V.** (Moscow), **Karpov Yu.** (Moscow)

- **Voevoda M.** (Novosibirsk). Genetics and molecular biology to help a clinician with dyslipidemia and atherosclerosis.
- **Podpalov V.** (Belarus). Lipid metabolism disorders: their prognostic role in cardiovascular events.
- **Ezhov M.** (Moscow). Organizational issues of cardiovascular risk correction in Russia: role of registries and lipid centers.

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Patients with ventricular arrhythmias – they are all different!

Chairpersons: **Berngardt E.** (Saint-Petersburg), **Zhdanova O.** (Saint-Petersburg), **Tikhonenko V.** (Saint-Petersburg)

- **Ryngach E., Tatarinova A.** (Saint-Petersburg). Clinical management of patients with stable coronary artery disease and ventricular arrhythmias – is everything so obvious?
- **Parmon E., Gordeeva M., Kurilenko T.** (Saint-Petersburg). New electrocardiographic phenomena in cardiac fibrosis assessment.
- **Tikhonenko V.** (Saint-Petersburg). Normal arrhythmias – what does it mean?
- **Tulintseva T., Zhabina E.** (Saint-Petersburg). Factors predisposing to ventricular arrhythmias.
- **Treshkur T., Alekseeva D., Zhdanova O.** (Saint-Petersburg). Algorithm – a choice of therapy in patients with idiopathic ventricular arrhythmias.
- **Berngardt E., Popov S., Volodicheva N.** (Saint-Petersburg). Management of pregnant patients with ventricular arrhythmias and without cardiac structural pathology.

CONFERENCE HALL №2 (E7, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Familial hypercholesterolemia: the diversity of clinical manifestations and the role of genetic testing

Chairpersons: **Zateischikov D.** (Moscow), **Konstantinov V.** (Saint-Petersburg), **Kuznetsova T.** (Petrozavodsk)

- **Zateischikov D., Brazhnik V., Averkova A.** (Moscow). Familial hypercholesterolemia and acute coronary syndrome.
- **Konstantinov V., Serebrenitskaya M., Panov A.** (Saint-Petersburg), **Sonicheva N.** (Moscow). Rare forms of familial hypercholesterolemia in St. Petersburg, diagnostic and treatment methods.
- **Korneva V., Kuznetsova T.** (Petrozavodsk). Variability of clinical manifestations in familial hypercholesterolemia.
- **Sonicheva N.** (Moscow). Rare forms of inherited dyslipidemia. Can mutations be protective?

CONFERENCE HALL №3 (D1, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Balancing at the tip of the spear: a difficult cardiovascular patient

Chairpersons: **Skibitsky V.** (Krasnodar), **Chesnikova A.** (Rostov-on-Don)

- **Skibitsky V.** (Krasnodar). Unsafe drugs for a patient with CHF: balancing between risk and benefit.
- **Chesnikova A.** (Rostov-on-Don). Problems of drugs choice in patients with cardiovascular diseases and COPD: controversies and limitations.
- **Fendrikova A.** (Krasnodar). Menopausal hormone therapy and cardiovascular diseases: unsafe or promising?

CONFERENCE HALL №4 (D2, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Non-invasive diagnosis of subclinical atherosclerosis: guidelines, clinical practice and cost-effectiveness

Simultaneous translation

Chairpersons: Boytsov S. (Moscow), Konradi A. (Saint-Petersburg)

- **Gavrilova N.** (Moscow). Current guidelines on non-invasive diagnosis of subclinical atherosclerosis.
- **Rotar O.** (Saint-Petersburg). How reasonable are various methods of noninvasive diagnostics of subclinical atherosclerosis: results of population-based studies.
- **Gurevich V.** (Saint-Petersburg). Markers of subclinical atherosclerosis in the clinical practice.
- **Sarkis E.** (France). Echocardiography for diagnosis of coronary artery lesions.
- **Ershova A.** (Moscow). Prevalence and severity of atherosclerosis in the carotid and femoral arteries.
- **Kontsevaya A.** (Moscow). Economic aspects of diagnostics of subclinical atherosclerosis.

CONFERENCE HALL №5 (D3, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Modern arrhythmology. Dialogue of specialists. Part 2. Combined approaches to management of difficult cases of atrial fibrillation

Chairpersons: Ardashev A. (Moscow), Saiganov S. (Saint-Petersburg)

- **Ardashev A.** (Moscow). Clinical case of combined therapy for AF patient: refractory hypertension, heart failure and renal insufficiency.
- **Saiganov S.** (Saint-Petersburg). Atrial fibrillation and acute myocardial infarction. Sudden cardiac death risk stratification.
- **Saiganov S.** (Saint-Petersburg). Drug therapy and interventions for SCD prevention.
- **Knigin A.** (Moscow). Cardiac contractility modulation with Optimizer IVs device as a novel approach to heart failure treatment.

CONFERENCE HALL №6 (D4, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Patients with atrial fibrillation: main aspects of rehabilitation

Chairpersons:

Aronov D. (Moscow), **Bubnova M.** (Moscow), **Perepech N.** (Saint-Petersburg)

- **Aronov D.** (Moscow). Prevention of cardiovascular, including arrhythmic, complications after myocardial revascularization.
- **Perepech N.** (Saint-Petersburg). Principles of cardiovascular risk reduction in patients with a combination of atrial fibrillation and chronic heart failure.
- **Yashin S.** (Saint-Petersburg). Interventions in atrial fibrillation: options and limitations.
- **Bubnova M.** (Moscow). Is rehabilitation needed for patients with atrial fibrillation after radiofrequency ablation?

CONFERENCE HALL №7 (B1, 2 FLOOR)

11.00–12.30

SYMPOSIUM

New concept of responsible partnership between a doctor and a patient in AH treatment

Chairpersons:

Savenkov M. (Moscow), **Ivanov S.** (Moscow)

- **Borschevskaya M.** (Moscow). Current legislation in management of patients with arterial hypertension.
- **Savenkov M.** (Moscow). Responsible partnership as a new level of cooperation between a doctor and a patient for effective blood pressure control.
- **Ivanov S.** (Moscow). Blood pressure regulation via heart rate change.
- **Mikhaylusova M.** (Moscow). An AH out-patient and a doctor: the meeting point cannot be changed.

CONFERENCE HALL №8 (B2, 2 FLOOR)

11.00–12.30

SYMPOSIUM

How do we treat a patient with hemodynamically significant stenosis of the internal carotid artery?

Chairpersons: **Alekyan B.** (Moscow), **Akchurin R.** (Moscow)

- **Gilyarov Yu.** (Moscow). Cardiology perspective.
- **Charchyan E.** (Moscow). Cardiac surgery perspective.
- **Alekyan B.** (Moscow). Endovascular surgery perspective.
- **Discussion.**

CONFERENCE HALL №9 (B6-B8, 2 FLOOR)

11.00–12.30

SCIENTIFIC SESSION

Hybrid surgery and interventional cardiology

Chairpersons:

Imaev T. (Moscow), **Merkulov E.** (Moscow), **Shugushev Z.** (Moscow)

- **Komlev A., Imaev T., Kolegaev A., Lepilin P., Margolina A., Saidova M., Ternovoy S., Akchurin R.** (Moscow). Outcomes of critical aortic stenosis after transcatheter implantation of various types of bioprostheses in high surgical risk patients.
- **Tishko V., Tyrenko V., Sokolov A., Zakharov M., Kozlov K.** (Saint-Petersburg). Long-term outcomes of coronary stenting and therapeutic apheresis in CAD patients.
- **Ognerubov D., Mironov V., Merkulov E., Samko A., Burkhondzoda Yu.** (Moscow). Deep guide wire penetration technique in CAD patients with complicated injury of coronary arteries.
- **Shugushev Z., Faibushevich A., Maksimkin D., Prischep O., Chepurnoi A.** (Moscow). Significance of fractional flow reserve and intravascular ultrasound in CAD diagnostic verification and evaluation of occupational fitness in railway workers.
- **Maksimkin D., Shugushev Z.** (Moscow). Endovascular strategy for CAD patients with left main coronary artery injury: results of five-year single-centre randomized study.

- **Shugushev Z., Maksimkin D., Faibushevich A., Chepurnoi A., Uchkin I., Tlischeva L., Goloschapov-Aksenov R.** (Moscow). Hybrid interventions in patients with critical ischemia of lower limbs: three-year angiography clinical results.
- **Faibushevich A., Musoev T., Maksimkin D., Bazanov I., Baranovich V., Gitelzon E.** (Moscow). Differential approach to treatment of patients with recurrent angina after coronary artery bypass surgery.
- **Khripun A., Chesnikova A., Kastanayan A., Malevanny M., Kulikovskikh Ya.** (Rostov-on-Don). Long-term outcomes of PCI with bioresorbable stents in STEMI.
- **Khripun A., Kastanayan A., Chesnikova A., Malevanny M., Kulikovskikh Ya.** (Rostov-on-Don). Short- and long-term outcomes of PCI with bioresorbable stents within pharmaco-invasive reperfusion in STEMI.

CONFERENCE HALL №10 (A1-A3, 3 FLOOR)

11.00–12.30

SYMPOSIUM

Original research and clinical practice. Focus on chronic heart failure

Chairpersons: **Garkina S.** (Saint-Petersburg),

Skorodumova E. (Saint-Petersburg), **Kozik V.** (Novosibirsk),

- **Skorodumova E.** (Saint-Petersburg). Pathogen-associated molecular pattern in patients with acute decompensation of heart failure.
- **Kozik V.** (Novosibirsk). Genetic predictors of heart failure in patients with myocardial infarction.
- **Skorodumova E.** (Saint-Petersburg). Acute decompensation of heart failure and depressed LV function: clinical manifestations and short-term prognosis.
- **Shilaeva N.** (Saint-Petersburg). Predictors of unfavorable prognosis in patients with CHF after myocardial infarction.
- **Vlasov A.** (Saint-Petersburg). Molecules of microbial origin in myocardial remodeling in chronic heart failure.
- **Gatsura V.** (Saint-Petersburg). Intestinal microflora and kidney function in various functional classes of chronic heart failure.

OCTOBER 27, 2017

PLENARY HALL

13.00–15.00

CLOSING PLENARY SESSION

Innovations in Cardiology 2017. Session 2

On-line broadcasting / Simultaneous translation

Chairperson: Shlyakhto E. (Saint-Petersburg)

- **Kim N.** (USA). PAH treatment evolution.
- **Konradi A.** (Saint-Petersburg). Value based medicine in cardiology.
- **Bukhanovsky A.** (Saint-Petersburg). Future prospects of the digital healthcare.
- **Omelyanovsky V.** (Moscow). Current trends in the Russian healthcare system development.
- The Battle of Scholars 2017 Awarding Ceremony.



RUSSIAN
SOCIETY
OF CARDIOLOGY

RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY

SATELLITE SYMPOSIA

OCTOBER 24–26, 2017 | SAINT-PETERSBURG



	1 floor						2 floor
	CONFERENCE HALL №1 (E8-E9)	CONFERENCE HALL №2 (E7)	CONFERENCE HALL №3 (D1)	CONFERENCE HALL №4 (D2)	CONFERENCE HALL №5 (D3)	CONFERENCE HALL №6 (D4)	CONFERENCE HALL №8 (B2)
07:30							
09:00 – 10:30					SATELLITE SYMPOSIUM A tale of the lost time (supported by Teva)		
10:30 – 11:00	BREAK			BREAK			
11:00 – 12:30			SATELLITE SYMPOSIUM Consistency of therapy at all stages of ACS patient management (supported by Astra Zeneca) On-line broadcasting		SATELLITE SYMPOSIUM Myocardial infarction 2017 (supported by Sanofi)	SATELLITE SYMPOSIUM Modern strategies in prevention of cardiovascular events (supported by Pfizer) On-line broadcasting	SATELLITE SYMPOSIUM Cytoprotectors and cardiovascular disease: options and future prospects (supported by Grindex)
12:30 – 13:00	BREAK			BREAK			
13:00 – 14:30		SATELLITE SYMPOSIUM Methodology of choosing new oral anticoagulants in patients with atrial fibrillation (supported by Bayer) On-line broadcasting	SATELLITE SYMPOSIUM The latest trends in AH treatment: ambitious goals and new options in the clinical practice (supported by Takeda)	SATELLITE SYMPOSIUM Anticoagulant therapy for atrial fibrillation patients in various clinical situations (supported by Boehringer Ingelheim)	SATELLITE SYMPOSIUM Myths and reality. Risk of cardiovascular complications in a comorbid patient (supported by Egis)	SATELLITE SYMPOSIUM Safety, efficacy and simplicity of therapy – three whales, on which a polymorbid patient treatment is based (supported by Teva)	SATELLITE SYMPOSIUM CV risk reduction as the most important factor of life expectancy increase (supported by Pfizer)
14:30 – 15:00	BREAK			BREAK			
15:00 – 16:45	SATELLITE SYMPOSIUM Dialogue of experts How to improve outcomes of pulmonary artery thromboembolism treatment? (supported by Bayer)	SATELLITE SYMPOSIUM ARNI – Angiotensin Receptor Nephilysin Inhibitors – a new class of CHF treatment (supported by Novartis)			SATELLITE SYMPOSIUM A moderate and high risk patient: neoclassicism in the clinical practice (supported by Gedeon Richter)	SATELLITE SYMPOSIUM Indirect anticoagulants in a new drug era (supported by Takeda)	SATELLITE SYMPOSIUM Cardio-vascular complications of NSAIDs: time to reconsider (supported by Pfizer)

CONFERENCE HALL №5 (D3, 1 FLOOR)

09.00–10.30

SYMPOSIUM

A tale of the lost time

(supported by Teva)

Chairperson: **Koziolova N.** (Perm)

- **Koziolova N.** (Perm). Optimal drug therapy – a modern strategy of life prolongation in patients with IHD.
- **Obrezan A.** (Saint-Petersburg). Long-term therapy as the basis of life prolongation in cardiovascular patients.

CONFERENCE HALL №3 (D1, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Consistency of therapy at all stages of ACS patient management

(supported by AstraZeneca)

On-line broadcasting

Chairperson:

Vasilieva E. (Moscow), **Yakovlev A.** (Saint-Petersburg)

- **Khripun A.** (Rostov-on-Don). Organization of medical care in ACS in the first 24 hours after the event: best practices.
- **Yakovlev A.** (Saint-Petersburg). Double antiplatelet therapy for the first 12 months after ACS.
- **Boldueva S.** (Saint-Petersburg). A patient with a high ischemic risk after MI: who needs DAT for more than 12 months?

CONFERENCE HALL №5 (D3, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Myocardial infarction 2017

(supported by Sanofi)

Chairperson: **Ruda M.** (Moscow)

- **Barbarash O.** (Kemerovo). Non-STEMI management.
- **Yavelov I.** (Moscow). MI in patients with no coronary artery obstructive lesions.
- **Averkov O.** (Moscow). STEMI management.

CONFERENCE HALL №6 (D4, 1 FLOOR)

11.00–12.30

Symposium

Current options in prevention of cardiovascular events

(supported by Pfizer)

*On-line broadcasting*Chairperson: **Karpenko M.** (Saint-Petersburg)

- **Mareev V.** (Moscow). Clinical recommendations and real practice or «Life is richly as textbook».
- **Ostoumova O.** (Moscow). Expanding horizons: the real clinical practice of using anticoagulants in AF.
- **Karpenko M.** (Saint-Petersburg). Anticoagulation therapy in AF patients with different risks of stroke and bleeding.

CONFERENCE HALL №8 (B2, 2 FLOOR)

11.00–12.30

SYMPOSIUM

**Cytoprotectors and cardiovascular disease:
options and prospects**
(supported by Grindex)

Chairperson: Mikhin V. (Kursk)

- **Mikhin V.** (Kursk). Cytoprotectors in acute and chronic coronary diseases.
- **Shishkova V.** (Moscow). Cerebro-vascular disorders in cardiovascular patients.

CONFERENCE HALL №2 (E7, 1 FLOOR)

13.00–14.30

SYMPOSIUM

**Methodology of new oral anticoagulants selection
for patients with atrial fibrillation**
(supported by Bayer)

On-line broadcasting

Chairperson: Shlyakhto E. (Saint-Petersburg)

- **Arutyunov G.** (Moscow). How does a Russian patient with atrial fibrillation differ from patients enrolled in randomized clinical trials? How to interpret clinical trials data in the clinical practice?
- **Lopatin Yu.** (Volgograd). A patient with atrial fibrillation and diabetes: what to pay attention to when selecting anticoagulation therapy?
- **Gilyarov M.** (Moscow). Management of patients with atrial fibrillation and chronic kidney disease.
- **Take home message.**

CONFERENCE HALL №3 (D1, 1 FLOOR)

13.00–14.30

SYMPOSIUM

**The latest trends in treatment of AH patients:
ambitious goals and new options in the clinical practice**
(supported by Takeda)

Chairperson: Kobalava Z. (Moscow)

- **Karpov Yu.** (Moscow). How will target BP be changing after the latest trials?
- **Kobalava Z.** (Moscow). Standards vs ACE in target AH patients therapy: what is the basis of selection?
- **Nedogoda S.** (Volgograd). 24-hour BP control as the most important factor of prognosis improvement in AH patients: fixed Edarbi Clo combinations.

CONFERENCE HALL №4 (D2, 1 FLOOR)

13.00–14.30

SYMPOSIUM

**Atrial fibrillation and anticoagulant therapy in various
clinical situations**
(supported by Boehringer Ingelheim)

Chairperson: Tkacheva O. (Moscow)

- **Novikova N.** (Moscow). Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome.
- **Vinogradov O.** (Moscow). Anticoagulant therapy in patients after cardioembolic stroke.
- **Tkacheva O.** (Moscow). Anticoagulant therapy in elderly patients.
- **Zotova I.** (Moscow). A patient with atrial fibrillation and comorbidities: choosing a safe anticoagulant.

CONFERENCE HALL №5 (D3, 1 FLOOR)

13.00–14.30

SYMPOSIUM**Myths and reality. Risk of cardiovascular complications in a comorbid patient**

(supported by Egis)

Chairperson: Martsevich S. (Moscow)

- **Averin E.** (Moscow). Myths and reality: a review of the world experience in AH treatment.
- **Martsevich S.** (Moscow). New options in correcting cardiovascular complications risk.
- **Kurasov E.** (Saint-Petersburg). Anxiety-depressive disorders and arterial hypertension: a myth or reality.

CONFERENCE HALL №6 (D4, 1 FLOOR)

13.00–14.30

SYMPOSIUM**Safety, efficacy and simplicity of therapy – three "whales", on which a polymorbid patient treatment is based**

(supported by Teva)

Chairperson: Koziolova N. (Perm)

- **Tarlovskaya E.** (Nizhny Novgorod). Polymorbidity and polypharmacy – two sides of the same coin.
- **Koziolova N.** (Perm). Drugs interaction: perspective of a patient and a doctor.
- **Chestnikova A.** (Rostov-on-Don). How to increase adherence to therapy in a cardiac patient.

CONFERENCE HALL №8 (B2, 2 FLOOR)

13.00–14.30

SYMPOSIUM**CV risk reduction as the most important factor of life expectancy increase**

(supported by Pfizer)

Chairpersons:**Konradi A.** (Saint-Petersburg), **Ostroumova O.** (Moscow)

- **Konradi A.** (Saint-Petersburg). AH and dyslipidemia as two strategic targets of primary and secondary cardiovascular prevention.
- **Ostroumova O.** (Moscow). Effective BP reduction – not the final goal but one of the ways to improve prognosis.
- **Sergienko I.** (Moscow). The efficacy and safety of statin therapy: no compromise.

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

15.00–16.30

DIALOGUE OF EXPERTS**How to improve outcomes of pulmonary artery thromboembolism treatment?**

(supported by Bayer)

Chairperson: Perepech N. (Saint-Petersburg)

- **Duplyakov D.** (Samara). Pulmonary artery thromboembolism management based on risk stratification.
- **Khasanov N.** (Kazan). Choice of antocoagulation therapy in separate patients with high risk of repeated pulmonary artery thromboembolism and/or hemorrhages.
- **Duplyakov D.** (Samara). Therapy of pulmonary artery thromboembolism in real life. What lessons can we get from observations and registries?
- **Khasanov N.** (Kazan). Long-term prevention of repeated pulmonary artery thromboembolism. Any place for aspirin?
- Discussion. Questions and answers.

CONFERENCE HALL №2 (E7, 1 FLOOR)

15.00–16.30

SYMPOSIUM

ARNI – Angiotensin Receptor Neprilysin Inhibitors – a new class of CHF treatment

(supported by Novartis)

Chairpersons: Mareev V. (Moscow), Nedoshivin A. (Saint-Petersburg)

- **Mareev V.** (Moscow). Neurohumoral systems balance restoration – a modern view on CHF therapy. Renewed guidelines on CHF diagnosis and treatment.
- Discussion. **Nedoshivin A.** (Saint-Petersburg), **Kobalava Z.** (Moscow), **Lopatin Yu.** (Volgograd), **Mareev V.** (Moscow).
- **Lopatin Yu.** (Volgograd). Initiation of therapy and ARNI effectiveness in various patient groups.
- Discussion. **Nedoshivin A.** (Saint-Petersburg), **Kobalava Z.** (Moscow), **Lopatin Yu.** (Volgograd), **Mareev V.** (Moscow).
- **Kobalava Z.** (Moscow). ARNI in clinical practice – real life experience.
- Discussion. **Nedoshivin A.** (Saint-Petersburg), **Kobalava Z.** (Moscow), **Lopatin Yu.** (Volgograd), **Mareev V.** (Moscow).

CONFERENCE HALL №5 (D3, 1 FLOOR)

15.00–16.30

SYMPOSIUM

A moderate and high risk patient: neoclassicism in the clinical practice

(supported by Gedeon Richter)

Chairperson: Podzolkov V. (Moscow)

- **Podzolkov V.** (Moscow). Guidelines and the clinical practice: is harmony possible?
- **Kislyak O.** (Moscow). Dyslipidemia correction and cardiovascular complications prevention in moderate-risk patients.
- **Protasov K.** (Irkutsk). When 2 + 1 > 3: a new solution in treatment of hypertension and atherosclerosis.

CONFERENCE HALL №6 (D4, 1 FLOOR)

15.00–16.30

SYMPOSIUM

Indirect anticoagulants in a new drug era

(supported by Takeda)

Chairpersons:

Zateischikov D. (Moscow), **Vavilova T.** (Saint-Petersburg)

- **Zateischikov D.** (Moscow). Long-term intake of anticoagulants 2017.
- **Zotova I.** (Moscow). Warfarin in current cardiology practice.
- **Vavilova T.** (Saint-Petersburg). Achievements and problems in organization of anticoagulation therapy monitoring. Saint-Petersburg experience.

CONFERENCE HALL №8 (B2, 2 FLOOR)

15.00–16.30

SYMPOSIUM

Cardiovascular complications of NSAIDs: time to reconsider

(supported by Pfizer)

Chairperson: Karpov Yu. (Moscow)

- **Novikova D.** (Moscow). Effect of NSAIDs on cardiovascular system: hidden threat?
- **Gaydukova I.** (Saint-Petersburg). Cardiovascular disease and long-term intake of NSAIDs.
- **Karpov Yu.** (Moscow). Reducing the risk of cardiovascular complications of NSAIDs intake is possible.

	1 floor						2 floor	
	CONFERENCE HALL №1 (E8-E9)	CONFERENCE HALL №2 (E7)	CONFERENCE HALL №3 (D1)	CONFERENCE HALL №4 (D2)	CONFERENCE HALL №5 (D3)	CONFERENCE HALL №6 (D4)	CONFERENCE HALL №7 (B1)	CONFERENCE HALL №8 (B2)
09:00–10:30					SATELLITE SYMPOSIUM Standards of anti-platelet therapy: clinical pharmacology and the Russian reality (supported by Takeda)	SATELLITE SYMPOSIUM How to improve prognosis in a very high risk patient with AH (supported by Sanofi)	SATELLITE SYMPOSIUM Beta blockers in clinical practice: is everything known to a practical doctor? (supported by Egis)	SATELLITE SYMPOSIUM Lessons, achievements and future prospects in treatment of stable CAD patients. (supported by Bayer)
10:30–11:00	BREAK						BREAK	
11:00–12:30	SATELLITE SYMPOSIUM Redefining possible (supported by Sanofi) On-line broadcasting	SATELLITE SYMPOSIUM Prevention of cardiovascular complications in CAD patients: status quo and new options (supported by Takeda)	SATELLITE SYMPOSIUM Foundations of very high cardiovascular risk patients therapy (supported by Astra Zeneca)			SATELLITE SYMPOSIUM A patient with arterial hyper-tension: a differential approach to the choice of therapy (supported by Teva)	SATELLITE SYMPOSIUM Current technologies and devices in arrhythmology (supported by Cardiomedics / Boston Scientific)	SATELLITE SYMPOSIUM Theory and practical consideration of PE treatment (supported by Pfizer) On-line broadcasting
12:30–13:30	BREAK						BREAK	
13:30–15:00				SATELLITE SYMPOSIUM The Philosopher's Stone of today, or what are the options to slow down ageing? (supported by Teva)	SATELLITE SYMPOSIUM Latest studies of the clinical practice: primary and secondary prevention (supported by Astra Zeneca)		SATELLITE SYMPOSIUM Hot topics in diuretic therapy (supported by Takeda)	SATELLITE SYMPOSIUM Current options in CHF management: from bench to bedside (supported by Pfizer)
15:00–15:30	BREAK						BREAK	
15:30–17:00	SATELLITE SYMPOSIUM Choice of anticoagulation therapy for the AF patients not mentioned in the guidelines. What can we do for them? (supported by Bayer)	SATELLITE SYMPOSIUM Multidisciplinary approach to management of CHF patients: new horizons and therapy options (supported by Novartis)		SATELLITE SYMPOSIUM Endovascular techniques assisting cardiologists: structural heart disease and resistant hypertension (supported by Cardiomedics / Boston Scientific) Simultaneous translation	SATELLITE SYMPOSIUM Current approaches to CHF treatment (supported by Akrikhin)	SATELLITE SYMPOSIUM Polypharmacy or Pharmageddon of our time? (supported by Gedeon Richter)		SATELLITE SYMPOSIUM Pulmonary arterial hypertension: current understanding of the problem (supported by Pfizer)

CONFERENCE HALL №5 (D3, 1 FLOOR)

09.00–10.30

Symposium

Standards of anti-platelet therapy: clinical pharmacology and the Russian reality

(supported by Takeda)

Chairperson: Glezer M. (Moscow)

- **Ageev F.** (Moscow). Review of international guidelines on anti-platelet therapy: role of aspirin.
- **Glezer M.** (Moscow). Unsolved issues in anti-platelet therapy in complicated cases.
- **Zyryanov S.** (Moscow). How to avoid resistance and side effects in anti-platelet therapy? Pharmacokinetic and pharmacodynamic basis of the processes.

CONFERENCE HALL №6 (D4, 1 FLOOR)

09.00–10.30

Symposium

How to improve prognosis in patients with hypertension and high CV risk

(supported by Sanofi)

Chairpersons: Karpov Yu. (Moscow), **Podzolkov V.** (Moscow)

- **Karpov Yu.** (Moscow). Very high risk patients: guidelines and clinical practice.
- **Podzolkov V.** (Moscow). Renin-angiotensin-aldosterone system blockade: just BP lowering?
- **Napalkov D.** (Moscow). Personalized approach to statin therapy.

CONFERENCE HALL №7 (B1, 2 FLOOR)

09.00–10.30

SYMPOSIUM

Beta blockers in clinical practice: is everything known to a practical doctor?

(supported by Egis)

Chairpersons: Martsevich S. (Moscow), **Nebieridze D.** (Moscow)

- **Martsevich S.** (Moscow). Evidence base of beta-blockers and real clinical practice.
- **Nebieridze D.** (Moscow). The existing stereotypes around beta blockers.
- **Averin E.** (Moscow). Topical issues of using beta blockers in various clinical situations.

CONFERENCE HALL №8 (B2, 2 FLOOR)

09.00–10.30

SYMPOSIUM

Lessons, achievements and future prospects in treatment of stable CAD patients

(supported by Bayer)

Chairperson: Arutyunov G. (Moscow)

- **Arutyunov G.** (Moscow). CAD patients with high risk of cardiovascular events. What do the registries say?
- **Koziołova N.** (Perm). Current approaches to treatment of stable CAD patients: guidelines review and ways to improve prognosis.
- **Perepech N.** (Saint-Petersburg). Factor Xa inhibitor Rivaroxaban in clinical practice: registered indications and the research programme.

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Redefining possible

(supported by Sanofi)

*On-line broadcasting*Chairpersons: **Ezhov M.** (Moscow), **Karpov Yu.** (Moscow)

- **Yakovlev A.** (Saint-Petersburg). LDL-cholesterol reduction in patients with very high cardiovascular risk.
- **Karpov Yu.** (Moscow). Innovative concept of PCSK9 inhibition for LDL-cholesterol control.
- **Ezhov M.** (Moscow). ODYSSEY Programme: focus on patients with very high cardiovascular risk.
- **All experts.** Questions and Answers.

CONFERENCE HALL №2 (E7, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Prevention of cardiovascular complications in CAD patients: status quo and new options

(supported by Takeda)

Chairpersons:

Arutyunov G. (Moscow), **Perepech N.** (Saint-Petersburg)

- **Perepech N.** (Saint-Petersburg). Improving outcomes in CAD patients: analysis of guidelines.
- **Orlova Ya.** (Moscow). Secondary prevention of cardiovascular events: any results in the real-life practice?
- **Arutyunov G.** (Moscow). Polypill as an innovative strategy to improve effectiveness of CAD therapy.

CONFERENCE HALL №3 (D1, 1 FLOOR)

11.00–12.30

SYMPOSIUM

Foundation of very high risk patients therapy

(supported by AstraZeneca)

Chairpersons:

Kobalava Z. (Moscow), **Susekov A.** (Moscow),
Mareev V. (Moscow), **Fomin I.** (Nizhny Novgorod)

- **Susekov A.** (Moscow). Strengthen the fortress: highly intensive statin therapy in very high risk patients.
- **Kobalava Z.** (Moscow). Fortification issues: safety of statins.
- **Mareev V.** (Moscow). How to build for long: statin therapy.
- **Fomin I.** (Nizhny Novgorod). Beta-blocker as a universal instrument for cardiovascular treatment.

CONFERENCE HALL №6 (D4, 1 FLOOR)

11.00–12.30

SYMPOSIUM

A patient with arterial hypertension: a differential approach to the choice of therapy

(supported by Teva)

Chairperson: **Glezer M.** (Moscow)

- **Glezer M.** (Moscow). Current antihypertensive therapy: focus on target BP level.
- **Ageev F.** (Moscow). Arterial hypertension as a risk factor of CHF. Evidence-based therapy.
- **Ostroumova O.** (Moscow). Target organs protection in AH: a justified choice of therapy.

CONFERENCE HALL №7 (B1, 2 FLOOR)

11.00–12.30

SYMPOSIUM

Modern technologies and devices for the treatment of cardiac arrhythmias.

(supported by Cardiomedics / Boston Scientific)

Chairpersons: Lebedev D. (Saint-Petersburg), Popov S. (Tomsk)

- **Mikhailov E.** (Saint-Petersburg). Cardiac contractility modulation in chronic heart failure: what can we expect?
- **Lebedev D.** (Saint-Petersburg). Subcutaneous ICD: is it a new standard in sudden cardiac death prevention?
- **Krivolapov S.** (Tomsk). What is new in modern CRT systems to improve the effectiveness of chronic heart failure treatment?
- **Romanov A.** (Novosibirsk). MRI compatible devices: what is really important?
- **Drozdov I.** (Moscow). How not to miss cardiac implantable device infection? Cardiologist's tactics.
- Best question contest.

CONFERENCE HALL №8 (B2, 2 FLOOR)

11.00–12.30

SYMPOSIUM

Theory and practical consideration of PE treatment

(supported by Pfizer)

Chairpersons: Andreev D. (Moscow), Obrezan A. (Saint-Petersburg)

On-line broadcasting

- **Obrezan A.** (Saint-Petersburg). Anticoagulant therapy for acute PE: impact on life and prognosis.
- **Andreev D.** (Moscow). What is important in management of a patient after PE. Aspects of prolonged thromboprophylaxis: when, what and why.
- **Obrezan A.** (Saint-Petersburg), **Andreev D.** (Moscow). Clinical case: succession management of a patient with PE from an acute episode of prolonged treatment and further prevention.

CONFERENCE HALL №4 (D2, 1 FLOOR)

13.30–15.00

SYMPOSIUM

The Philosopher's Stone of today, or what are the options to slow down ageing?

(supported by Teva)

Chairperson: Tkacheva O. (Moscow)

- **Tkacheva O.** (Moscow). Introductory speech. Causes of ageing and possible ways of slowing it down.
- **Tkacheva O.** (Moscow). From metal to gold" or from conventional diuretic therapy to prolonging life.
- **Dzgoeva F.** (Moscow). Prevention of age-associated diseases: from phyto-chemical correction to pharmacological support.
- **Susekov A.** (Moscow). How to prepare an elixir of life from ordinary drugs.

CONFERENCE HALL №5 (D3, 1 FLOOR)

13.30–15.00

SYMPOSIUM

Latest studies of the clinical practice: primary and secondary prevention

(supported by AstraZeneca)

Chairperson: Boitsov S. (Moscow)

- **Boitsov S.** (Moscow). CEPHEUS II: do we achieve our goals in the primary and secondary cardiovascular prevention.
- **Karpov Yu.** (Moscow). OPTIMA II and CVD-Real: Statins and anti-hyperglycemic drugs and impact on prognosis.
- **Oshepkova E.** (Moscow). STREAM: 1-year dual antiplatelet therapy in the Russian post-ACS population.

CONFERENCE HALL №7 (B1, 2 FLOOR)

13.30–15.00

SYMPOSIUM

Hot topics in diuretic therapy

(supported by Takeda)

Chairpersons:

Arutyunov G. (Moscow), **Tarlovskaya E.** (Nizhny Novgorod)

- **Tarlovskaya E.** (Nizhny Novgorod). Clinical niches for prolonged release diuretics administration.
- **Kozioleva N.** (Perm). CHF and special clinical situations: how can diuretics help?
- **Arutyunov G.** (Moscow). Long-term natriuresis as a strategic goal in diuretic treatment.
- Discussion of experts on difficulties in administration of diuretics in clinical practice.

CONFERENCE HALL №8 (B2, 2 FLOOR)

13.30–15.00

SYMPOSIUM

Current option in CHF management: from bench to bedside

(supported by Pfizer)

Chairperson: Andreev D. (Moscow)

- **Andreev D.** (Moscow). Patient with CHF after MI: how to improve the prognosis?
- **Obrezan A.** (Saint-Petersburg). Patient with CHF and ventricular extrasystole.
- **Arutyunov G.** (Moscow). Early start of therapy as the key to successful treatment of a HF patient.

CONFERENCE HALL №1 (E8-E9, 1 FLOOR)

15.30–17.00

SYMPOSIUM

Choice of anticoagulation therapy for the AF patients not mentioned in the guidelines. What can we do for them?

(supported by Bayer)

Chairperson: Belenkov Yu. (Moscow)

- **Mareev V.** (Moscow). Venous thromboses: do we know everything of them and what questions are left unanswered?
- **Gilyarevsky S.** (Moscow). Evidence-based cardiology and controversial issues in anticoagulation therapy. Clinical pharmacologist perspective.
- **Shubik Yu.** (Saint-Petersburg). Non-typical patients in the arrhythmology practice. Case study.
- Take home message.

CONFERENCE HALL №2 (E7, 1 FLOOR)

15.30–17.00

SYMPOSIUM

Multidisciplinary approach to management of CHF patients: new horizons and therapy options

(supported by Novartis)

Chairpersons: Shlyakhto E. (Saint-Petersburg), Kobalava Z. (Moscow)

- **Kobalava Z.** (Moscow). Cardiovascular continuum in CHF. Focus on prevention of recurrent cardiovascular events.
- Discussion. **Shlyakhto E.** (Saint-Petersburg), **Kobalava Z.** (Moscow), **Nedoshivin A.** (Saint-Petersburg), **Fomin I.** (Nizhny Novgorod).
- **Fomin I.** (Nizhny Novgorod). New areas of ARNI investigation: what is waiting for us in the near future?
- Discussion. **Shlyakhto E.** (Saint-Petersburg), **Kobalava Z.** (Moscow), **Nedoshivin A.** (Saint-Petersburg), **Fomin I.** (Nizhny Novgorod).
- **Nedoshivin A.** (Saint-Petersburg). Practical aspects of specialized care organization for CFH patients.
- Discussion. **Shlyakhto E.** (Saint-Petersburg), **Kobalava Z.** (Moscow), **Nedoshivin A.** (Saint-Petersburg), **Fomin I.** (Nizhny Novgorod).

CONFERENCE HALL №4 (D2, 1 FLOOR)

15.30–17.00

SYMPOSIUM

Endovascular techniques assisting cardiologists: structural heart disease and resistant hypertension
(supported by Cardiomedics / Boston Scientific)

Simultaneous translation

Chairpersons: Boytsov S. (Moscow), Zverev D. (Saint-Petersburg), Georgiou G. (Cyprus)

- **Zverev D.** (Saint-Petersburg). TAVI in Russia: implementation in clinical practice, specificities, tactics of patient selection and post-procedural management.
- **Georgiou G.** (Cyprus). TAVI: extending horizons.
- **Davtyan K.** (Moscow). Watchman left atrial appendage occlusion device: latest data on stroke prevention in AF patients from EWOLUTION registry. Selection of optimal candidate and tactic of post-procedural antithrombotic therapy.
- **Pavlov P.** (Khanty-Mansijsk). How to treat a patient with resistant hypertension? Renal denervation: results in Russia, selection of optimal category of patients.
- **Mikhaylov E.** (Saint-Petersburg). Beyond resistant hypertension: does renal denervation affect other conditions associated with sympathetic hyperactivation?
- Discussion.

CONFERENCE HALL №5 (D3, 1 FLOOR)

15.30–17.00

SYMPOSIUM

Current approaches to CHF treatment
(supported by Akrikhin)

Chairpersons: Arutyunov G. (Moscow), Ageev F. (Moscow), Mareev V. (Moscow)

- **Mareev V.** (Moscow). Advantages and disadvantages of mineralocorticoid receptor antagonists for CHF.

- **Arutyunov G.** (Moscow). How to save cognitive function in a cardiovascular patient?
- **Ageev F.** (Moscow). Choice of therapy for CHF with preserved LV ejection fraction.

CONFERENCE HALL №6 (D4, 1 FLOOR)

15.30–17.00

SYMPOSIUM

Polypharmacy or Pharmageddon of our time?
(supported by Gedeon Richter)

Chairperson: Lopatin Yu. (Volgograd)

- **Nedogoda S.** (Volgograd). Comorbidity and polypharmacy: prescribe never cancel.
- **Tkacheva O.** (Moscow). Gerontology practice: when a patient is enthralled by drug illusions.
- **Lopatin Yu.** (Volgograd). Discussion.

CONFERENCE HALL №8 (B2, 2 FLOOR)

15.30–17.00

SYMPOSIUM

Pulmonary arterial hypertension: current understanding of the problem
(supported by Pfizer)

Chairpersons: Moiseeva O. (Saint-Petersburg), Martyniuk T. (Moscow)

- **Moiseeva O.** (Saint-Petersburg). PAH: a way from the first symptoms to specialized care.
- **Martyniuk T.** (Moscow). Basic principles of PAH treatment. Sildenafil in guidelines and clinical practice.
- **Simakova M.** (Saint-Petersburg). Clinical cases of PAH patients.

	1 floor	2 floor	
	CONFERENCE HALL №5 (D3)	CONFERENCE HALL №7 (B1)	CONFERENCE HALL №8 (B2)
11:00–12:30	SATELLITE SYMPOSIUM A journey through the time: from Leonardo Da Vinci to our days (supported by Gedeon Richter)	SATELLITE SYMPOSIUM Long-term double anti-platelet therapy in patients after myocardial infarction: how long and to whom? (supported by AstraZeneca)	
12:30–13:30	BREAK		
13:30–15:00			SATELLITE SYMPOSIUM Historic parallels: Polypill in the concept of new science of power by Machiavelli (supported by Gedeon Richter)

CONFERENCE HALL №5 (D3, 1 FLOOR)

11.00–12.30

SYMPOSIUM

A journey through the time: from Leonardo Da Vinci to our days
(supported by Gedeon Richter)

Chairperson: Ageev F. (Moscow)

- **Drapkina O.** (Moscow). The perfect components of the combination as a guarantee of the therapy success.
- **Ageev F.** (Moscow). High and very high risk patients: do we use every possibility? ALROSA study results.
- **Averin E.** (Moscow). What is classic and what is new in the treatment of chronic heart failure?

CONFERENCE HALL №7 (B1, 2 FLOOR)

11.00–12.30

Symposium

Long-term double anti-platelet therapy in patients after myocardial infarction: how long and to whom?
(supported by AstraZeneca)

Chairperson: Ruda M. (Moscow)

- **Barbarash O.** (Kemerovo). DAT in ACS patients in clinical practice.
- **Panchenko E.** (Moscow). High cardiovascular risk a year after MI and how to reduce it: PEGASUS results.
- **Averkov O.** (Moscow). Choosing a patient: who needs long-term DAT?

CONFERENCE HALL №8 (B2, 2 FLOOR)

13.30–15.00

SYMPOSIUM

Historic parallels: Polypill in the concept of new science of power by Machiavelli
(supported by Gedeon Richter)

Chairperson: Arutyunov G. (Moscow)

- **Arutyunov G.** (Moscow). Management of cardiovascular risks: antihypertensive therapy perspective.
- **Arutyunov A.** (Moscow). Management of cardiovascular risks: lipid-lowering therapy perspective.
- **Arutyunov G.** (Moscow), **Arutyunov A.** (Moscow). Discussion: Therapy onset: the sooner, the better? Indications for early start of statin therapy.

GENERAL PARTNERS



Science For A Better Life



ГЕДЕОН РИХТЕР



PARTNERS



GENERAL INFORMATION PARTNERS



ИНТЕРНЕТ СЕССИЯ
ВСЕРОССИЙСКАЯ ОБРАЗОВАТЕЛЬНАЯ ПРОГРАММА ДЛЯ ВРАЧЕЙ

INFORMATION PARTNERS



EXHIBITORS





 БРИЛИНТА®
тикагрелор таблетки

Только у Ксарелто® есть специальная дозировка 15 мг для пациентов с нарушением функции почек, изученная в проспективном исследовании^{4,5}

КАСРЕЛО® Международное непатентованное название: ривароксабан. Лекарственная форма: таблетки покрытые пленочной оболочкой. 1 таблетка покрытая пленочной оболочкой содержит 25/150/150 мг ривароксабана микроинкапсулированного. **ПОКАЗАНИЯ К ПРИМЕНЕНИЮ:** Лечение венозной тромбоэмболии (ВТЭ) и профилактика рецидивов ВТЭ у пациентов после острого коронарного синдрома (ОКС), протекания с повышением кардиоспецифических биомаркеров, в комбинационной терапии с ацетилсалициловой кислотой или с ацетилсалициловой кислотой и тиагродипирином; для профилактики тромбозов (для таблеток 150 мг); для профилактики инсульта и системной тромбоэмболии у пациентов с фибрилляцией предсердий (для таблеток 150 мг); для профилактики тромбозов глубоких вен и тромбоэмболии легочной артерии и профилактики рецидивов ТБЕ и ЭЛА (для таблеток 150 мг). **ПРОТИВОПОКАЗАНИЯ.** Повышенная чувствительность к ривароксабану или любому вспомогательному веществу таблеток; клинически значимые активные кровотечения; тяжелая почечная недостаточность (клиренс креатинина < 30 мл/мин); одновременное лечение, протекающее с коагулопатией, ведущей к клинически значимому риску кровотечения; беременность и период лактации (период грудного вскармливания); детский возраст до 18 лет. Противопоказано применение препарата одновременно с другими антикоагулянтами, например, непрямыми пероральными гепаринами, низкомолекулярными гепаринами (энксапарин, далтепарин и др.), производными гепарина (фондапаринкс и др.), пероральными антикоагулянтами (варфарин, апиксадон, дабигатран этезилат и др.). Следует избегать приема препаратов, содержащих витамин K. Прием препарата Касрело®, или же когда HbG назначается в низкие дозы для поддержания проходимости центрального венозного или абдоминального катетера, наследственная непереносимость лактозы, дефицит сахаразы/лактазы, дефицит фермента сульфатазы, синдром «сахарного мочеиспускания» (в связи с наличием в составе лактозы). **Дополнительно для таблеток 25 мг:** цирроз печени и нарушения функции печени класса B и C по классификации Чайлд-Пью, лечение ОЖС.

[illegible]

Литература: 1. Patel M.R. et al. N Engl J Med 2011; 2. Tamayo S. et al. Clin Cardiol 2015; 3. Gamm J. et al. Eur Heart J. 2015; 4. Fox KA., Piccini JP., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387-94; 5. Xarelto® (rivaroxaban) Summary of Product Characteristics as approved by the European Commission; 6. Colleen A. McHorney et al. Current Medical Research and Opinion <http://dx.doi.org/10.1185/03007995.2015.1096242>.

*Оценка по шкале CHADS₂ от 1 до 6
ФП – фибрилляция предсердий не

[illegible][illegible][illegible]

AstraZeneca 

АО «БАЙЕР». 107113, Москва, 3-я Рыбинская ул., д. 18, стр. 2. Тел.: +7 (495) 231 1200, факс: +7 (495) 231 1202, www.pharma.bayer.ru

ЭКВАМЕР®

АМЛОДИПИН | ЛИЗИНОПРИЛ | РОЗУВАСТАТИН

1 капсула 1 раз в день
УВЕРЕННОСТЬ ВРАЧА,
УДОБСТВО ПАЦИЕНТА!

Эквимер® – единственная
тройная фиксированная
комбинация для комплекс-
ной терапии пациентов
с артериальной гипертензией
и дислипидемией^{1,2}



ВЕСОМЫЕ ПРЕИМУЩЕСТВА

- Суточный контроль артериального давления и холестерина²⁻⁴
- Благоприятный профиль безопасности⁴
- Увеличение приверженности к терапии благодаря однократному приему⁵

1. <http://grls.rosminzdrav.ru/GRLS>

2. См. инструкцию по медицинскому применению препарата Эквимер®.

3. Карпов Ю.А. Кардиология. 2015; 55(9): 10–15.

4. Карпов Ю.А. РМЖ. 2015; 27: 1581–83.

5. Mancini G. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal. 2013; 34: 2194.



На правах рекламы

Представительство ОАО «Гедеон Рихтер» (Венгрия):
Россия, 119049, Москва, 4-й Добрынинский переулок, 8.
Тел.: +7 (495) 987 1555, факс: +7 (495) 987 1556, www.g-richter.ru
Для медицинских и фармацевтических работников.



ГЕДЕОН РИХТЕР

Dr.Reddy's

ТЕЛСАРТАН

телмисартан 40/80 мг

ТЕЛСАРТАН Н

телмисартан 40/80 мг + гидрохлоротиазид 12,5 мг

УВЕРЕННОСТЬ В ЗАВТРАШНЕМ ДНЕ



**ПОЛНОЦЕННЫЙ СУТОЧНЫЙ
КОНТРОЛЬ АД¹**



**КОМПЛЕКСНАЯ ЗАЩИТА
ПАЦИЕНТОВ ВЫСОКОГО СС-РИСКА^{1,2}**



**ПОВЫШЕНИЕ ПРИВЕРЖЕННОСТИ
К ЛЕЧЕНИЮ³**



1. Инструкция по медицинскому применению лекарственного препарата Телсартан Н® ЛП-004256. 2. The ONTARGET Investigators Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events N Engl J Med 2008; 358:1547–1559. 3. 2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal (2013) 34, 2159–2219

Регистрационное удостоверение №ЛП-004256, ЛП-004161. Для конференций. Информация для медицинских и фармацевтических работников. Реклама.

При возникновении вопросов обращаться: ООО «Др. Редди'с Лабораторис», 115035, г. Москва, Овчинниковская наб., д.20, стр.1, тел: +7(495)783-29-01



KRKA – лидер в области кардиологии! ¹

Вальсакор®
таблетки вальсартана/гидрохлоротиазида
80/12,5 мг и 160/12,5 мг №30, №90, 160/25 мг №30

Вальсакор®
таблетки вальсартана
80 мг и 160 мг №30, №90, 320 мг №30

Вамлосет®
таблетки амлодипина/вальсартана
5/80 мг, 5/160 мг, 10/160 мг №30

Victory*

У 91% пациентов был достигнут целевой уровень АД²

В 93% случаев не было отмечено нежелательных явлений²

Уже на 4 неделе терапии большинство пациентов достигло целевого АД²

Победа в нашем сердце!

Показания к применению препарата Вальсакор®: Артериальная гипертензия. Хроническая сердечная недостаточность (II-IV функциональный класс по классификации NYHA) в составе комплексной терапии (на фоне стандартной терапии) у пациентов, не получающих ингибиторы АПФ. Повышение выживаемости пациентов после перенесенного острого ИМ, осложненного левожелудочковой недостаточностью и/или систолической дисфункцией левого желудочка, при наличии стабильных показателей гемодинамики.

Показания к применению препаратов Вальсакор® Н80, Вальсакор® Н160, Вальсакор® НД160: Артериальная гипертензия (пациентам, которым показана комбинированная терапия).

Показания к применению препарата Вамлосет®: Артериальная гипертензия (пациентам, которым показана комбинированная терапия).

Форма выпуска: Вальсакор® – таблетки, покрытые пленочной оболочкой, по 80 мг, 160 мг и 320 мг. **Вальсакор® Н80, Вальсакор® Н160, Вальсакор® НД160** – таблетки, покрытые пленочной оболочкой, по 80/12,5 мг, 160/12,5 мг, 160/25 мг. По 30 и 90 таблеток в упаковке. **Вамлосет®** – таблетки, покрытые пленочной оболочкой, по 5/80 мг, 5/160 мг и 10/160 мг. По 30 таблеток в упаковке. **Способ применения и дозы:** Внутрь, вне зависимости от приема пищи, 1 раз в день. **Условия отпуска из аптек:** По рецепту.

* международное клиническое исследование эффективности и безопасности антигипертензивной монотерапии вальсартаном и его фиксированной комбинации с гидрохлоротиазидом в разных дозовых режимах.

Источники информации: 1. Премии XXIII Российского национального конгресса «Человек и лекарство», май 2016 г. Москва 2. Чазова И.Е., Мартынюк Т.В. Первые результаты международного клинического исследования ICTORY: эффективности и безопасности антигипертензивной монотерапии вальсартаном и его фиксированной комбинации с гидрохлоротиазидом в разных дозовых режимах у пациентов с артериальной гипертензией 1–2 степени. Системные гипертензии. 2015; 12 (2): 71–82.

Информация предназначена для медицинских и фармацевтических работников.


Заказчик размещения рекламы ООО «KRKA ФАРМА»

125212, г. Москва, Головинское шоссе, дом 5, корпус 1.

Тел.: (495) 981 1095, факс: (495) 981 1091. E-mail: info@krka.ru, www.krka.ru



ГОРДОСТЬ ВРАЧА – СПАСЕННЫЕ ЖИЗНИ



**1 ТАБЛЕТКА
РАЗ В ДЕНЬ
ГОД**

Плавикс®/ Коплавикс®
♥ **Универсальный антиагрегант при любой стратегии лечения ОКС^{1,2}**
♥ **Двойная защита от повторного сердечно-сосудистого события²**

¹ CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with Acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494–502.

² Sabatine M., et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med. 2005; 352: 1179–1189.

Плавикс® МЕЖДУНАРОДНОЕ НЕПАТЕНТОВАННОЕ НАЗВАНИЕ. Клопидогрел. ДЕЙСТВУЮЩЕЕ ВЕЩЕСТВО. Клопидогрел гидросульфат в форме II. Фармакотерапевтическая группа: антиагрегантное средство. Код АТХ B01AC04. ЛЕКАРСТВЕННАЯ ФОРМА. Таблетки, покрытые пленочной оболочкой. В 1 таблетке содержится: действующее вещество: клопидогрел гидросульфат в форме II — 97,875 мг (в пересчете на клопидогрел — 75,0 мг) и вспомогательные вещества. ФАРМАКОДИНАМИЧЕСКИЕ СВОЙСТВА. Клопидогрел представляет собой пролекарство, один из активных метаболитов которого является ингибитором агрегации тромбоцитов. Активный метаболит клопидогрела селективно ингибирует связывание АДФ с P2Y₁₂-рецептором тромбоцитов и последующую АДФ-опосредованную активацию комплекса GPIIb/IIIa, приводя к подавлению агрегации тромбоцитов. ПОКАЗАНИЯ К ПРИМЕНЕНИЮ. Предотвращение атеротромботических осложнений у взрослых пациентов с инфарктом миокарда, ишемическим инсультом или с диагностированной окклюзионной болезнью периферических артерий, у взрослых пациентов с острым коронарным синдромом. Предотвращение атеротромботических и тромбоэмболических осложнений при фибрилляции предсердий. ОКС: без подъема сегмента ST (нестабильная стенокардия или инфаркт миокарда без зубца Q), включая пациентов, которым было проведено стентирование; с подъемом сегмента ST (острый инфаркт миокарда) при медикаментозном лечении и возможности проведения тромболизиса (в комбинации с АСК). ПРОТИВОПОКАЗАНИЯ. Повышенная чувствительность к клопидогрелу или любому из вспомогательных веществ препарата, тяжелая печеночная недостаточность, острое кровоотечение, например кровоотечение из желудочно-кишечного тракта, редкая наследственная непереносимость галактозы, дефицит лактазы и глюкозо-галактозная мальабсорбция, беременность и период грудного вскармливания, детский возраст до 18 лет. БЕРЕМЕННОСТЬ. Не рекомендуется прием клопидогрела во время беременности, за исключением тех случаев, когда, по мнению врача, его применение настоятельно необходимо. ПЕРИОД КОРМЛЕНИЯ ГРУДНОГО. Печеный врач, исходя из важности приема препарата Плавикс® для матери, должен рекомендовать ей прекратить прием препарата или принимать препарат, но отказаться от грудного вскармливания. СПОСОБ ПРИМЕНЕНИЯ И ДОЗЫ. Клопидогрел следует принимать внутрь, независимо от приема пищи. Инфаркт миокарда, ишемический инсульт и диагностированная окклюзионная болезнь периферических артерий: препарат принимается по 75 мг 1 раз в сутки. Острый коронарный синдром без подъема сегмента ST: лечение клопидогрелом должно быть начато с однократного приема нагрузочной дозы, составляющей 300 мг, а затем продолжено приемом дозы 75 мг 1 раз в сутки (в сочетании с ацетилсалициловой кислотой в дозах 75–325 мг в сутки). Острый коронарный синдром с подъемом сегмента ST: клопидогрел следует принимать однократно в сутки в дозе 75 мг с пероральными однократными приемом нагрузочной дозы клопидогрела 300 мг в комбинации с ацетилсалициловой кислотой в сочетании с тромболизисом или без сочетания с тромболизисом. У пациентов старше 75 лет лечение клопидогрелом должно начинаться без приема его нагрузочной дозы. ПОБОЧНОЕ ДЕЙСТВИЕ. Кровоотечения и кровоизлияния, нарушения со стороны крови, диспепсия, абдоминальные боли, диарея. Для ознакомления с побочными эффектами, возникающими нечасто, редко и очень редко, ознакомьтесь с официальной инструкцией по медицинскому применению лекарственного препарата. ПЕРЕДОЗИРОВКА. При появлении кровоотечения требуется проведение соответствующих лечебных мероприятий. Антидот клопидогрела не установлен. Если необходима быстрая коррекция удлинившегося времени кровоотечения, то рекомендуется проведение переливания тромбоцитарной массы. ФОРМА ВЫПУСКА. Таблетки, покрытые пленочной оболочкой, 75 мг. По 7, 10, 14 и 14 таблеток в блистерах из ПВХ/ПВХ и фольги алюминированной или ПВХ/Ал/ПВХ и фольги алюминированной. По 1, 2 или 3 блистера по 7 или 14 таблеток, по 1, 2, 3 или 10 блистеров по 10 таблеток вместе с инструкцией по применению в картонную пачку. УСЛОВИЯ ХРАНЕНИЯ. Хранить при температуре не выше 30 °С. Хранить в недоступном для детей месте. СРОК ГОДНОСТИ И ДОЗЫ. УСЛОВИЯ ОТПУСКА. Отпускается по рецепту. РЕГИСТРАЦИОННЫЙ НОМЕР. ЛП № 015542/01. Дата регистрации 05.03.2009. Дата последних изменений 11.04.2016. С подробной информацией о препарате можно ознакомиться в официальной инструкции по медицинскому применению лекарственного препарата.

Коплавикс® МЕЖДУНАРОДНОЕ НЕПАТЕНТОВАННОЕ НАЗВАНИЕ. Ацетилсалициловая кислота + клопидогрел. ДЕЙСТВУЮЩЕЕ ВЕЩЕСТВО. Клопидогрел гидросульфат в форме II, ацетилсалициловая кислота. Фармакотерапевтическая группа: антиагрегантное средство. Код АТХ B01AC04. ЛЕКАРСТВЕННАЯ ФОРМА. Таблетки, покрытые пленочной оболочкой. ФАРМАКОДИНАМИЧЕСКИЕ СВОЙСТВА. Клопидогрел представляет собой пролекарство, один из активных метаболитов которого является ингибитором агрегации тромбоцитов. Его активный метаболит необратимо связывается с тромбоцитарными АДФ-рецепторами (рецепторами аденилицилициклофосфата) и селективно ингибирует связывание АДФ с АДФ-рецепторами тромбоцитов и последующую активацию комплекса GPIIb/IIIa под действием АДФ, благодаря чему подавляется АДФ-индуцируемая агрегация тромбоцитов. Ацетилсалициловая кислота (АСК) подавляет агрегацию тромбоцитов за счет необратимого ингибирования простагландинной циклооксигеназы-1 в результате этого уменьшается образование тромбоксана А₂. ПОКАЗАНИЯ К ПРИМЕНЕНИЮ. Предотвращение у пациентов, которые уже получают однократно клопидогрел и ацетилсалициловую кислоту. Предотвращение атеротромботических осложнений у взрослых пациентов с острым коронарным синдромом. Предотвращение атеротромботических и тромбоэмболических осложнений при фибрилляции предсердий. ПРОТИВОПОКАЗАНИЯ. Повышенная чувствительность к любому из вспомогательных веществ препарата, тяжелая печеночная недостаточность, острое кровоотечение, кровоизлияние, индукция приема салицилатов и других индукторов противосвертывающих препаратов (НВГ), синдром бронхитальной астмы, ринит и рецидивирующего поллиноза носа и слизистых глаз, гиперчувствительность к НВГ, кровотечения, редкие наследственные состояния: непереносимость галактозы, дефицит лактазы вследствие дефицита лактазы, синдром мальабсорбции глюкозы-галактозы, беременность и период грудного вскармливания, детский возраст до 18 лет. БЕРЕМЕННОСТЬ. В связи с наличием в составе препарата АСК не рекомендуется прием Коплавикс® не следует применять в течение первых двух триместров беременности, за исключением случаев, когда клиническое состояние женщины требует лечения клопидогрелом в комбинации с АСК. В качестве анальгетика в составе препарата АСК не противопоказан в 3-м триместре беременности. ПЕРИОД КОРМЛЕНИЯ ГРУДНОГО. Грудное вскармливание в случае лечения препаратом Коплавикс® следует прекратить. СПОСОБ ПРИМЕНЕНИЯ И ДОЗЫ. Препарат Коплавикс® следует принимать 1 раз в сутки вне зависимости от приема пищи. Острый коронарный синдром (ОКС): прием препарата Коплавикс® начинать после однократной нагрузочной дозы клопидогрела в комбинации с АСК в виде отдельных препаратов, а именно: клопидогрел в дозе 300 мг и АСК в дозах 75–325 мг в сутки. Фибрилляция предсердий: препарат Коплавикс® следует принимать 1 раз в сутки после начала лечения клопидогрелом 75 мг и АСК 100 мг в виде отдельных препаратов. ПОБОЧНОЕ ДЕЙСТВИЕ. Кровоотечения и кровоизлияния, желудочно-кишечные кровоотечения, диспепсия, абдоминальные боли, диарея. Для ознакомления с побочными эффектами, возникающими нечасто, редко и очень редко, ознакомьтесь с официальной инструкцией по медицинскому применению лекарственного препарата. ПЕРЕДОЗИРОВКА. При появлении кровоотечения требуется проведение соответствующего лечения. Антидот клопидогрела не установлен. Если необходима быстрая коррекция удлинившегося времени кровоотечения, то рекомендуется переливание тромбоцитарной массы. При выявлении симптомов тяжелой передозировки АСК требуется госпитализация. При умеренной интоксикации можно попытаться искусственно вызвать рвоту, в случае неудачи показана промывание желудка. ФОРМА ВЫПУСКА. По 7 таблеток в ПВХ/ПВХ/Ал/фольгированной блистер. По 1, 2 или 4 блистера вместе с инструкцией по применению в картонную пачку. По 10 таблеток в ПВХ/ПВХ/Ал/фольгированной блистер. По 10 блистеров вместе с инструкцией по применению в картонную пачку. УСЛОВИЯ ХРАНЕНИЯ. Хранить при температуре не выше 25 °С. Хранить в недоступном для детей месте. СРОК ГОДНОСТИ. 2 года. УСЛОВИЯ ОТПУСКА. Отпускается по рецепту. РЕГИСТРАЦИОННЫЙ НОМЕР. ЛП-000163. Дата регистрации 15.12.2014. Дата последних изменений 26.02.2016. С подробной информацией о препарате можно ознакомиться в официальной инструкции по медицинскому применению лекарственного препарата.

Представительство АО «Санofi-авентис груп» (Франция).

125009, Москва, ул. Тверская, 22. Тел.: (495) 721-14-00, факс: (495) 721-14-11. www.sanofi.ru

Материал предназначен для медицинских (фармацевтических) работников.

С ПОДРОБНОЙ ИНФОРМАЦИЕЙ О ПРЕПАРАТЕ МОЖНО ОЗНАКОМИТЬСЯ В ИНСТРУКЦИИ ПО МЕДИЦИНСКОМУ ПРИМЕНЕНИЮ.

Реклама.



Пралуэнт

алирокумаб
РАСШИРЯЯ ГРАНИЦЫ ВОЗМОЖНОГО

Единственный ингибитор PCSK9,
доступный в двух дозировках,
обеспечивающий два уровня
снижения ХС-ЛНП^{1,2,*}

**ДОСТИЖЕНИЕ ЦЕЛЕВЫХ
ЗНАЧЕНИЙ ХС-ЛНП****
при добавлении к максимально
переносимым дозам статинов...³

**...и усиление ЭФФЕКТА
ПРИ НЕОБХОДИМОСТИ.**
Обеспечивает >60% дополнительного
снижения ХС-ЛНП^{4,5,***}

Лечение первичной гиперхолестеринемии и смешанной дислипидемии у взрослых в комбинации с максимально переносимой дозой статинов или в качестве монотерапии у пациентов с непереносимостью статинов²

ХС-ЛНП – холестерин липопротеинов низкой плотности.

* При сравнении с лекарственным препаратом Репата по количеству зарегистрированных случаев: в инструкции по применению лекарственного препарата Репата (РУ ПП-003574 от 19.04.2016) указана одна дозировка 140 мг/мл, в инструкции по применению лекарственного препарата Пралуэнт указаны две дозировки: 75 мг/мл и 150 мг/мл.

** У пациентов ОЧЕНЬ ВЫСОКОГО сердечно-сосудистого риска целевой уровень ХС-ЛНП <1,8 ммоль/л. [Европейские рекомендации по ведению дислипидемий 2016, Catapano, Alberico L., et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European heart journal 37.39 (2016): 2999-3058].

*** В сравнении с плацебо у пациентов, которые уже получают терапию максимально переносимыми дозами статинов +/- другие липидснижающие препараты.

1. McDonald, Marian, et al. A systematic review of PCSK9 inhibitors alirocumab and evolocumab. Journal of managed care & specialty pharmacy 22.6 (2016): 641-653q. 2. Инструкция по медицинскому применению лекарственного препарата Пралуэнт. Регистрационное удостоверение в РФ: ЛП-004078 от 16.01.2017. Дата последних изменений: 24.03.2017. 3. Cannon, Christopher P., et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. European heart journal 36.19 (2015): 1186-1194. 4. Kastelein, John JP, et al. Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia. Coronary artery disease 28.3 (2017): 190. 5. Robinson, Jennifer G., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. New England Journal of Medicine 372.16 (2015): 1489-1499.

Краткая инструкция по применению препарата Пралуэнт. МЕЖДУНАРОДНОЕ НЕПАТЕНТОВАННОЕ НАИМЕНОВАНИЕ: алирокумаб. СОСТАВ: алирокумаб 75 мг/мл или 150 мг/мл. ФОРМА ВЫПУСКА: раствор для подкожного введения. ПОКАЗАНИЯ К ПРИМЕНЕНИЮ. Длительное лечение взрослых пациентов первичной гиперхолестеринемией (несемейной и гетерозиготной формой семейной гиперхолестеринемии) или смешанной дислипидемией, включая пациентов с сахарным диабетом 2 типа, в дополнение к диете, для снижения концентрации холестерина липопротеинов низкой плотности (ХС-ЛНП), общего холестерина (общего ХС), холестерина липопротеинов, не являющихся липопротеинами высокой плотности (ХС-ЛНПb), аполипопротеина В (Аpo В), триглицеридов (ТГ) и аполипопротеина А (Аpo А), повышения концентрации холестерина липопротеинов высокой плотности (ХС-ЛНПa) и аполипопротеина А-1 (Аpo А-1). Препарат Пралуэнт показан: в комбинации со статинами (ингибиторами ГМГ-КоА-редуктазы) в сочетании или без сочетания другой липид-модифицирующей терапии при невозможности достижения у пациентов целевой концентрации ХС-ЛНП при приеме максимально допустимых доз статинов; в монотерапии или как дополнение к другим, не содержащим статинов липид-модифицирующей терапии, у пациентов с непереносимостью статинов или при наличии противопоказаний к их применению. СПОСОБ ПРИМЕНЕНИЯ И ДОЗЫ. Начальная доза препарата составляет 75 мг, которую вводят подкожно 1 раз в 2 недели. У пациентов, которым требуется большее снижение концентрации ХС-ЛНП (>60%), начальная доза препарата Пралуэнт может составлять 150 мг, которую также вводят подкожно 1 раз в 2 недели. Дозу препарата Пралуэнт следует подбирать индивидуально. ПРОТИВПОКАЗАНИЯ. Повышенная чувствительность к алирокумабу или какому-либо вспомогательному веществу препарата; беременность; период грудного вскармливания; детский возраст до 18 лет. С ОСТОРОЖНОСТЬЮ. Печеночная недостаточность тяжелой степени; печеночная недостаточность тяжелой степени. ОСОБЫЕ УКАЗАНИЯ. В клинических исследованиях сообщалось о развитии генерализованных аллергических реакций. При появлении симптомов и признаков серьезных аллергических реакций лечение препаратом Пралуэнт должно быть прекращено и следует начать проведение соответствующей симптоматической терапии. Данные о применении алирокумаба у пациентов старше 75 лет ограничены. Пралуэнт следует применять с осторожностью у пациентов с печеночной или печеночной недостаточностью тяжелой степени. ВЗАИМОДЕЙСТВИЕ С ДРУГИМИ ЛЕКАРСТВЕННЫМИ СРЕДСТВАМИ. Не ожидается каких-либо фармакокинетических эффектов алирокумаба на другие лекарственные препараты. В клинических исследованиях не наблюдалось каких-либо значимых изменений концентрации статинов в крови при повторных введениях алирокумаба. Повышение концентрации PCSK9 может привести к уменьшению системной экспозиции алирокумаба. Однако это не влияет на продолжительность действия препарата при применении алирокумаба 1 раз в 2 нед. ПОБОЧНЫЕ ДЕЙСТВИЯ. Субъективные симптомы и объективные признаки со стороны верхних дыхательных путей, включая боль в ротоглотке, ринорею, чихание; кожный зуд; реакции в месте введения препарата. Для исключения побочных эффектов, возникающих вследствие приема, и/или очень редких, ознакомьтесь с официальной инструкцией по медицинскому применению лекарственного препарата. ПЕРЕДОЗИРОВКА. В контролируемых клинических исследованиях не было выявлено никаких изменений безопасности при более частом введении доз, чем рекомендованный режим дозирования 1 раз в 2 недели. ФАРМАКОЛОГИЧЕСКИЕ СВОЙСТВА. Полностью гуманизированное моноклональное антитело (IgG1). Ингибитор пропротеиновой конвертазы субтилизин-кисленин типа 9 (PCSK9). Код АТХ: С10АХ14. Ингибирование связывания PCSK9 с рецепторами ЛНПb, алирокумаб увеличивает количество рецепторов ЛНПb для выведения ЛНПb, снижая концентрацию ХС-ЛНПb в крови. Лечение алирокумабом может снизить концентрацию липопротеинов (ЛПb) и липопротеинов промежуточной плотности (ЛПb) и липопротеинов высокой плотности (ЛПb) и липопротеинов высокой плотности (ХС-ЛНПb) и ТГ. Алирокумаб также снижает концентрацию липопротеинов (a). РЕГИСТРАЦИОННОЕ УДОСТОВЕРЕНИЕ в РФ: ЛП-004078. Дата регистрации: 16.01.2017. Дата последних изменений: 24.03.2017. Представительство АО «Санofi-авентис групп» (Франция). 125009, Москва, ул. Тверская, 22. Тел.: (495) 721-14-00, факс: (495) 721-14-11. www.sanofi.ru. Материал предназначен для медицинских (фармацевтических) работников. С ПОДРОБНОЙ ИНФОРМАЦИЕЙ О ПРЕПАРАТЕ МОЖНО ОЗНАКОМИТЬСЯ В ИНСТРУКЦИИ ПО МЕДИЦИНСКОМУ ПРИМЕНЕНИЮ. Реклама. SARU.RA.11.07.02.016(2)

Краткая инструкция по медицинскому применению препарата Трипликсан®
СОСТАВ: Трипликсан 5 мг/2,5 мг/5 мг/5,0 мг/10 мг/15 мг/20 мг/25 мг/30 мг/35 мг/40 мг/45 мг/50 мг/55 мг/60 мг/65 мг/70 мг/75 мг/80 мг/85 мг/90 мг/95 мг/100 мг/105 мг/110 мг/115 мг/120 мг/125 мг/130 мг/135 мг/140 мг/145 мг/150 мг/155 мг/160 мг/165 мг/170 мг/175 мг/180 мг/185 мг/190 мг/195 мг/200 мг/205 мг/210 мг/215 мг/220 мг/225 мг/230 мг/235 мг/240 мг/245 мг/250 мг/255 мг/260 мг/265 мг/270 мг/275 мг/280 мг/285 мг/290 мг/295 мг/300 мг/305 мг/310 мг/315 мг/320 мг/325 мг/330 мг/335 мг/340 мг/345 мг/350 мг/355 мг/360 мг/365 мг/370 мг/375 мг/380 мг/385 мг/390 мг/395 мг/400 мг/405 мг/410 мг/415 мг/420 мг/425 мг/430 мг/435 мг/440 мг/445 мг/450 мг/455 мг/460 мг/465 мг/470 мг/475 мг/480 мг/485 мг/490 мг/495 мг/500 мг/505 мг/510 мг/515 мг/520 мг/525 мг/530 мг/535 мг/540 мг/545 мг/550 мг/555 мг/560 мг/565 мг/570 мг/575 мг/580 мг/585 мг/590 мг/595 мг/600 мг/605 мг/610 мг/615 мг/620 мг/625 мг/630 мг/635 мг/640 мг/645 мг/650 мг/655 мг/660 мг/665 мг/670 мг/675 мг/680 мг/685 мг/690 мг/695 мг/700 мг/705 мг/710 мг/715 мг/720 мг/725 мг/730 мг/735 мг/740 мг/745 мг/750 мг/755 мг/760 мг/765 мг/770 мг/775 мг/780 мг/785 мг/790 мг/795 мг/800 мг/805 мг/810 мг/815 мг/820 мг/825 мг/830 мг/835 мг/840 мг/845 мг/850 мг/855 мг/860 мг/865 мг/870 мг/875 мг/880 мг/885 мг/890 мг/895 мг/900 мг/905 мг/910 мг/915 мг/920 мг/925 мг/930 мг/935 мг/940 мг/945 мг/950 мг/955 мг/960 мг/965 мг/970 мг/975 мг/980 мг/985 мг/990 мг/995 мг/1000 мг/1005 мг/1010 мг/1015 мг/1020 мг/1025 мг/1030 мг/1035 мг/1040 мг/1045 мг/1050 мг/1055 мг/1060 мг/1065 мг/1070 мг/1075 мг/1080 мг/1085 мг/1090 мг/1095 мг/1100 мг/1105 мг/1110 мг/1115 мг/1120 мг/1125 мг/1130 мг/1135 мг/1140 мг/1145 мг/1150 мг/1155 мг/1160 мг/1165 мг/1170 мг/1175 мг/1180 мг/1185 мг/1190 мг/1195 мг/1200 мг/1205 мг/1210 мг/1215 мг/1220 мг/1225 мг/1230 мг/1235 мг/1240 мг/1245 мг/1250 мг/1255 мг/1260 мг/1265 мг/1270 мг/1275 мг/1280 мг/1285 мг/1290 мг/1295 мг/1300 мг/1305 мг/1310 мг/1315 мг/1320 мг/1325 мг/1330 мг/1335 мг/1340 мг/1345 мг/1350 мг/1355 мг/1360 мг/1365 мг/1370 мг/1375 мг/1380 мг/1385 мг/1390 мг/1395 мг/1400 мг/1405 мг/1410 мг/1415 мг/1420 мг/1425 мг/1430 мг/1435 мг/1440 мг/1445 мг/1450 мг/1455 мг/1460 мг/1465 мг/1470 мг/1475 мг/1480 мг/1485 мг/1490 мг/1495 мг/1500 мг/1505 мг/1510 мг/1515 мг/1520 мг/1525 мг/1530 мг/1535 мг/1540 мг/1545 мг/1550 мг/1555 мг/1560 мг/1565 мг/1570 мг/1575 мг/1580 мг/1585 мг/1590 мг/1595 мг/1600 мг/1605 мг/1610 мг/1615 мг/1620 мг/1625 мг/1630 мг/1635 мг/1640 мг/1645 мг/1650 мг/1655 мг/1660 мг/1665 мг/1670 мг/1675 мг/1680 мг/1685 мг/1690 мг/1695 мг/1700 мг/1705 мг/1710 мг/1715 мг/1720 мг/1725 мг/1730 мг/1735 мг/1740 мг/1745 мг/1750 мг/1755 мг/1760 мг/1765 мг/1770 мг/1775 мг/1780 мг/1785 мг/1790 мг/1795 мг/1800 мг/1805 мг/1810 мг/1815 мг/1820 мг/1825 мг/1830 мг/1835 мг/1840 мг/1845 мг/1850 мг/1855 мг/1860 мг/1865 мг/1870 мг/1875 мг/1880 мг/1885 мг/1890 мг/1895 мг/1900 мг/1905 мг/1910 мг/1915 мг/1920 мг/1925 мг/1930 мг/1935 мг/1940 мг/1945 мг/1950 мг/1955 мг/1960 мг/1965 мг/1970 мг/1975 мг/1980 мг/1985 мг/1990 мг/1995 мг/2000 мг/2005 мг/2010 мг/2015 мг/2020 мг/2025 мг/2030 мг/2035 мг/2040 мг/2045 мг/2050 мг/2055 мг/2060 мг/2065 мг/2070 мг/2075 мг/2080 мг/2085 мг/2090 мг/2095 мг/2100 мг/2105 мг/2110 мг/2115 мг/2120 мг/2125 мг/2130 мг/2135 мг/2140 мг/2145 мг/2150 мг/2155 мг/2160 мг/2165 мг/2170 мг/2175 мг/2180 мг/2185 мг/2190 мг/2195 мг/2200 мг/2205 мг/2210 мг/2215 мг/2220 мг/2225 мг/2230 мг/2235 мг/2240 мг/2245 мг/2250 мг/2255 мг/2260 мг/2265 мг/2270 мг/2275 мг/2280 мг/2285 мг/2290 мг/2295 мг/2300 мг/2305 мг/2310 мг/2315 мг/2320 мг/2325 мг/2330 мг/2335 мг/2340 мг/2345 мг/2350 мг/2355 мг/2360 мг/2365 мг/2370 мг/2375 мг/2380 мг/2385 мг/2390 мг/2395 мг/2400 мг/2405 мг/2410 мг/2415 мг/2420 мг/2425 мг/2430 мг/2435 мг/2440 мг/2445 мг/2450 мг/2455 мг/2460 мг/2465 мг/2470 мг/2475 мг/2480 мг/2485 мг/2490 мг/2495 мг/2500 мг/2505 мг/2510 мг/2515 мг/2520 мг/2525 мг/2530 мг/2535 мг/2540 мг/2545 мг/2550 мг/2555 мг/2560 мг/2565 мг/2570 мг/2575 мг/2580 мг/2585 мг/2590 мг/2595 мг/2600 мг/2605 мг/2610 мг/2615 мг/2620 мг/2625 мг/2630 мг/2635 мг/2640 мг/2645 мг/2650 мг/2655 мг/2660 мг/2665 мг/2670 мг/2675 мг/2680 мг/2685 мг/2690 мг/2695 мг/2700 мг/2705 мг/2710 мг/2715 мг/2720 мг/2725 мг/2730 мг/2735 мг/2740 мг/2745 мг/2750 мг/2755 мг/2760 мг/2765 мг/2770 мг/2775 мг/2780 мг/2785 мг/2790 мг/2795 мг/2800 мг/2805 мг/2810 мг/2815 мг/2820 мг/2825 мг/2830 мг/2835 мг/2840 мг/2845 мг/2850 мг/2855 мг/2860 мг/2865 мг/2870 мг/2875 мг/2880 мг/2885 мг/2890 мг/2895 мг/2900 мг/2905 мг/2910 мг/2915 мг/2920 мг/2925 мг/2930 мг/2935 мг/2940 мг/2945 мг/2950 мг/2955 мг/2960 мг/2965 мг/2970 мг/2975 мг/2980 мг/2985 мг/2990 мг/2995 мг/3000 мг/3005 мг/3010 мг/3015 мг/3020 мг/3025 мг/3030 мг/3035 мг/3040 мг/3045 мг/3050 мг/3055 мг/3060 мг/3065 мг/3070 мг/3075 мг/3080 мг/3085 мг/3090 мг/3095 мг/3100 мг/3105 мг/3110 мг/3115 мг/3120 мг/3125 мг/3130 мг/3135 мг/3140 мг/3145 мг/3150 мг/3155 мг/3160 мг/3165 мг/3170 мг/3175 мг/3180 мг/3185 мг/3190 мг/3195 мг/3200 мг/3205 мг/3210 мг/3215 мг/3220 мг/3225 мг/3230 мг/3235 мг/3240 мг/3245 мг/3250 мг/3255 мг/3260 мг/3265 мг/3270 мг/3275 мг/3280 мг/3285 мг/3290 мг/3295 мг/3300 мг/3305 мг/3310 мг/3315 мг/3320 мг/3325 мг/3330 мг/3335 мг/3340 мг/3345 мг/3350 мг/3355 мг/3360 мг/3365 мг/3370 мг/3375 мг/3380 мг/3385 мг/3390 мг/3395 мг/3400 мг/3405 мг/3410 мг/3415 мг/3420 мг/3425 мг/3430 мг/3435 мг/3440 мг/3445 мг/3450 мг/3455 мг/3460 мг/3465 мг/3470 мг/3475 мг/3480 мг/3485 мг/3490 мг/3495 мг/3500 мг/3505 мг/3510 мг/3515 мг/3520 мг/3525 мг/3530 мг/3535 мг/3540 мг/3545 мг/3550 мг/3555 мг/3560 мг/3565 мг/3570 мг/3575 мг/3580 мг/3585 мг/3590 мг/3595 мг/3600 мг/3605 мг/3610 мг/3615 мг/3620 мг/3625 мг/3630 мг/3635 мг/3640 мг/3645 мг/3650 мг/3655 мг/3660 мг/3665 мг/3670 мг/3675 мг/3680 мг/3685 мг/3690 мг/3695 мг/3700 мг/3705 мг/3710 мг/3715 мг/3720 мг/3725 мг/3730 мг/3735 мг/3740 мг/3745 мг/3750 мг/3755 мг/3760 мг/3765 мг/3770 мг/3775 мг/3780 мг/3785 мг/3790 мг/3795 мг/3800 мг/3805 мг/3810 мг/3815 мг/3820 мг/3825 мг/3830 мг/3835 мг/3840 мг/3845 мг/3850 мг/3855 мг/3860 мг/3865 мг/3870 мг/3875 мг/3880 мг/3885 мг/3890 мг/3895 мг/3900 мг/3905 мг/3910 мг/3915 мг/3920 мг/3925 мг/3930 мг/3935 мг/3940 мг/3945 мг/3950 мг/3955 мг/3960 мг/3965 мг/3970 мг/3975 мг/3980 мг/3985 мг/3990 мг/3995 мг/4000 мг/4005 мг/4010 мг/4015 мг/4020 мг/4025 мг/4030 мг/4035 мг/4040 мг/4045 мг/4050 мг/4055 мг/4060 мг/4065 мг/4070 мг/4075 мг/4080 мг/4085 мг/4090 мг/4095 мг/4100 мг/4105 мг/4110 мг/4115 мг/4120 мг/4125 мг/4130 мг/4135 мг/4140 мг/4145 мг/4150 мг/4155 мг/4160 мг/4165 мг/4170 мг/4175 мг/4180 мг/4185 мг/4190 мг/4195 мг/4200 мг/4205 мг/4210 мг/4215 мг/4220 мг/4225 мг/4230 мг/4235 мг/4240 мг/4245 мг/4250 мг/4255 мг/4260 мг/4265 мг/4270 мг/4275 мг/4280 мг/4285 мг/4290 мг/4295 мг/4300 мг/4305 мг/4310 мг/4315 мг/4320 мг/4325 мг/4330 мг/4335 мг/4340 мг/4345 мг/4350 мг/4355 мг/4360 мг/4365 мг/4370 мг/4375 мг/4380 мг/4385 мг/4390 мг/4395 мг/4400 мг/4405 мг/4410 мг/4415 мг/4420 мг/4425 мг/4430 мг/4435 мг/4440 мг/4445 мг/4450 мг/4455 мг/4460 мг/4465 мг/4470 мг/4475 мг/4480 мг/4485 мг/4490 мг/4495 мг/4500 мг/4505 мг/4510 мг/4515 мг/4520 мг/4525 мг/4530 мг/4535 мг/4540 мг/4545 мг/4550 мг/4555 мг/4560 мг/4565 мг/4570 мг/4575 мг/4580 мг/4585 мг/4590 мг/4595 мг/4600 мг/4605 мг/4610 мг/4615 мг/4620 мг/4625 мг/4630 мг/4635 мг/4640 мг/4645 мг/4650 мг/4655 мг/4660 мг/4665 мг/4670 мг/4675 мг/4680 мг/4685 мг/4690 мг/4695 мг/4700 мг/4705 мг/4710 мг/4715 мг/4720 мг/4725 мг/4730 мг/4735 мг/4740 мг/4745 мг/4750 мг/4755 мг/4760 мг/4765 мг/4770 мг/4775 мг/4780 мг/4785 мг/4790 мг/4795 мг/4800 мг/4805 мг/4810 мг/4815 мг/4820 мг/4825 мг/4830 мг/4835 мг/4840 мг/4845 мг/4850 мг/4855 мг/4860 мг/4865 мг/4870 мг/4875 мг/4880 мг/4885 мг/4890 мг/4895 мг/4900 мг/4905 мг/4910 мг/4915 мг/4920 мг/4925 мг/4930 мг/4935 мг/4940 мг/4945 мг/4950 мг/4955 мг/4960 мг/4965 мг/4970 мг/4975 мг/4980 мг/4985 мг/4990 мг/4995 мг/5000 мг/5005 мг/5010 мг/5015 мг/5020 мг/5025 мг/5030 мг/5035 мг/5040 мг/5045 мг/5050 мг/5055 мг/5060 мг/5065 мг/5070 мг/5075 мг/5080 мг/5085 мг/5090 мг/5095 мг/5100 мг/5105 мг/5110 мг/5115 мг/5120 мг/5125 мг/5130 мг/5135 мг/5140 мг/5145 мг/5150 мг/5155 мг/5160 мг/5165 мг/5170 мг/5175 мг/5180 мг/5185 мг/5190 мг/5195 мг/5200 мг/5205 мг/5210 мг/5215 мг/5220 мг/5225 мг/5230 мг/5235 мг/5240 мг/5245 мг/5250 мг/5255 мг/5260 мг/5265 мг/5270 мг/5275 мг/5280 мг/5285 мг/5290 мг/5295 мг/5300 мг/5305 мг/5310 мг/5315 мг/5320 мг/5325 мг/5330 мг/5335 мг/5340 мг/5345 мг/5350 мг/5355 мг/5360 мг/5365 мг/5370 мг/5375 мг/5380 мг/5385 мг/5390 мг/5395 мг/5400 мг/5405 мг/5410 мг/5415 мг/5420 мг/5425 мг/5430 мг/5435 мг/5440 мг/5445 мг/5450 мг/5455 мг/5460 мг/5465 мг/5470 мг/5475 мг/5480 мг/5485 мг/5490 мг/5495 мг/5500 мг/5505 мг/5510 мг/5515 мг/5520 мг/5525 мг/5530 мг/5535 мг/5540 мг/5545 мг/5550 мг/5555 мг/5560 мг/5565 мг/5570 мг/5575 мг/5580 мг/5585 мг/5590 мг/5595 мг/5600 мг/5605 мг/5610 мг/5615 мг/5620 мг/5625 мг/5630 мг/5635 мг/5640 мг/5645 мг/5650 мг/5655 мг/5660 мг/5665 мг/5670 мг/5675 мг/5680 мг/5685 мг/5690 мг/5695 мг/5700 мг/5705 мг/5710 мг/5715 мг/5720 мг/5725 мг/5730 мг/5735 мг/5740 мг/5745 мг/5750 мг/5755 мг/5760 мг/5765 мг/5770 мг/5775 мг/5780 мг/5785 мг/5790 мг/5795 мг/5800 мг/5805 мг/5810 мг/5815 мг/5820 мг/5825 мг/5830 мг/5835 мг/5840 мг/5845 мг/5850 мг/5855 мг/5860 мг/5865 мг/5870 мг/5875 мг/5880 мг/5885 мг/5890 мг/5895 мг/5900 мг/5905 мг/5910 мг/5915 мг/5920 мг/5925 мг/5930 мг/5935 мг/5940 мг/5945 мг/5950 мг/5955 мг/5960 мг/5965 мг/5970 мг/5975 мг/5980 мг/5985 мг/5990 мг/5995 мг/6000 мг/6005 мг/6010 мг/6015 мг/6020 мг/6025 мг/6030 мг/6035 мг/6040 мг/6045 мг/6050 мг/6055 мг/6060 мг/6065 мг/6070 мг/6075 мг/6080 мг/6085 мг/6090 мг/6095 мг/6100 мг/6105 мг/6110 мг/6115 мг/6120 мг/6125 мг/6130 мг/6135 мг/6140 мг/6145 мг/6150 мг/6155 мг/6160 мг/6165 мг/6170 мг/6175 мг/6180 мг/6185 мг/6190 мг/6195 мг/6200 мг/6205 мг/6210 мг/6215 мг/6220 мг/6225 мг/6230 мг/6235 мг/6240 мг/6245 мг/6250 мг/6255 мг/6260 мг/6265 мг/6270 мг/6275 мг/6280 мг/6285 мг/6290 мг/6295 мг/6300 мг/6305 мг/6310 мг/6315 мг/6320 мг/6325 мг/6330 мг/6335 мг/6340 мг/6345 мг/6350 мг/6355 мг/6360 мг/6365 мг/6370 мг/6375 мг/6380 мг/6385 мг/6390 мг/6395 мг/6400 мг/6405 мг/6410 мг/6415 мг/6420 мг/6425 мг/6430 мг/6435 мг/6440 мг/6445 мг/6450 мг/6455 мг/6460 мг/6465 мг/6470 мг/6475 мг/6480 мг/6485 мг/6490 мг/6495 мг/6500 мг/6505 мг/6510 мг/6515 мг/6520 мг/6525 мг/6530 мг/6535 мг/6540 мг/6545 мг/6550 мг/6555 мг/6560 мг/6565 мг/6570 мг/6575 мг/6580 мг/6585 мг/6590 мг/6595 мг/6600 мг/6605 мг/6610 мг/6615 мг/6620 мг/6625 мг/6630 мг/6635 мг/6640 мг/6645 мг/6650 мг/6655 мг/6660 мг/6665 мг/6670 мг/6675 мг/6680 мг/6685 мг/6690 мг/6695 мг/6700 мг/6705 мг/6710 мг/6715 мг/6720 мг/6725 мг/6730 мг/6735 мг/6740 мг/6745 мг/6750 мг/6755 мг/6760 мг/6765 мг/6770 мг/6775 мг/6780 мг/6785 мг/6790 мг/6795 мг/6800 мг/6805 мг/6810 мг/6815 мг/6820 мг/6825 мг/6830 мг/6835 мг/6840 мг/6845 мг/6850 мг/6855 мг/6860 мг/6865 мг/6870 мг/6875 мг/6880 мг/6885 мг/6890 мг/6895 мг/6900 мг/6905 мг/6910 мг/6915 мг/6920 мг/6925 мг/6930 мг/6935 мг/6940 мг/6945 мг/6950 мг/6955 мг/6960 мг/6965 мг/6970 мг/6975 мг/6980 мг/6985 мг/6990 мг/6995 мг/7000 мг/7005 мг/7010 мг/7015 мг/7020 мг/7025 мг/7030 мг/7035 мг/7040 мг/7045 мг/7050 мг/7055 мг/7060 мг/7065 мг/7070 мг/7075 мг/7080 мг/7085 мг/7090 мг/7095 мг/7100 мг/7105 мг/7110 мг/7115 мг/7120 мг/7125 мг/7130 мг/7135 мг/7140 мг/7145 мг/7150 мг/7155 мг/7160 мг/7165 мг/7170 мг/7175 мг/7180 мг/7185 мг/7190 мг/7195 мг/7200 мг/7205 мг/7210 мг/7215 мг/7220 мг/7225 мг/7230 мг/7235 мг/7240 мг/7245 мг/7250 мг/7255 мг/7260 мг/7265 мг/7270 мг/7275 мг/7280 мг/7285 мг/7290 мг/7295 мг/7300 мг/7305 мг/7310 мг/7315 мг/7320 мг/7325 мг/7330 мг/7335 мг/7340 мг/7345 мг/7350 мг/7355 мг/7360 мг/7365 мг/7370 мг/7375 мг/7380 мг/7385 мг/7390 мг/7395 мг/7400 мг/7405 мг/7410 мг/7415 мг/7420 мг/7425 мг/7430 мг/7435 мг/7440 мг/7445 мг/7450 мг/7455 мг/7460 мг/7465 мг/7470 мг/7475 мг/7480 мг/7485 мг/7490 мг/7495 мг/7500 мг/7505 мг/7510 мг/7515 мг/7520 мг/7525 мг/7530 мг/7535 мг/7540 мг/7545 мг/7550 мг/7555 мг/7560 мг/7565 мг/7570 мг/7575 мг/7580 мг/7585 мг/7590 мг/7595 мг/7600 мг/7605 мг/7610 мг/7615 мг/7620 мг/7625 мг/7630 мг/7635 мг/7640 мг/7645 мг/7650 мг/7655 мг/7660 мг/7665 мг/7670 мг/7675 мг/7680 мг/7685 мг/7690 мг/7695 мг/7700 мг/7705 мг/7710 мг/7715 мг/7720 мг/7725 мг/7730 мг/7735 мг/7740 мг/7745 мг/7750 мг/7755 мг/7760 мг/7765 мг/7770 мг/7775 мг/7780 мг/7785 мг/7790 мг/7795 мг/7800 мг/7805 мг/7810 мг/7815 мг/7820 мг/7825 мг/7830 мг/7835 мг/7840 мг/7845 мг/7850 мг/7855 мг/7860 мг/7865 мг/7870 мг/7875 мг/7880 мг/7885 мг/7890 мг/7895 мг/7900 мг/7905 мг/7910 мг/7915 мг/7920 мг/7925 мг/7930 мг/7935 мг/7940 мг/7945 мг/7950 мг/7955 мг/7960 мг/7965 мг/7970 мг/7975 мг/7980 мг/7985 мг/7990 мг/7995 мг/8000 мг/8005 мг/8010 мг/8015 мг/8020 мг/8025 мг/8030 мг/8035 мг/8040 мг/8045 мг/8050 мг/8055 мг/8060 мг/8065 мг/8070 мг/8075 мг/8080 мг/8085 мг/8090 мг/8095 мг/8100 мг/8105 мг/8110 мг/8115 мг/8120 мг/8125 мг/8130 мг/8135 мг/8140 мг/8145 мг/8150 мг/8155 мг/8160 мг/8165 мг/8170 мг/8175 мг/8180 мг/8185 мг/8190 мг/8195 мг/8200 мг/8205 мг/8210 мг/8215 мг/8220 мг/8225 мг/8230 мг/8235 мг/8240 мг/8245 мг/8250 мг/8255 мг/82

КАРДИОМАГНИЛ
Дарит Вам время



Кардиомагнил – надежная защита от инфаркта и тромбоза

Высоко достоверные результаты снижения сердечно-сосудистых событий на 40% были показаны на желудочно-растворимой АСК 75 мг.¹

Кардиомагнил предлагает эффективную дозировку 75 мг АСК, которая превосходит по безопасности АСК в дозах 100 мг и более²



ООО "Такета Фармэсьютикалс" г. Москва, ул. Усачёва, д. 2, стр. 1, бизнес-центр "Фьюжн Парк". Тел.: +7(495) 933-55-11, факс: +7(495) 502-16-25. Рег. уд. № П N013875/01 от 25.12.2007 (дата переоформления 07.10.2016).

Сокращённая информация по применению

Торговое название: Кардиомагнил. **МНН или группировочное название:** Ацетилсалициловая кислота + магния гидроксид. **Лекарственная форма:** таблетки, покрытые плёночной оболочкой. **Показания к применению:** Первичная профилактика сердечно-сосудистых заболеваний, таких как тромбоз и острая сердечная недостаточность при наличии факторов риска. Профилактика повторного инфаркта миокарда и тромбоза кровеносных сосудов. Профилактика тромбозов после хирургических вмешательств на сосудах. Нестабильная стенокардия. **Противопоказания:** Повышенная чувствительность к АСК, вспомогательным веществам препарата и другим НПВП; кровоизлияние в головной мозг; склонность к кровотечениям; бронхиальная астма, индуцированная приёмом салицилатов и НПВП; эрозивно-язвенное поражение желудочно-кишечного тракта; желудочно-кишечное кровотечение; тяжёлая почечная недостаточность; беременность; период лактации; дефицит глюкозо-6-фосфатдегидрогеназы; одновременный приём с метотрексатом; детский возраст до 18 лет. Полный перечень побочных эффектов содержится в инструкции по применению. **С осторожностью:** При подагре, гиперурикемии, наличии в анамнезе язвенных поражений желудочно-кишечного тракта или желудочно-кишечных кровотечений, почечной и/или печёночной недостаточности, бронхиальной астмы, сенной лихорадки, полипоза носа, аллергических состояниях, во II триместре беременности.

¹ Juii-Moeller S., et al. Lancet, Vol. 340, Dec12, 1992, 1421-5.

² Charles L. Campbell et al. Aspirin Dose for the Prevention of Cardiovascular Disease JAMA, May 9, 2007–Vol 297, No. 18, 2018–2024.

Дата выхода материала: август 2017 г. Реклам.

Информация для специалистов здравоохранения

АТТЕНТО

Амлодипин+Олмесартан

НОВАЯ фиксированная комбинация:

Эффективное снижение АД^{1,2}

Кардио- и ангиопротективный эффект³



- Redon J, Fabia MJ. J Renin Angiotensin Aldosterone Syst. 2009 Sep;10(3):147-56.
- Chrysant SG et al. Clin Ther. 2008 Apr;30 (4):587-604.
- De la Sierra A, Volpe M. J. Hypertens. 2013 Mar;31 Suppl 1:S13-7.

Инструкция по применению лекарственного препарата для медицинского применения Аттенто® Регистрационный номер: ЛП-003818 от 01.09.2016. Торговое патентованное наименование: Аттенто®. **Международное непатентованное название:** амлодипин + олмесартан медоксила. Таблетки 5 мг + 20 мг, 5 мг + 40 мг, 10 мг + 40 мг. **Показания к применению:** эссенциальная гипертензия (при неэффективности монотерапии олмесартана медоксилом или амлодипином). **Противопоказания:** повышенная чувствительность к олмесартану медоксилу, амлодипину и другим производным дигидропиридина или к другим компонентам препарата; печеночная недостаточность тяжелой степени тяжести (более 9 баллов по шкале Чайлд-Пью); обструкция желчевыводящих путей и холестаза; тяжелая артериальная гипотензия (САД менее 90 мм рт. ст.); шок (включая кардиогенный); гемодинамически нестабильная сердечная недостаточность после инфаркта миокарда; почечная недостаточность тяжелой степени тяжести (клиренс креатинина (КК) менее 20 мл/мин, опыт клинического применения отсутствует); состояние после трансплантации почки (был клинический опыт применения Аттенто®); состояние, сопровождающееся выраженным нарушением оттока крови из левого желудочка (например, стеноз устья аорты тяжелой степени); беременность; период грудного вскармливания; возраст до 18 лет (эффективность и безопасность не установлены); одновременное применение с алискиреном и алискиренсодержащими препаратами у пациентов с сахарным диабетом и/или нарушением функции почек (скорость клубочковой фильтрации менее 60 мл/мин/1,73 м² площади поверхности тела). **С осторожностью:** стеноз аортального и митрального клапана; гипертрофическая обструктивная кардиомиопатия; одновременное применение с препаратами лития; гиперкалиемия; гипонатриемия; гиповолемия (в том числе вследствие диарей, рвоты или одновременного применения диуретиков), а также у пациентов, соблюдающих диету с ограничением потребления поваренной соли; почечная недостаточность легкой и умеренной степени тяжести (КК 20-60 мл/мин); первичный альдостеронизм; вазоренальная гипертензия (двусторонний стеноз почечных артерий или стеноз артерии единственной почки); прочие состояния, сопровождающиеся активацией ренин-ангиотензин-альдостероновой системы; хроническая сердечная недостаточность (ХСН) (III-IV функциональный класс по классификации NYHA); хронические формы ишемической болезни сердца; острые формы ишемической болезни сердца (острый инфаркт миокарда, в т.ч. в течение одного месяца после него; нестабильная стенокардия); синдром слабости синусового узла; артериальная гипотензия; цереброваскулярные заболевания; печеночная недостаточность легкой и умеренной степени тяжести (менее 9 баллов по шкале Чайлд-Пью); возраст старше 65 лет; применение у пациентов негроидной расы. **Способ применения и дозы:** ежедневно по 1 таблетке препарата Аттенто®, при отсутствии адекватного снижения АД на фоне монотерапии олмесартану медоксилом или амлодипином. **Побочное действие:** ниже приведены наиболее часто встречающиеся побочные эффекты. Комбинация амлодипина и олмесартана медоксила. **Со стороны нервной системы:** головокружение, головная боль. **Общие нарушения:** повышенная утомляемость, периферические отеки, отек мягких тканей. Олмесартану медоксилу (монотерапия). **Со стороны обмена веществ и питания:** повышение концентрации триглицеридов в плазме крови, повышение концентрации мочевой кислоты в плазме крови. **Со стороны нервной системы:** головноекружение, головная боль. **Со стороны дыхательной системы:** органы грудной клетки и средостения: фарингит, ринит, бронхит, кашель. **Со стороны органов пищеварения:** диарея, диспепсия, гастроинтест. боль в животе, тошнота. **Со стороны печени и желчевыводящих путей:** повышение активности печеночных ферментов. **Со стороны опорно-двигательного аппарата:** боль в спине, боль в костях, артрит. **Со стороны почек и мочевыводящих путей:** гематурия, инфекции мочевых путей. **Общие нарушения:** боль в грудной клетке, периферические отеки, гриппоподобные симптомы, повышенная утомляемость, боль неутонченной локализации. **Со стороны лабораторных показателей:** повышение концентрации мочевины в плазме крови, повышение активности креатинфосфокиназы. Амлодипин (монотерапия) **Со стороны нервной системы:** головокружение, головная боль, сонливость. **Со стороны сердечно-сосудистой системы:** приливы крови к лицу, ощущение сердцебиения. **Со стороны органов пищеварения:** боль в животе, тошнота. **Со стороны опорно-двигательного аппарата:** отек в области лодыжек. **Общие нарушения:** повышенная утомляемость, отеки. Подробная информация содержится в инструкции по применению препарата для медицинского применения Аттенто® ЛП-003818 от 01.09.2016.

Адрес компании: ООО «Берлин-Хеми/А.Менарини» 123112, г. Москва, Пресненская набережная, д. 10 БЦ «Башня на набережной», блок Б Тел.: (495) 785-01-00, факс: (495) 785-01-01
http://www.berlin-chemie.ru

* АД – артериальное давление

RU_Attento_2_2017 Одобрено в печать июнь 2017.

БЕРЛИН-ХЕМИ

Леркамен®

Лерканидипин

Первый лерканидипин,
зарегистрированный в России*



Лерканидипин -
эффективное снижение АД
и хорошая переносимость^{1,2,3}

*Даты государственной регистрации: инструкция по медицинскому применению Леркамен® 10 от 07.09.2009 (с внесенными изменениями к инструкции №1 от 14.05.2010, №2 от 09.04.2012, №3 от 11.09.2014) и Леркамен® 20 от 01.09.2008 (с внесенными изменениями к инструкции №1 от 17.11.2009, №2 от 14.05.2010, №3 от 09.04.2012, №4 от 01.12.2014)



КРАТКАЯ ИНСТРУКЦИЯ ПО ПРИМЕНЕНИЮ ТН-Леркамен® 10, Леркамен® 20. МНН: лерканидипин. ФАРМАКОТЕРАПЕВТИЧЕСКАЯ ГРУППА: селективные блокаторы кальциевых каналов с преимущественным влиянием на сосуды. ПОКАЗАНИЯ К ПРИМЕНЕНИЮ: эссенциальная и вторичная гипертензия легкой и умеренной степени тяжести. СПОСОБ ПРИМЕНЕНИЯ И ДОЗЫ: 10-20 мг внутрь, один раз в сутки, не менее чем за 15 минут до еды, предпочтительно утром, запивая достаточным количеством воды, не разжевывая. Терапевтическая доза подбирается постепенно, при необходимости увеличение дозы до 20 мг/сут осуществляется через 2 недели после начала приема препарата. ПРОТИВОПОКАЗАНИЯ: повышенная чувствительность к лерканидипину, другим производным дигидропиридинового ряда или к любому компоненту препарата; нелеченная сердечная недостаточность; нестабильная стенокардия; обструкция сосудов, исходящих из левого желудочка; период в течение 1 месяца после перенесенного инфаркта миокарда; тяжелая печеночная недостаточность; тяжелая почечная недостаточность (клиренс креатинина менее 30 мл/мин); непереносимость лактозы, дефицит лактазы, синдром глюкозно-галактозной мальабсорбции; беременность и период грудного вскармливания; применение у женщин детородного возраста при отсутствии надежной контрацепции; возраст до 18 лет (эффективность и профиль безопасности не установлены). С осторожностью: почечная недостаточность (КК более 30 мл/мин); печеночная недостаточность легкой или средней степени тяжести; пожилой возраст; синдром слабости синусового узла (без наличия ЭКС); ИБС; дисфункция левого желудочка. ПОБОЧНЫЕ ЭФФЕКТЫ: препарат хорошо переносится; нечасто: эффекты, связанные с сосудорасширяющим действием препарата (периферические отеки, ощущение приливов крови к лицу, сердцебиение, снижение АД. Подробная информация содержится в инструкциях по медицинскому применению препаратов Леркамен® 10 ЛСР-007057/09 от 07.09.2009, Леркамен® 20 ЛСР-006976/08 от 01.09.2008

Информация для специалистов здравоохранения.
RU_Lerc_1_2017 Одобрено 08.2017



000 «Берлин-Хеми/А.Менарини», 123112, Москва,
Пресненская наб. д. 10, БЦ «Башня на Набережной», блок «Б»,
Тел.: (495) 785-01-00, факс: (495) 785-01-01,
<http://www.berlin-chemie.ru>.

По лицензии Recordati

1. Barrios V, Navarro A, Estévez A, Luque M, Romero J, Tamargo J, Piéto L, Carrasco JL, Herranz I, Navarro-Cl J, Bullock LM. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The Eypise study. Blood Pressure. 2002; 11: 95-100. 2. Barrios V, Escobar C, Navarro A, et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA Study. Int J Clin Pract. November 2006; 60, 11, 1364-1370. 3. Barrios V. The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LEZAMG study. Br J Card. 2006; 13: 434-440.

Диувер

Таблетки 5 мг и 10 мг
№20 и №60

ЕЩЁ МНОГОЕ ПРЕДСТОИТ УСПЕТЬ!



• Способствует замедлению
развития фиброза миокарда¹

• Возвращает контроль
артериального давления²



ДИУВЕР. Краткая инструкция по применению лекарственного препарата для медицинского применения.

Регистрационный номер: ЛСР-001027. Торговое название: Диувер. МНН: торасемид. Лекарственная форма: таблетки. Фармакотерапевтическая группа: диуретическое средство. Показания к применению: отечный синдром различного генеза, в т.ч. при хронической сердечной недостаточности, заболеваниях печени, легких и почек; артериальная гипертензия. Противопоказания: (полная информация – см. инструкцию по применению); повышенная чувствительность к торасемиду или к любому из компонентов препарата; у пациентов с аллергией на сульфонамиды; почечная недостаточность с азотемией; печеночная кома и прекома; выраженная гипокалиемия; выраженная гипонатриемия; гиповолемия или дегидратация; резко выраженные нарушения оттока мочи любой этиологии; гликозидная интоксикация; острый гломерулонефрит; декомпенсированный аортальный и митральный стеноз; гипертрофическая обструктивная кардиомиопатия; повышение центрального венозного давления (свыше 10 мм рт. ст.); гиперурикемия; возраст до 18 лет; период лактации; непереносимость лактозы, дефицит лактазы или глюкозо-галактозная мальабсорбция. Способ применения и дозы (полная информация – см. инструкцию по применению): внутрь, один раз в день, после завтрака, запивая небольшим количеством воды. Побочное действие (полная информация – см. инструкцию по применению): гипонатриемия, гипохлоремия, гипокалиемия, гипомagnesемия, гипокальциемия, метаболический алкалоз. Симптомами, указывающими на развитие нарушений электролитного и кислотно-щелочного состояния, могут быть головная боль, спутанность сознания, судороги, тетания, мышечная слабость, нарушения ритма сердца и диспетические расстройства, гиповолемия и дегидратация. Чрезмерное снижение артериального давления, ортостатическая гипотензия, коллапс, тахикардия, аритмия, снижение объема циркулирующей крови. Гиперхолестеринемия, гипертриглицеридемия; прекожное повышение концентрации креатинина и мочевины в крови; повышение концентрации мочевины в крови, что может вызвать или усилить проявления подгры: снижение толерантности к глюкозе (возможна манифестация латентно протекающего сахарного диабета). Олигурия, острая задержка мочи (например, при гипертонии предстательной железы, сужении мочеиспускательного канала, гидронефроз); интерстициальный нефрит, гематурия, снижение потенции. Тошнота, рвота, диарея, внутрипеченочный холестаз, повышение активности печеночных ферментов, острый панкреатит. Нарушение слуха, обычно обратимое, и/или шум в ушах, особенно у пациентов с почечной недостаточностью или гипопролетемией (нефротический синдром), парестезии. Кожный зуд, крапивница, другие виды сыпи или буллезное поражение кожи, полиморфная сыпь, эксфолиативная дерматит, пурпура, лихорадка, васкулит, эозинофилия, фотосенсибилизация; тяжелые анафилактические или анафилактикоподобные реакции вплоть до шока, которые до настоящего времени были описаны лишь после внутривенного введения. Тромбоцитопения, лейкопения, агранулоцитоз, апластическая или гемолитическая анемия. Срок годности: 3 года. Условия отпуска из аптек: по рецепту.

С подробной информацией о препарате можно ознакомиться в инструкции по применению.

1. Lopez B. // JACC. – 2014. – №43 (11). – P. 2028-2035.

2. Coca A. // American Journal of Hypertension. – 2002. – №15 (113A-114A). – P. 231.

Информация предназначена для специалистов. Перед применением необходимо ознакомиться с полной инструкцией по медицинскому применению.

teva

За дополнительной информацией обращаться:
Общество с ограниченной ответственностью «Тева»
Россия, 115054, Москва, ул. Ваванов, д. 35
Тел. +7 495 6442234 | Факс +7 495 6442235 | www.teva.ru
DIU-100165-DOK-FARM



**VI GLOBAL
EDUCATIONAL FORUM**
RUSSIAN CARDIOVASCULAR DAYS



2 AKKURATOVA ST., ST-PETERSBURG
ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE

APRIL 19–21, 2018

www.scardio.ru 



RUSSIAN
SOCIETY
OF CARDIOLOGY

RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY 2018

SEPTEMBER 25–28 | MOSCOW

INTERNATIONAL TRADE CENTRE
MOSCOW, 12 KRASNOPRESNENSKAYA EMB.

www.scardio.ru

